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A new, improved-throughput lipid-water interface assay was developed in which the inhibition of β-haematin 
formation by diverse inhibitors was investigated. Monopalmitoyl-rac-glycerol was used as a model lipid, and 
following the introduction of the inhibitors into the aqueous buffer layer, β-haematin inhibitory activity was 
investigated under biologically-relevant conditions. Clinically-relevant antimalarial drugs, namely 
chloroquine, amodiaquine, quinidine, quinine and mefloquine were used in order to validate the newly-
optimized assay as a means of assaying drug activity. Having developed this more efficient assay, a larger set 
of compounds, including short-chain chloroquine analogues and a series of benzamide non-quinoline 
inhibitors, were successfully introduced into the system. The IC50 values determined for the inhibition of           
β-haematin formation through this newly-optimized assay show good correlations with previously-determined 
IC50 values, also determined in the lipid-mediated system, as well as biological activities determined against 
chloroquine-sensitive strains of Plasmodium falciparum.  
Furthermore, the effect of each antimalarial drug, short-chain chloroquine analogue and benzamide non-
quinoline compound on the kinetics of β-haematin formation was investigated in the lipid-mediated system. A 
theoretical kinetic model, which is based on the Avrami equation and the Langmuir isotherm, was used to 
analyse the experimental data. Importantly, it has been possible to extract equilibrium adsorption constants 
(Kads) for each compound, which provides a quantitative measure of the strength of interaction between an 
inhibitor and the surface of growing β-haematin. Thus, the experimental data support a mechanism of inhibitor 
action via adsorption for both quinoline- and non-quinoline inhibitors. An important observation made during 
this study suggests that both Kads and the rate of the proposed precipitation of an inhibitor-Fe(III)PPIX complex 
(k2) have an effect on the IC50 value of an inhibitor. While the latter process was not investigated in the current 
work, the interplay between the two parameters appears to be of uttermost importance in determining the 
overall activity of a family of β-haematin inhibitors. 
Finally, the direct adsorption of an inhibitor to preformed β-haematin crystals was investigated in independent 
studies in order to support the conclusions drawn from the kinetics studies. A decrease in the absorbance of a 
solution was observed in all cases when preformed β-haematin was added, which was attributed to the physical 
adsorption of the inhibitor to the crystals. From these studies an adsorption constant was extracted which 
indicated a good correlation with the inhibitory activity and Kads values determined in the kinetics experiments. 
The work in this research project provides important insight into the possible mode of β-haematin inhibition 
by diverse inhibitors. If the interactions that aid the adsorption of compounds to surface binding sites are 
identified, the insight will be invaluable in the rational design of novel haemozoin inhibitors. 
  





‘n Nuwe, verbeterde-deurset lipied-water tussenfase toets is ontwikkel waarin die inhibisie van β-haematien 
vorming deur verskillende inhibeerders ondersoek was. Monopalmitiengliserol was gebruik as ‘n model-lipied, 
en deur die inhibeerders in die waterige buffer laag in te sluit, was dit moontlik om die β-haematien inhiberende 
aktiwiteit onder biologies-relevante kondisies the ondersoek. Klinies-relevante antimalaria-middels, naamlik 
chlorokien, amodiakien, kinidien, kinien en meflokien was gebruik om die nuwe geoptimaliserende toets te 
evalueer as ‘n middel van toetsing van inhiberende aktiwiteit. Deur die ontwikkeling van hierdie meer 
doeltreffende toets, was dit moontlik om ‘n groter hoeveelheid verbindings, insluitend kort-ketting chlorokien 
analoë en ‘n reeks bensamied nie-kinolien inhibeerders, in die sisteem te inkorporeer. Die IC50 waardes bepaal 
vir die inhibisie van β-haematien vorming deur hierdie nuwe geoptimaliserende toets, dui op goeie korrelasies 
met voorheen bepaalde IC50 waardes, óók bepaal in die lipied-beheerde sisteem, asook die biologiese 
aktiwiteite bepaal teen chlorokien-sensitiewe stamme van Plasmodium falciparum. 
Verder is die effek van elke antimalarial-middel, kort-ketting chlorokien analoog en bensamied nie-kinoline 
inhibeerder op die kinetika van β-haematien vorming ondersoek in die lipied-beheerde sisteem. ‘n Teoretiese 
kinetiese model wat gebaseer is op die Avrami-vergelyking en die Langmuir-isoterm was gebruik om die 
eksperimentele data te analiseer. Dit was moontlik om ‘n ewewigs-adsorpsiekonstante (Kads) vir elke 
inhibeerder te bepaal. Die Kads waarde is ‘n kwantitatiewe meting van die sterkte van die interaksie tussen ‘n 
inhibeerder en die oppervlakte van groeiende β-haematien. Dus ondersteun die eksperimentele data ‘n 
meganisme van inhibeerder aksie deur adsorpsie deur beide die kinolien en nie-kinolien inhibeerders. ‘n 
Belangrike waarneming tydens die studie dui daarop dat beide Kads en die koers van die voorgestelde 
neerslagreaksie van ‘n inhibeerder-Fe(III)PPIX kompleks (k2) ‘n effek op die IC50 waarde van ‘n inhibeerder 
het. Terwyl die laasgenoemde proses nie ondersoek was in die huidige studie nie, blyk dit dat die wisselwerking 
tussen hierdie twee parameters die algehele aktiwiteit van ‘n familie van inhibeerders bepaal. 
Die direkte adsorpsie van ‘n inhibeerder aan reeds-gevormde β-haematien kristalle was ondersoek in 
onafhanklike studies om die gevolgtrekkings van die kinetika studies te ondersteun. ‘n Daling in die 
absorbansie van ‘n oplossing was waargeneem in alle gevalle wanneer reeds-gevormde β-haematien daarby 
gevoeg was. Hierdie waarneming is toegeskryf aan die fisiese adsorpsie van die inhibeerder aan die kristalle. 
Vanuit hierdie studies was ‘n adsorpsiekonstante bepaal wat goeie korrelasies met die inhiberende aktiwiteit 
en Kads waardes, verkry in die kinetika eksperimente, aandui. 
Die werk in hierdie navorsings projek verleen belangrike insig in die moontlike manier van β-haematien 
inhibisie deur verskillende inhibeerders. As die interaksies wat bydra tot die adsorpie van verbindings aan die 
oppervlak-bindings punte geïdentifiseer word, sal die insig van hierdie werk belangrik wees in die 
ontwikkeling van nuwe haemasoïen inhibeerders. 
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Malaria is one of the most deadly parasitic human diseases known worldwide and is responsible for over 
hundreds of thousands of deaths per year, especially among young children in Africa.1 It is, however, endemic 
in several nations, affecting millions of people annually, and is notably a contributor to economic 
underdevelopment in some of these countries. Malaria is one of few diseases which can be viewed as both a 
cause and a consequence of poverty, owing to its highest distribution in underprivileged regions and billions 
of US dollars spent annually on malaria control and elimination.1 The malaria parasite, Plasmodium 
falciparum, which is the primary causative agent of human malaria, has over the years started to demonstrate 
increasing resistance towards antimalarial drugs.1 Consequently, the development of novel chemotherapeutic 
agents has become of high importance, since malaria remains a great global health problem. Unfortunately, 
the mechanism of action of the majority of clinically-relevant antimalarial drugs is still not fully understood 
and this has motivated research in this area. 
 
1.2 Malaria Overview 
 
1.2.1 History and Discovery of Malaria 
Malaria is an ancient disease which dates as far back as early 2700 BC.2 In about 400 BC, Hippocrates was 
aware of the poor health, enlarged spleens and fevers amongst local populations living in marshy places, and 
was the first to make a connection between these symptoms.3 Owing to the relationship between these observed 
symptoms and marshy environments, the word malaria was derived from the Italian word “mal’aria”, meaning 
“bad air”.4  
This idea that malaria fevers were caused by miasmas rising from swamps continued for over 2500 years and 
the search for the cause of malaria intensified over the years after the discovery of bacteria in 1676, and the 
incrimination of microorganisms as causes of infectious diseases.3 In 1717, Giovanni Maria Lancisi discovered 
a brown-black pigment in the blood of patients affected by malaria.5 The search for the cause of the disease 
was an ongoing process and increased over the years until the first scientific study by Charles Louis Alphonse 
Laveran in the 1880s. Lavern discovered the etiological agent of malaria, the malaria parasite, and identified 
pigments in the body of living parasites in 26 patients.6,7 The idea that mosquitoes might be associated with 
malaria was first suggested by the American physician, Albert King,8 and was studied further by the British 
scientist, Patrick Manson, who was convinced that mosquitoes were involved in malaria transmission (he based 





this on his early findings that mosquitoes could transmit filarial worms responsible for lymphatic filariasis).9 
In 1897, Sir Ronald Ross discovered that the avian malaria parasite, Plasmodium relictum, was transmitted by 
culicine mosquitoes, and suggested that mosquitoes also transmit human malaria parasites.10 It was, however, 
during the period 1898-1900, that various Italian scientists, namely Giovanni Battista Grassi, Amico Bignami 
and Giuseppe Bastianelli, were able to conclusively demonstrate that human malaria parasites were indeed 
transmitted by female Anopheles mosquitoes.11  
 
1.2.2 Distribution and Statistics of Malaria 
An estimated 3.3 billion people in 97 countries are at risk of being infected with malaria. 198 million cases of 
malaria infections occurred globally in 2013, of which 584 000 led to death; 78% of these deaths occurred in 
children aged five years and younger. The disease predominates among the sub-Saharan Africa countries, in 
which 90% of all malaria deaths occur, however, it is also found in the South American-, Eastern 
Mediterranean-, European-, South-East Asia- and Western pacific regions (Figure 1.1).1  
As a result of the distribution of insecticide-treated mosquito bed nets, improvements have been reported for 
malaria infections and deaths over the last few years,1 however, regardless of these vast improvements, an 
overall increase in parasite resistance towards known quinoline-based antimalarial drugs and artemisinin-based 
combination therapy is evident in P. falciparum strains across different regions. This high level of resistance 
is limiting the use of certain cheap and previously highly effective drugs, such as chloroquine (CQ), in treating 




Figure 1.1 Worldwide distribution of malaria. Darker shading indicates countries with the highest ongoing 
malaria transmission in 2013. Reproduced with permission from reference 1. 
 





1.3 The Malaria Parasite 
 
1.3.1 The Life Cycle of the Malaria Parasite 
Malaria is caused by five species of protozoan parasites belonging to the genus Plasmodium, of which four of 
these species are infectious to humans: P. falciparum, P. ovale, P. vivax and P. malariae,12 while the fifth 
parasite species, P. knowlesi, causes malaria mainly among monkeys in certain areas of South-East Asia.1 Of 
these species, P. falciparum and P. vivax are the most virulent, with the former being responsible for the 
majority of deaths from malaria.1,13 P. falciparum predominates in the African regions, while P. vivax has a 
geographically wider distribution, owing to its ability to survive at lower temperatures and in regions with 
higher altitudes and cooler climates.1  
The malaria parasite is transmitted to its vertebrate host via the bite of an infected female Anopheles mosquito. 
It has a complicated life cycle, since it requires a vector and a host, and can be described in different stages. 
Once the human host is bitten by the infected female mosquito, sporozoites are transferred from the saliva of 
the mosquito into the host’s blood (Figure 1.2 (a)) and carried in the bloodstream to the liver cells (Figure 1.2 
(b)), where they undergo exoerythrocytic schizogony, a phase of asexual multiplication. In the liver, 
sporozoites replicate to form uninucleate merozoites (Figure 1.2 (c)) which go on to invade the red blood cells 
(RBCs) upon release from the liver. This initiates a second asexual multiplication phase known as the blood 
cycle (Figure 1.2 (d)). While undergoing asexual reproduction in the RBCs, merozoites develop through the 
ring- and later the trophozoite-stage. The parasite subdivides to produce daughter merozoites in the schizont 
stage, and these merozoites are released back into the bloodstream and the process is repeated. The 
intraerythrocytic stage of the parasite’s life cycle gives rise to all clinically known symptoms of malaria, and 
repeats every 48 hours in the P. falciparum parasite species. Known symptoms associated with malaria 
infection include fever, headaches, chills, sweats and fatigue.14 As part of the blood cycle, some merozoites 
develop as male and female gametocytes. These are transferred back to a different female Anopheles mosquito 
during its blood meal (Figure 1.2 (e)), after circulating around in the host’s bloodstream. The gametocytes 
mature to gametes that eventually form oocysts that divide to create sporozoites once more. After moving to 
the salivary glands of the mosquito, an uninfected host becomes infected when bitten (Figure 1.2 (a)) and the 
cycle of infection starts once more.3,12,14,15,16 
The malaria parasites are clever organisms for dwelling inside the cells of its host, since this strategy helps 
them to avoid the host’s immune system. The complex lifecycle involves several mechanisms by which the 
parasite can sustain its chemical composition and obtain the nutrients required for its survival.12 The blood 
stage of the parasite’s life cycle is, however, of most importance and interest, since it is the stage associated 
with the symptoms of this infectious disease.  
 
 






Figure 1.2 The complex life cycle of a malaria parasite, Plasmodium falciparum. Reproduced with permission 
from reference 16. 
 
1.3.2 The Blood Stage of the Parasite’s Life Cycle 
After entering the RBCs of the host in the blood stage of the parasite’s life cycle, the parasite grows and 
matures while surrounded by cytosol, mainly consisting of haemoglobin (Hb).17 Hb is a convenient source of 
amino acids. At least 65% of Hb present in the RBC cytoplasm is degraded to peptide fragments by multiple 
proteases18 within an acidic compartment known as the digestive vacuole (DV) within the parasite (pH 4.8).19 
Some of these parasite proteases, important for Hb proteolysis, include different acidic proteases, aspartic 
proteases, a cysteine protease and a zinc metallo-protease.17,20,21,22,23 Only a fraction of amino acids derived 
from Hb proteolysis are needed for the biosynthesis of parasite proteins, which provide a source of nutrition 
for normal parasite growth and development.17,18 The rest of the Hb is subsequently degraded to make space 
for parasite growth. 
During Hb degradation, four haem (iron (II) protoporphyrin IX, Fe(II)PPIX) (Figure 1.3 (a)) equivalents per 
unit of Hb are released into the DV, where the iron centre is rapidly oxidised from the Fe(II) to Fe(III) state.24 
The structure of Fe(III)PPIX is characterized by an iron centred (ferric state) porphyrin with 4 methyl-, 2 vinyl- 
and 2 propionic acid side chains. The five-coordinate Fe(III) centre also has an axial ligand which is pH-
dependent, being either an aqua (H2O) or a hydroxide (-OH) group. The resulting Fe(III)PPIX product (Figure 
1.3 (b)) is, however, toxic to the parasite, possibly promoting the formation of reactive oxygen species and 
subsequent membrane damage via lipid peroxidation. These processes ultimately result in parasite death.24  
As a survival mechanism, the parasite detoxifies the harmful Fe(III)PPIX via biocrystallisation, by converting 
at least 95% of it into a highly insoluble, inert crystalline material called haemozoin or malaria pigment.25 This 
material consists of centrosymmetric dimers of Fe(III)PPIX (Figure 1.3 (c)).25,26 Figure 1.4 is a schematic 
representation summarizing the biological pathway for haemozoin formation in the DV of a parasite within 










Figure 1.3 The molecular structures of (a) haem (Fe(II)PPIX) and (b) haematin (Fe(III)PPIX), both with a 
hydroxide axial ligand, and (c) haemozoin (malaria pigment). 
 
 
Figure 1.4 Schematic representation of the biological pathway for haemozoin formation in the digestive 
vacuole (DV) of P. falciparum (Pf) within the red blood cell (RBC) of a host. Haemoglobin (Hb) present in 
the RBC cytoplasm is ingested by Pf and transported to the DV by transport vesicles (a). Upon entering the 
DV (b), Hb is digested to peptides (c), which are further degraded to amino acids and used as a nutrient source 
for parasite growth and development (d). Free haem (Fe(II)PPIX) released as a by-product of Hb degradation 
(e), undergoes rapid oxidation to yield toxic haematin (Fe(III)PPIX) (f). As a detoxification mechanism, the 
Fe(III)PPIX is converted into haemozoin (malaria pigment) (g). Adapted from reference 26. 
 
Taking into consideration that quinoline-containing antimalarial drugs demonstrate their antiplasmodial 
activity in the blood stage of the malaria parasite’s life cycle,27 it is important to realise that the parasite can be 
in danger to drug action at any given point while it is located within the host’s RBCs. Two main ideas of drug 
action have been considered, namely the disruption of Hb degradation or the Fe(III)PPIX detoxification 
process, respectively.27 Over the last few years, the latter process has been studied and investigated as the target 
of drug action, and understanding the structure and formation of haemozoin has been of great interest and 
importance in aiding the development of new therapeutic antimalarial drugs. The discovery of haemozoin 
crystals in other blood-feeding organisms, unrelated to the Plasmodium malaria parasite, including Rhodnius 
prolixus (insect),27 Schistosoma mansoni, Echinostoma trivolvis and Haemoproteus columbae (helmith 






























The first discovery of haemozoin dates back close to 150 years before the discovery of the malaria parasite. In 
the 18th century, Giovanni Maria Lancisi observed a black discolouration in the brains of cadavers of malaria 
victims.5 Later, Johann Heinrich Meckel, a German physician, rediscovered the malaria pigment in 1847,31 
while Rudolf Virchow was the first to relate the presence of the pigment to malaria in 1849.32 Initially the 
malaria pigment was believed to be melanin, however, W. H. Brown demonstrated that the chromophore 
responsible for the pigment’s brown-black colour, is in fact haem.33 For almost 80 years, no significant 
discoveries were made regarding haemozoin, until 1987, when Fitch and Kanjananggulpan demonstrated that 
haemozoin is comprised entirely of ferriprotoporphyrin IX (Fe(III)PPIX).34 In 1991, it was Slater and co-
workers who published a ground-breaking paper in which they confirmed Fitch and Kanjananggulpan’s 
findings, and explained the chemical composition of haemozoin by elemental analysis.35 This paper forms the 
basis of our understanding of haemozoin, however, numerous controversies have existed regarding its 
proposed structure. 
 
1.4.1 Haemozoin Structure and Crystal Morphology 
At first haemozoin was considered to be a linear polymer,35 and later an antiparallel polymer.36 However, more 
recently the structure of haemozoin has been described as a periodic array of cyclic dimers of Fe(III)PPIX.37 
The molecular structures of these various forms are shown below (Figure 1.5). 
 
 
Figure 1.5 The proposed structures of haemozoin. (a) Slater et al. initially suggested that haemozoin was a 
linear polymer containing Fe(III)PPIX units linked via the coordination of propionate groups,35 followed by 
the idea of (b) an antiparallel polymer by Bohle et al.36 It was, however, shown than haemozoin was not a 
polymer, but rather contained (c) a periodic array of hydrogen-bonded cyclic dimers of Fe(III)PPIX.37  
 
(a) (b) (c)





A synthetic product of Fe(III)PPIX, called β-haematin, precipitated from an aqueous solution with acetic acid, 
was first discovered and described in the 1930s by Hamsik, enabling the earliest study of the formation of 
haemozoin in vitro.38 The haemozoin isolated by Fitch and Kanjananggulpan was suggested to be identical to 
this insoluble aggregate,34 and solubilisation, infrared spectroscopy and powder X-ray diffraction (PXRD) 
studies by Slater et al. indeed confirmed this observation.35 The authors initially proposed that haemozoin (and 
β-haematin) was a linear polymer, containing Fe(III)PPIX units linked via the coordination of a propionate 
group of one molecule to the iron centre of an adjacent monomer (Figure 1.5 (a)), which they concluded using 
extended X-ray adsorption fine structure (EXAFS) spectroscopy.35 EXAFS was used to investigate the local 
environment of iron in haemozoin by identifying both the type and the distance of each shell of atoms around 
the absorbing metal. The strong absorbance bands present at 1211 cm-1 and 1664 cm-1 in the Fourier-transform 
infrared (FT-IR) spectrum of haemozoin and β-haematin confirmed this conclusion, and were assigned to the 




Figure 1.6 (a) The FT-IR spectrum of haemozoin (solid line) and β-haematin (broken line). The characteristic 
peaks are seen at 1211 and 1664 cm-1 for the C-O and C=O stretching frequencies, respectively. Reproduced 
with permission from reference 35. (b) A schematic representation of the proposed linear haemozoin structure 
viewed side on. C ̶ O and C=O stretching frequencies are indicated. The thick black lines represent the 
porphyrin plane. 
 
It was only years later in 1997 when Bohle et al., using synchrotron PXRD, confirmed that haemozoin, is 
indeed identical to β-haematin. The sample of the latter material had been prepared by dehydrohalogenation 













belongs to the centrosymmetric space group P1, and hence proposed that the structure of haemozoin (and β-
haematin) was comprised of two antiparallel polymer chains linked to each other via hydrogen bonds (Figure 
1.5 (b)).36 Knowledge of the haemozoin crystal structure has progressed over time, and in 2000, Pagola et al. 
finally solved the structure of β-haematin from high resolution synchrotron PXRD patterns using Rietveld 
refinement.37 The outcome, however, indicated that β-haematin was a crystal formed of discrete cyclic dimers 
of Fe(III)PPIX, rather than a polymer. It was shown that the propionate group of each Fe(III)PPIX molecule 
is coordinated to the iron centre of another molecule, while neighbouring dimers are connected by hydrogen 
bonds between the uncoordinated propionic acids groups (Figure 1.5 (c)).37  
In 2002, Buller et al. published a paper in which they described the theoretical growth form and crystal 
morphology of β-haematin.39 They determined a needle-like crystal morphology (extended along the c-axis) 
and explained that the relationship between the macroscopic morphology of the crystals and the unit cell 
structure is of importance to understand possible molecular mechanisms of haemozoin formation, and also its 
inhibition by antimalarial drugs (Figure 1.7 (a, c and d)).39 More recently, Gildenhuys et al. obtained single 
crystals of solvated β-haematin from a CQ-containing DMSO solution (Figure 1.7 (b)).40 The authors 
determined that the repeating unit in the crystal structure is a µ-propionato dimer of Fe(III)PPIX using single 
crystal X-ray diffraction (SCD), which is almost in agreement to what have been reported for β-haematin and 
haemozoin from PXRD data.37 Based on the reported PXRD crystal structure of β-haematin,37 Buller et al. 
further showed that the crystal form of β-haematin is similar in overall shape and form to that of haemozoin 
crystals using emission in-lens scanning electron microscopy (SEM) (Figure 1.7 (e, f and g).39  
 
 
Figure 1.7 (a) The packing arrangement of β-haematin viewed along the c-axis. (b) The µ-propionato dimer 
of Fe(III)PPIX from solvated β-haematin obtained by single crystal X-ray diffraction. The theoretical growth 
form of β-haematin (c and d). Dominant faces include (100) and (010), while (011) is a lesser-developed face 
and (001) is a minor face. Field emission in-lens scanning electron microscopy images of haemozoin crystals 
purified from (e) P. falciparum, (f) S. mansoni and (g) H. columbae. (f). Reproduced with permission from 













1.4.2 Haemozoin Formation In Vivo 
Haemozoin formation is a very effective method of Fe(III)PPIX detoxification, however, there is still much 
uncertainty regarding the mechanism of its formation. While it is believed that haemozoin formation occurs 
via a biocrystallisation process,41 there is controversy surrounding whether proteins or lipids facilitate its 
formation.  
 
1.4.2.1 Protein-Facilitated Haemozoin Formation 
The proposal that proteins contribute to the formation of haemozoin dates back to when it was still considered 
to be a polymer. Sullivan et al. showed that histidine-rich protein (HRP) II, which is plentiful in P. falciparum, 
promoted haemozoin formation, and they proposed that HRP II may be responsible for initiating or catalysing 
haemozoin formation in the malaria parasite.42 HRP II has further been shown to bind to Fe(III)PPIX43,44 and 
later in 1999, Ziegler et al. indicated that a dendrimer, comprised of the long peptide repeat unit of HRP II 
(His-His-Ala-His-His-Ala-Ala-Asp) also promoted β-haematin and suggested that this specific peptide 
sequence may represent a biomineralising template.45 In 2001, Papalexis et al. continued to study the role of 
HRPs and discovered using confocal immunofluorescence labelling of HRP II, that this protein is indeed 
present in the DV of the parasite, however, it is mainly localised in the RBC cytoplasm.46 This observation 
was confirmed when only 3% of HRPII was located in the DV,47 suggesting that the concentration of HRPII 
is too low to support haemozoin formation alone. The role of HRP in the formation of haemozoin was 
ultimately ruled out when it was later demonstrated that haemozoin formation occurred normally in a P. 
falciparum clone that lacked both genes for HRP II and HRP III.48 Furthermore, no HRP homologues have 
been recognized in P. vivax or P. berghei, both malaria parasites being able to produce haemozoin.49 More 
recently, Chugh et al. reported the presence of a protein complex containing several parasite proteins such as 
plasmepsin II and IV, histo-aspartic protease, falcipain 2 and most importantly, haem-detoxification protein 
(HDP), within the DV.50 The authors developed an in vitro assay in which they showed that falcipain 2 and 
HDP coexist with one another to convert haem to haemozoin. Earlier in 1995, however, Dorn et al. reported 
that the parasite factor responsible for promoting β-haematin formation was not deactivated by boiling or 
protease activity and that both haemozoin and preformed β-haematin support β-haematin formation in the 
absence of proteins.51 
 
1.4.2.2 Lipid-Facilitated Haemozoin Formation 
Compared to the fading evidence for the contribution of HRP in haemozoin formation, the role that lipids play 
in the detoxification process has been expanding substantially since early studies on their possible 
involvement.52,53 Fitch et al. performed a study where they investigated purified lipids, and showed that 70% 
of the initial β-haematin activity present in parasite-infected erythrocytes could be recovered from chloroform 
extraction, with no activity remaining in the residue.54  They found that several unsaturated fatty acids, mono- 





and dioleoylglycerol and a few detergents promoted β-haematin formation, while lipids incapable of β-
haematin formation included trioleoylglycerol, cholesterol, dioleoylphosphatidylethanolamin, and both 
palmitic and stearic saturated fatty acids. The authors further proposed that the lipids play a role in haemozoin 
formation by co-precipitation with monomeric Fe(III)PPIX in the acidic DV, converting dissolved Fe(III)PPIX 
in the lipid into haemozoin.54 
More recent studies in the last decade have suggested the role of neutral lipid bodies (NLBs) within the DV, 
after Jackson et al. investigated NLBs in P. falciparum by means of fluorescence microscopy (using Nile Red 
labelling) and transmission electron microscopy (TEM).55 These NLBs were shown to contain mainly mono- 
and diacylglycerols, while a series of these, including triacylglycerols, were found to promote β-haematin 
formation. Shortly after this discovery, Coppens and Vielemeyer studied NLBs in apicomplexa and published 
for the first time a TEM image of a malaria parasite stained with malachite green (a substance which is used 
to fix neutral lipids), which indicated that haemozoin located in the DV is entirely encapsulated within a NLB 
(Figure 1.8 (a)).56 This review followed a detailed investigation on NLBs and their ability to promote β-
haematin by Pisciotta et al. in 2007 and included TEM images indicating haemozoin within vesicles referred 
to as lipid nanospheres (Figure 1.8 (b)).57 Isolation and characterization of the lipids were made possible by 
sucrose cushion centrifugation, followed by thin layer chromatography, which indicated that the foremost 
components of these nanospheres are monoacylglycerols. Lipid hydrolysis followed by gas-liquid 
chromatography-mass spectrometry (GLC-MS) showed that the fatty acid components of the lipids are 
predominantly comprised of stearic- and palmitic acid, proposing that the nanospheres contains mostly 
monostearoylglycerol (MSG (C21H42O4), Figure 1.8 (c)) and monopalmitoylglycerol (MPG (C19H38O4)).57 
 
 
Figure 1.8 (a) Intravacuolar trophozoite of P. falciparum inside a human RBC. The arrows show the close 
association of neutral lipid deposits and haemozoin crystals. Reproduced with permission from reference 56. 
(b) Transmission electron microscopy image of trophozoites shows small haemozoin crystals surrounded by 
neutral lipid spheres inside the DV. Reproduced with permission from reference 57. (c) The molecular structure 
of monostearoylglycerol (MSG). 
(a) (b)
(c)





The association between haemozoin formation and lipids has further been established in other haemozoin 
forming organisms, which are unrelated to P. falciparum. Oliveira et al. indicated that the formation of 
haemozoin in S. mansoni also arises within lipid bodies, which are located in the gut of the worm (Figure 1.9 
(a)), while the formation of haemozoin in R. prolixus appears to occur within bilayer membrane-bound vesicles 
(Figure 1.9 (b)).58 In both cases the haemozoin is in direct contact with the lipid. 
 
 
Figure 1.9 TEM images of haemozoin crystals (C) observed in (a) S. mansoni inside lipid droplets (L) and (b) 
R. prolixus inside membrane-bound vesicles. Arrows in (a) indicate the absence of a phospholipid double 
membrane in the lipid droplet-like particle, while the arrowheads in (b) indicate the presence of a phospholipid 
double membrane in perimicrovillar membranes. Reproduced with permission from reference 58. 
 
The overall majority of information stemming from early to most recent studies strongly supports the 
contribution of lipids in the process of haemozoin formation.  
 
1.4.3 β-Haematin Formation In Vitro 
1.4.3.1 β-Haematin Formation under Abiotic Conditions 
The formation of synthetic haemozoin, β-haematin, is readily performed in the laboratory, enabling one to 
investigate β-haematin crystal morphologies, structural properties and to develop an understanding of 
Fe(III)PPIX in different solvent environments. Understanding the mechanism of β-haematin formation in vitro 
is essential for understanding haemozoin formation in vivo. Previously, the majority of methods used for β-
haematin synthesis made use of non-biological conditions; experiments were carried out either in an aqueous 
acetate solution from haematin (H2O-Fe(III)PPIX),35,53,59,51,60,61 or in dry methanol using haemin (Cl-
Fe(III)PPIX) with 2,6-lutidine under anhydrous conditions.36,62 
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In 1991, Slater et al. synthesized β-haematin by dissolving haematin in 0.1 M sodium hydroxide (NaOH) and 
precipitating the porphyrin by the addition of acetic acid.35 The reaction was run overnight at 70 °C, after 
which the precipitate was washed multiple times with distilled water. The β-haematin crystals were 
characterised by FT-IR and EXAFS spectroscopy, as well as PXRD. The first study in which the time course 
of β-haematin formation was reported was carried out by Adams et al. in 1996.63 The authors monitored the 
progress of β-haematin formation at 60 °C in 4.5 M sodium acetate, pH 4.5, using Mössbauer spectroscopy. 
The results appeared to show that β-haematin formation is a zero-order process, continuing at a constant rate 
until completion. 
In 2001, Egan et al. investigated the formation of β-haematin in a detailed study, using quantitative infrared 
spectroscopy, X-ray diffraction, SEM and TEM, to probe the parallel between haemozoin formation and 
biomineralisation processes.64 The authors reported a method in which β-haematin was formed in less than an 
hour at 60 °C in 4.5 M acetate buffer, pH 4.5. The authors further investigated the kinetics of β-haematin 
formation and reported that the sigmoidal time dependence of formation could be accounted for by fitting the 
experimental data to the Avrami equation (Equation 1.1). The Avrami equation describes crystallization 
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     (Eq. 1.1) 
 
In the Avrami equation, mR is the mass of the reactant (Fe(III)PPIX in this case) remaining after a specific time 
t, relative to the initial mass of the reactant, m0. z is the experimental rate constant and n is the Avrami constant, 
which is generally an integer value between 1 and 4. The value of n describes the degrees of freedom and is a 
function of dimensionality of the growth process and the manner of crystal nucleation. When the Avrami 
constant is equal to 1, the model suggests that nuclei are preformed and crystal growth is in one dimension, 
resulting in linear crystal growth. However, when n is equal to 2 or 3, random or instantaneous nucleation is 
predicted and crystal growth is rod-like. Finally, when the Avrami constant is equal to 4, the reaction involves 
sporadic nucleation and crystal growth takes place in three dimensions. In the study by Egan et al., they showed 
that the best fit of the experimental time course data to the Avrami equation was when n was equal to 4 (Figure 
1.10).64 
In the experiment, β-haematin was formed from Fe(III)PPIX in a jacketed reaction vessel, and it was found 
that the reaction stirring rate influenced the geometry and the rate of crystal growth from the nucleation sites. 
Furthermore, it was shown that β-haematin formation was dependent on acetate concentration, reaction 
temperature and pH. The authors proposed that β-haematin formation occurred via rapid precipitation of 
amorphous Fe(III)PPIX, which was later converted into the desired product in the presence of acetate, which 
may have acted as a phase transfer catalyst in the dissolution and re-precipitation of haematin.64  






Figure 1.10 Time course of β-haematin formation in 4.5 M acetate, pH 4.5, 60 °C. The best fit through the 
experimental data (●) was achieved with n = 4 (solid line) in the Avrami equation. Reproduced with permission 
from reference 64. 
 
Egan and Tshivhase reported a study in 2006 in which they investigated the formation of β-haematin in the 
presence of aqueous benzoic acid and derivatives of benzoic acid.67 The experiments were otherwise carried 
out under the same the conditions as those used in the acetate medium. The authors showed that the acids are 
far more active in promoting β-haematin formation than acetic acid, in that β-haematin formed within 2 hours 
in the presence of 0.05 M benzoic acid (pH 4.5, 60 °C), compared to a higher concentration of acetate solution 
required (3.5 M) for β-haematin formation in a similar reaction time under the same conditions. The kinetics 
data were also fitted to the Avrami equation, with a value of n= 4 yielding the best fit. This indicated that β-
haematin formation in the presence of benzoic acid, similar as in the acetate medium, involves sporadic 
nucleation and crystal growth in three dimensions. Egan and Tshivhase explained that the greater activity of 
benzoic acid compared to acetic acid may be accounted for by the ability of the benzene ring in the benzoic 
acid to π-stack over the Fe(III)PPIX molecule, assisting in the disruption of porphyrin-porphyrin interactions, 
and subsequently promoting the necessary rearrangements to form β-haematin. It was proposed that the role 
of the carboxylic acid was also to disrupt the hydrogen bond network in the Fe(III)PPIX molecule, and to assist 
in the formation of new hydrogen bonds, enabling β-haematin formation.67 
 
A criticism of the above-mentioned work is the non-biologically relevant conditions. Consequently, studies 
began to focus on more biomimetic conditions to probe haemozoin formation. One way in which to mimic the 
lipid environment is the use of detergent-mediated methods for β-haematin formation. Various detergents have 
been studied as possible substitutes for the lipid environment in which β-haematin formation is performed, 
since detergents are less expensive materials and thus overall more affordable. In 1999, Fitch et al. carried out 
a study in which they showed that various detergents, including sodium dodecyl sulfate (SDS), n-octyl-
glucopyranoside and Tween-80, actively promoted β-haematin formation by possibly increasing the solubility 
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haematin crystallisation promotors, from which they optimized and validated a Nonidet P-40 (NP40) 
detergent-mediated assay, which now serves as a screening mechanism for β-haematin inhibitors.68 More 
recently, Sandlin et al. carried out studies in which they utilized the NP40 detergent-mediated assay in order 
to promote β-haematin formation as part of a high-throughput screen to identify β-haematin inhibitors, and to 
probe their β-haematin inhibitory activities.69,70 In addition to the selection of detergents used for β-haematin 
formation, different solvent systems have been investigated as well. Huy et al. studied β-haematin formation 
induced by a series of short-chain alcohols, namely methanol, ethanol, n-propanol, and n-butanol. The authors 
showed that the induction of β-haematin formation by these alcohols is related with their respective degree of 
hydrophobicity and ability to solubilize heam.71 In 2009 Stiebler et al. investigated the effect of water content 
on spontaneous β-haematin formation in dimethyl sulfoxide (DMSO) and a series of polyethyleneglycols. The 
authors demonstrated that reduced medium polarity increases haem solubility under acidic conditions, which 
in turn assisted in the nucleation of β-haematin crystals in vitro in the absence of any biological sample.72 
While detergents such as NP40 are successful mediators of β-haematin formation, it is still ideal to carry out 
investigations using synthetic lipid particles in a biologically-relevant temperature and pH environment in 
order to facilitate β-haematin formation in vitro.  
 
1.4.3.2 β-Haematin Formation under Biologically-Relevant Conditions 
Given the attention that lipids have received regarding their role in the formation of haemozoin formation in 
vivo, lipid-mediated β-haematin formation has also been studied in the laboratory more recently.54,73 In 2006, 
Egan et al. performed an independent study on the formation of β-haematin under biomimetic conditions, in 
order to investigate the possible role of lipids in this regard.73 Two organic solvents, pentanol and octanol, as 
well as the model lipid monomyristoylglycerol (MMG), were used to mimic the lipid environment. The organic 
solvent or lipid solution (dissolved in acetone/methanol) was layered on top of aqueous citrate buffer to yield 
an interface. By introducing Fe(III)PPIX dissolved in 0.1 NaOH directly to the interface, the authors showed 
that β-haematin forms rapidly at 37 °C, pH 4.8,19 near the pentanol-water, octanol-water and lipid-water 
interfaces. Kinetics of β-haematin formation in this system indicated an apparent first-order reaction, with a 
half-life of 5.3 minutes (Figure 1.11). Furthermore, the study indicated that no β-haematin formation occurred 
within 30 minutes in either the aqueous medium or organic solvents alone, pointing to the important role of 
the interface region. Compared to the previous non-biological methods for β-haematin formation,64,67 the 
kinetics results in this particular study differ notably from the familiar sigmoidal profile observed in acetate. 
However, the experimental data were not analysed and according to the Avrami model, and a systematic study 
was not conducted until later. 






Figure 1.11 Kinetics of β-haematin formation brought about near the interface of MMG and water. The 
experimental data are fitted to a hyperbolic equation for a first-order reaction, corresponding to a half-life of 
5.3 minutes. Reproduced with permission from reference 73. 
 
Hoang et al. further investigated β-haematin formation at the lipid-water interface, using a model consisting 
of an emulsion of neutral lipid particles.74 The effect of various neutral lipids, including mono-, di- and 
triglycerides, in promoting the formation of β-haematin under biologically-relevant conditions (37 °C, pH 4.8) 
indicated that monoglycerides, including MPG, MMG, MSG and rac-1-monooleoylglycerol (MOG), exhibit 
the highest efficiency in mediating β-haematin formation with yields of about 60-80% (Figure 1. 12). Kinetics 
studies indicated fast rates of β-haematin formation with half-lives of about 0.5 minutes for MPG, MMG and 
MSG, which are an order of magnitude faster than previously reported.73 The data indicated that reactions were 
complete within five minutes, and additional experiments showed that the rate of the reaction stays constant, 
with a change in the percentage of β-haematin formation, when changing the surface area of the reaction vessel. 
 
 
Figure 1.12 β-Haematin formation using various neutral lipids. The percentage yield of β-haematin formation 
using mono-, di- and tri-glycerides after 60 minutes incubation time. The monoglycerides show the highest 
yield of β-haematin formation, while the control reaction in which Fe(III)PPIX was incubated in pure aqueous 
medium, shows no yield. Reproduced with permission from reference 74. 





Furthermore, Hoang et al. reported the presence of homogeneous lipid particles, which are spontaneously 
organised into a lipid emulsion, near the interface, using fluorescence, confocal and TEM imaging, as well as 
dynamic light scattering analysis.74 β-Haematin crystals recovered from the lipid-water interface using MSG 
and MPG were confirmed by FT-IR spectroscopy, PXRD and TEM imaging. Further TEM images were 
obtained of Fe(III)PPIX-lipid samples after 10 minutes of incubation at the lipid-water interface (Figure 1.13), 




Figure 1.13 TEM images of β-haematin formed between the MSG-water (a-c) and MPG-water (e-g) interface 
after 10 minutes of incubation. β-Haematin crystals were observed aligned along the lipid-water interface (a 
and e), while clusters of β-haematin crystals are oriented parallel to each other and the lipid-water interface (b, 
c, e and f). Reproduced with permission from reference 74. 
 
In 2013, Ketchum et al. compared the crystallisation of β-haematin from haematin in an aqueous buffer, pH 
4.8, which is in agreement to the DV, to crystallisation in a water-saturated octanol solution, which is a mimic 
of a lipid nanosphere environment.75 Investigating their crystal morphologies by atomic force microscopy, it 
was shown that β-haematin crystals grown in the octanol-water system are similar to biological haemozoin 
extracted from parasites. The authors also commented on the higher solubility of haematin at the water-
saturated octanol interface compared to in the aqueous buffer, further suggesting that lipid bodies indeed play 
a role in facilitating haemozoin in vivo.75,76 More recently, the formation of a monolayer of a phospholipid 
membrane surrounding β-haematin has also been shown.77  





1.4.4 Proposed Mechanisms of Haemozoin Formation 
To truly explain the molecular mechanism of haemozoin formation and the structure of Fe(III)PPIX complexes 
with antimalarial inhibitors, it is import to understand the behaviour and structure of Fe(III)PPIX in different 
solutions. Owing to its varied speciation in solution, it is important to comprehend under which conditions 
Fe(III)PPIX is most favourable for β-haematin formation. 
Early studies on aqueous Fe(III)PPIX have recognised that the porphyrin self-associates in aqueous 
solution,78,79 and it was widely accepted that Fe(III)PPIX spontaneously forms a µ-oxo dimer, whereby the 
iron centres of neighbouring porphyrins are connected by an oxo (Fe-O-Fe) bridge. This hypothesis, believed 
for almost 40 years, was based on infrared spectroscopic data obtained for the solid precipitated from an 
alkaline solution by the addition of solid NaOH or 1 M NaOH, or from an alkaline DMSO solution.80 Brown 
et al. continued their research and further reported equilibrium constants for Fe(III)PPIX dimerization.81 In an 
attempt to verify these dimerization constants, de Villiers et al. showed that spontaneous dimerization of H2O-
Fe(III)PPIX and HO-Fe(III)PPIX leads to π-π complexes in aqueous solution, rather than a µ-oxo dimer.82 The 
π-π dimer is believed to form via a noncovalent interaction of the unligated face of the each porphyrin 
molecule, with the axial ligands pointing outwards (Figure 1. 14 (A, i)). The authors based their conclusion on 
both UV-visible and 1H nuclear magnetic resonance (NMR) spectra of aqueous Fe(III)PPIX, which are 
markedly different from those of the µ-oxo dimer.83,84 There is support in the literature for the formation of 
such π-π dimers given the reported X-ray crystal structures of Cl-Fe(III)PPIX85 and aqua-
iron(III)octaethylporphyrin,86 which themselves pack in the solid state as π-π dimers. Furthermore, it has been 
shown that solvent concentration, temperature, pH and the presence of salts have an effect on Fe(III)PPIX 
speciation in different solvent systems,87 however, from the study carried out by de Villiers et al., it is clear 
that the formation of the π-π dimer species predominates in aqueous solution and understanding this structure 
is of importance in unravelling the mechanism of haemozoin formation.82 
Molecular dynamics simulations have provided further insight into the possible molecular mechanism by 
which haemozoin may form at the lipid-water interface.73 Egan et al. carried out simulations of the interactions 
of a π-stacked dimer of H2O-Fe(III)PPIX in vacuum, and showed that the porphyrins rapidly reorganise to 
form a haemozoin precursor dimer (Figure 1.14 (B)), in which the positively charged iron centre of one 
Fe(III)PPIX molecule interacts with the negatively charged propionate group of the other.73 Following 
displacement of the axial water molecules from the iron centres, and simultaneous bond formation between 
the iron centre and the propionate groups, the formation of haemozoin (β-haematin) takes place. It is further 
speculated that in the absence of competing hydrogen bonding from water solvent molecules, hydrogen 
bonding between the haemozoin dimers will be induced, facilitating in the formation of the haemozoin crystal. 
However, in the presence of water molecules, and hence competing hydrogen bonding, the simulation showed 
that the haemozoin precursor dimer is unstable, with the propionate groups preferentially interacting with the 
solvent water molecules, rather than the neighbouring iron centre. The molecular dynamics simulations 
therefore further suggest that a lipid environment (specifically a low dielectric medium) will better promote 
haemozoin crystal formation, owing to the lower water concentration. 






Figure 1.14 Molecular dynamics simulation of the interaction of H2O-Fe(III)PPIX molecules. (A) The 
molecules were placed back-to-back as expected for a π-π dimer, with the propionate and propionic acid groups 
extended from the porphyrin core (i). In vacuo, the β-haematin precursor is rapidly formed (ii). In an aqueous 
environment, the precursor breaks down and the propionate groups interact with the solvent molecules (iii). 
Enlarged in (B), simulations suggest that the coordination of the propionate groups to the Fe(III) centre and 
the subsequent loss of an axial H2O ligand will yield the precursor dimer (left) to the β-haematin dimer (right). 
Reproduced with permission from reference 73. 
 
Based on the insight provided on Fe(III)PPIX π-π dimer species82 and molecular dynamics simulations in 
vacua,73 de Villiers et al. hypothesised how aqueous Fe(III)PPIX, in its π-π dimer form (Figure 1.15, 1), may 
be converted into haemozoin (β-haematin).88 The molecular dynamics simulations suggest that when 
Fe(III)PPIX enters a lipid environment, which is a low dielectric medium, it forms an intermolecular 
haemozoin precursor dimer molecule (Figure 1.15, 2), which may convert to a haemozoin dimer by reciprocal 
coordination of the iron centre with the propionate groups and displacement of water ligands (Figure 1.15, 3). 
Upon hydrogen bonding between haemozoin dimers, the haemozoin crystal is formed (Figure 1.15, 4). 
In 2009, de Villiers et al. investigated the orientation of β-haematin crystals nucleated by MMG on the water 
surface using grazing incidence synchrotron X-ray diffraction (GIXD).89 The authors showed that β-haematin 
nanocrystals, prepared from premixed haematin with MMG, were orientated with the (100) face parallel to the 
water surface. They explained this observation in that the methanol-acetone-aqueous NaOH spreading solution 
allowed molecular aggregation of MMG into clusters, exposing the OH groups and oxygen lone-pair electrons 
that interact with the respective haematin molecules. These interactions induced oriented β-haematin 
formation, with crystal growth predominantly taking place in one dimension along the c-axis89 






Figure 1.15 Schematic representation of the proposed route of haemozoin (Hz) formation.88 The aqueous π-π 
dimer (1) enters the lipid environment and forms the haemozoin precursor (2), which goes on to form the 
haemozoin dimer (3) by the reciprocal coordination of the propionate groups with the Fe(III) centre and the 
displacement of H2O ligands. Upon hydrogen bonding between the dimers, the haemozoin crystal (4) is 
formed. Adapted from reference 88. 
 
1.5 Quinoline Antimalarial Drugs 
 
1.5.1 Site of Drug Action 
As mentioned in section 1.3.1, clinically known symptoms that are related to malaria infection are associated 
with the blood stage (intraerythrocytic stage) of the malaria parasite’s life cycle. While residing inside the host 
RBCs, P.falciparum may be exposed to antimalarial drug action at multiple stages, of which the potential 
targets for drug action have been broadly classified into three categories by Olliaro et al.27 The categories 
include (1) processes arising in the DV of P.falciparum, including haem detoxification and haemoglobin 
digestion; (2) enzymes involved in metabolite and macromolecular synthesis; and (3) those responsible for 
membrane processes and signalling. Several studies have drawn focus to processes occurring in the DV. Saliba 
et al. confirmed the involvement of the DV of the parasite in the mechanism of CQ resistance, by showing that 
CQ-resistant (CQR) strains have a decreased CQ accumulation in comparison to CQ-sensitive (CQS) strains.90 
CQ and other quinoline antimalarial drugs have been shown to be active against the trophozoite stage of the 
parasite life cycle,91 while Yayon et al. demonstrated the accumulation of CQ in malaria-infected erythrocytes 
by fluoromicroscopic examination.92 Overall, the most likely drug targets in the DV of the parasite are the 
interruption of either haemoglobin degradation or haematin detoxification, resulting in the death of the parasite 
in either case. 
The quinoline antimalarial drugs accumulate in the DV by a mechanism known as pH trapping.49 In their 
neutral weak base form, quinoline antimalarial drugs are able to traverse the lipid membrane and enter the 
acidic environment of the DV, where the drugs are protonated and become membrane-impermeable. The result 







































1.5.2 History and Discovery of Quinoline Antimalarial Drugs 
The most successful and effective antimalarial drugs that have been used to date include the quinoline-based 
and related drug compounds; CQ, amodiaquine (AQ), quinidine (QD), quinine (QN), mefloquine (MQ) and 
halofantrine (Hf) (Figure 1.16).  
 
 
Figure 1.16 Molecular structures of several quinoline (CQ, AQ, QD, QN and MQ) and phenanthrene (Hf) 
antimalarial drugs. 
 
For hundreds of years prior to understanding the mosquito or the malaria parasite life cycle, a herbal treatment, 
from Cinchona bark, was used to treat malaria.94 In 1820, Pierre Pelletier and Joseph Caventou, two French 
chemists, were the first to isolate the pure alkaloids QN and cinchonine from the Cinchona bark.95 From the 
1940s, QN became the standard therapy for malaria-related fever worldwide, with the Dutch plantations of 
Java producing 97% of the world’s supply of QN.96,97 After the high demand of QN in World War I and 
especially in World War II, the Japanese takeover of Java saw the need for new antimalarial drugs to increase 
radically, which led to great research efforts by British and German scientists to develop alternative 
Chloroquine (CQ) Amodiaquine (AQ)
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treatments.98 The first attempts in preparing synthetic antimalarials included the design of 8-aminoquinolines; 
plasmaquine (pamaquine) and primaquine, followed by the design of several 4-aminoquinolines, of which CQ 
was to be the most important.98,99 CQ is recognized historically as the most effective antimalarial drug, owing 
to its efficacy, affordability and low toxicity.94 AQ was, however, soon introduced as an alternative to CQ, 
owing to the widespread resistance against CQ since the 1960s, and is still used in some cases today for the 
treatment of uncomplicated malaria.98,99 In the mid-1970s, another synthetic derivative of QN, MQ (Larium), 
a quinoline methanol compound, was introduced with potent antimalarial activity,100,101 and has proven to be 
an effective antimalarial, especially against CQS strains of malaria.102,103 
 
1.5.3 Quinoline Antimalarial Drug Resistance 
A great deal of research has focussed on the development of new and effective antimalarial drugs, owing to 
the great increase in the appearance of drug resistance to clinically-relevant antimalarial drugs. 
As mentioned above, a diprotic weak base such as CQ can be driven across the DV membranes of the parasite 
in its unprotonated form, by a pH gradient, to accumulate within the DV. It is believed that the resistance to 
CQ in P. falciparum is associated with an increased ability for the parasite to eject CQ out of the DV at a rate 
that does not allow CQ to reach the required levels needed for the inhibition of haemozoin formation.104 
Krongstad et al. investigated the reduced uptake of CQ and showed that this CQ efflux occurs at a rate of 40 
to 50 times faster in CQR parasites than in CQS parasites.105 The rapid efflux of CQ out of the DV of CQR 
parasites, compared to CQS parasites, may be accounted for by a possible enhanced permeation pathway for 
CQ across the DV membrane,93 possibly through a channel, or via active transportation across the membrane, 
since the pH gradient across the DV membranes of both the CQR and CQS parasite shows no significant 
difference.19 
Furthermore, at a molecular level, it has been shown that CQ resistance is related to mutations in two genes 
that encode transmembrane proteins. The 424 amino acid transmembrane protein, P. falciparum CQ-resistance 
transporter (PfCRT), which is located on the surface of the DV, is coded for by the gene pfcrt on chromosome 
7.106 A mutation at position 76 in the amino acid sequence of the protein (K76T), is associated with the CQR 
strain.107 In this mutation, the lysine α-amino acid (K) is replaced by the threonine α-amino acid (T). P. 
falciparum multidrug resistance gene 1 (Pfmdr1), located on chromosome 5, is another DV transporter protein 
which is associated with drug resistance, and encodes P-glycoprotein homologue 1 (Pgh1).108 Cowman et al. 
demonstrated that resistance to QN, MQ and HF is caused by an over-expression of Pgh1.109 Ferdig et al. 
showed that even though the mechanism for QN resistance is poorly understood, it is also associated to P. 
falciparum sodium proton exchanger (pfnhe-1).110 At first the exact mechanism of CQ resistance by mutated 
PfCRT proteins was not definitively understood, however, Sanchez et al. later proposed that PfCRT acts either 
as a channel, allowing CQ to passively move out of the DV via an electrochemical gradient, or as a transporter, 
in which CQ is actively transported out of the DV.93 





P. falciparum is one of the most well-known human pathogens that repeatedly encounters drug pressure and 
within-host competition among different malaria parasite strains.111 Fidock and co-workers have been 
investigating the role of PfCRT in antimalarial drug resistance over the last few years. Results show that PfCRT 
variants can affect parasite fitness, alter P. falciparum vulnerability to current therapies and protect immature 
gametocytes against CQ drug action, and these authors have subsequently investigated the selection and 
dissemination of geographically diverse halotypes (a set of DNA variations) of PfCRT genetically.111,112 
 
1.5.4 Proposed Mechanisms of Antimalarial Drug Action 
It is known that the quinoline antimalarial drugs CQ, AQ, QD, QN and MQ inhibit the formation of β-haematin 
under various conditions.59,51,113,114,115 The exact mechanism of action of these antimalarial drugs is, however, 
not entirely understood and substantial research has been devoted to understand this phenomenon. To date, 
two main hypothesis exist regarding the mechanism by which inhibition occurs. It has been suggested that 
antimalarial drug compounds form complexes with free Fe(III)PPIX in the aqueous solution of the DV of the 
parasite, either via π-stacking or coordination, preventing the conversion of Fe(III)PPIX into β-
haematin.116,117,118 Early studies demonstrated that nitrogen-containing compounds and nitrogen-donor ligands 
are able to complex with Fe(III)PPIX species.78,119,120 Alternatively, the other hypothesis proposes that drugs 
adsorb onto the fastest growing crystal face (001) of β-haematin, impeding further growth.39,114 Owing to the 
diverse speciation of Fe(III)PPIX (as a monomer, µ-oxo dimer , π-π dimer or cyclic dimer precursor for the 
formation of haemozoin formation),87 the possible drug interactions with Fe(III)PPIX which could be of 
importance in antimalarial drug action are endless. Investigating quinoline drug-Fe(III)PPIX complexes is one 
way of understanding their mode of action. 
 
1.5.4.1 Drug-Fe(III)PPIX Complexation 
Drug complexes with free Fe(III)PPIX are proposed to prevent the formation of haemozoin and possibly 
influence the overall toxicity within the parasite, leading to its overall death. The exact structures of the 4-
aminoquinoline and quinoline methanol drug complexes have been widely debated and resolving these 
structures has been of great interest. Recently, the structures of the complexes of several quinoline methanol 
drugs and Fe(III)PPIX have been resolved. On the other hand, there is great controversy with respect to the 
proposed structure of 4-aminoquinoline complexes, such as CQ-Fe(III)PPIX. 
 
1.5.4.1.1 Quinoline Methanol Complexes with Fe(III)PPIX 
In 2008, de Villiers et al. reported the first crystal structure of a Fe(III)PPIX complex with an antimalarial 
drug.88 The structure of the coordination complex formed between Fe(III)PPIX and Hf was determined using 





SCD and shows coordination of Hf to the iron centre of the Fe(III)PPIX through the deprotonated aryl alcohol 
functionality of Hf, along with π-stacking of the phenanthrene ring over the porphyrin, resulting in a five-
coordinate complex (Figure 1.17 (a)). Intermolecular hydrogen bonding between the propionate group of 
Fe(III)PPIX and the protonated nitrogen atom of Hf, as well as hydrogen bonding between the same propionate 
group and the propionic acid group of the neighbouring Fe(III)PPIX molecule also occurs. The structure further 
shows that Fe(III)PPIX is a monomer, rather than a µ-oxo dimer, in its interaction with Hf, and the length of 
the Fe  ̶O bond is consistent with the length of an Fe-alkoxide bond.121,122,123  
Furthermore, owing to structural resemblances between Hf and the quinoline methanol antimalarial drugs, QD 
and QN, de Villiers et al. carried out an in vacuo molecular mechanics modelling investigation of the 
complexes of QD and QN, and their respective inactive epimers, 9-epiquinidine (EQD) and 9-epiquinine 
(EQN) with Fe(III)PPIX.88 The comparable spectral changes observed when titrating Fe(III)PPIX with Hf and 
QD free bases in acetonitrile, respectively, provided qualitative support for their above reasoning and 
suggested homologous coordination in Hf and QD. The molecular mechanics modelling proposed that the 
formation of the haemozoin precursor dimer may be prevented by the formation of an important intramolecular 
salt bridge between the protonated quinuclidine tertiary amino group and the unprotonated haem propionate 
group. The theoretical studies further indicated that the formation of the salt bridge is readily permitted by QD 
and QN, which can adopt the required lower energy conformations. 
On the contrary, this was not the case for EQD and EQN. It has previously been shown that QD, QN, EQD 
and EQN associate with Fe(III)PPIX in an aqueous environment, allowing Fe(III)PPIX to exist as a π-π dimer 
(through its unligated faces).118 The authors thus further proposed that as the association complexes of the 
inactive isomers enter the lipid environment, haemozoin precursor dimer formation dominates complex 
formation, due to their inability to form the salt bridge, allowing normal haemozoin formation to continue. On 
the other hand, when complexes of the active isomers enter the lipid environment, the salt bridge forms and 
therefore interrupts haemozoin precursor dimer formation, which in turn impedes haemozoin formation.88 The 
inhibition of haemozoin formation via the interaction of the Cinchona alkaloids with monomeric Fe(III)PPIX 
is in agreement with previous studies.124,125 
Structural evidence in support of the hypothesis discussed above was recently obtained. Importantly, the crystal 
structures of complexes formed between Fe(III)PPIX and the two Cinchona alkaloids, QD and QN, 
respectively, were determined by means of SCD (Figure 1.17 (b and c)).126 The crystal structures confirm the 
formation of five-coordinate complexes between QD and QN with Fe(III)PPIX, respectively, through their 
benzylic alcohol functional group and the length of the Fe-O bond is also consistent with that of the length of 
an Fe-alkoxide bond, rather than an alcohol.88 The crystal packing in both complexes indicates additional π-
stacking between the unligated faces of Fe(III)PPIX of neighbouring alkaloid-Fe(III)PPIX moieties. The offset 
π-π dimerization is consistent with the Fe(III)PPIX speciation expected in aqueous82 and aqueous methanol 
solutions.87 Intermolecular hydrogen bonding between Fe(III)PPIX propionic acid side chains and propionate 
groups, allows the interaction of neighbouring π-π dimers. The authors further discussed that additional 
stability in the alkaloid complexes is provided by the intramolecular hydrogen bond which is observed between 





the protonated quinuclidine nitrogen atom of each alkaloid and a propionate side chain of Fe(III)PPIX. It is 
proposed that these interactions, namely coordination, π-stacking and intramolecular hydrogen bonding, may 
be responsible for preventing the conversion of Fe(III)PPIX into haemozoin. 
 
 
Figure 1.17  The single crystal X-ray diffraction structures of (a) Hf-Fe(III)PPIX, (b) QD-Fe(III)PPIX and (c) 
QN-Fe(III)PPIX. For (a) thermal ellipses are drawn at 50% probability and for (b and c) solvent molecules are 
omitted and hydrogen bonds are shown red dashed lines. Atom colour coding: C – grey, H – white, Cl – lime 
green, F – Prussian blue, Fe – cyan, N – blue and O – red. Reproduced with permission from reference 88 and 
126. 
 
Most recently, Gildenhuys et al. determined the crystal structure of the complexes formed between racemic 
erythro MQ and Fe(III)PPIX using SCD, and showed that alkoxide coordination is an important interaction in 
the solid state.127 
 
1.5.4.1.2 4-Aminoquinoline Complexes with Fe(III)PPIX  
The main focus of 4-aminoquinoline-Fe(III)PPIX complexes has been on CQ. Early spectrophotometric 
studies by Cohen et al. in 1964 were the first to qualitatively provide evidence of a CQ-Fe(III)PPIX complex 
in solution,116 and interest in the CQ-ferrihaem complex remains high, even today. To date, various studies 
have suggested different structures of the CQ-Fe(III)PPIX complex. In 2003, De Dios et al. proposed that CQ 
coordinates to the iron centre of monomeric Fe(III)PPIX via its quinolinyl nitrogen atom to form a covalent 
complex (Figure 1.18 (a)).128 The authors proposed the structure on the basis of solid state nuclear magnetic 
resonance (NMR) spectra of acid-precipitated CQ-Fe(III)PPIX aggregates formed in an aqueous solution. 
NMR inversion recovery experiments by Leed et al., followed by the studies of Natarajan et al. a few years 
later, suggested that CQ rather forms a non-covalent complex in solution with the µ-oxo dimer of Fe(III)PPIX 
via π-stacking with the outer unligated face of Fe(III)PPIX (Figure 1.18 (b)).129,130 It was suggested that CQ-
Fe(III)PPIX complex was stabilised through these π-π interactions between the tetrapyrrole region of the 
porphyrin and the aromatic rings of CQ. Furthermore, Schwedhelm et al. proposed that two CQ drug molecules 
π-stack with the outer faces of a Fe(III)PPIX tetramer adduct, in which the two µ-oxo Fe(III)PPIX dimers are 
coordinated through neighbouring iron centres and propionate side chains (Figure 1.18 (c)).131 Later, using 
excitonic Raman enhancement, Webster et al. suggested that CQ drug molecules acts as molecular spacers 
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which bind noncovalently to the unligated faces of µ-oxo dimeric Fe(III)PPIX aggregates via π-π interactions 
and dispersion forces (Figure 1.18 (d)).132 This has also been suggested by Morau et al., using NMR 
spectroscopic studies.133 Recently, Acharige and Durrant showed using quantum mechanical calculations that 
CQ may form hydrogen bonds via its 4-amino substituent group and tertiary amine to the axial ligand and 
propionate side chains of Fe(III)PPIX, respectively (Figure 1.18 (e)).134 It is clear from these findings that there 
is no consensus regarding the CQ-Fe(III)PPIX complex structure in solution, resulting in much controversy. 
 
 
Figure 1.18 Proposed structures of CQ-Fe(III)PPX complexes. (a) CQ coordinated to monomeric 
Fe(III)PPIX,128 (b) CQ π-stacked to µ-oxo Fe(III)PPIX dimer,129,130 (c) two CQ molecules π-stacked to µ-oxo 
Fe(III)PPIX tetramer adduct,131 (d) CQ molecules π-stacked between µ-oxo Fe(III)PPIX dimers132,133 and (e) 
CQ hydrogen-bonded to Fe(III)PPIX.134 Reproduced with permission from reference 135. 
 
Most recently, Kuter et al. undertook a computational investigation of the CQ-Fe(III)PPIX complex structure, 
in which they probed two possible conformations of the complex using molecular dynamics (MD) 
simulations.135 In light of previous studies suggesting that CQ induces µ-oxo dimer formation,129,136 two CQ-
[µ-oxo-Fe(III)PPIX] complexes were considered. The first structure was similar to previously 
discussed,129,130,133 in which CQ π-stacked over the unligated face of the µ-oxo dimer (Figure 1.18 (b)). This 
structure is referred to as the π-stacked model. The second structure was novel, in that the CQ molecule is 
positioned between the two porphyrin rings with the protonated quinolinium nitrogen atom facing towards the 
bridging oxide ligand (Figure 1.19 (a)).135 This structure is referred to as the docked model. Subsequent 
experimental EXAFS spectra, as well as magnetic and infrared spectroscopic data, most importantly the 











suggesting that the CQ drug molecule docks between the porphyrin rings of µ-oxo Fe(III)PPIX in aqueous 
solution. The authors further indicated that important interactions between CQ and the µ-oxo Fe (III)PPIX 
dimer in the docked model of the CQ-[µ-oxo-Fe(III)PPIX] complex can be observed (Figure 1.19(b)). 
Intermolecular hydrogen bonds are formed between the protonated quinolinium nitrogen atom of CQ and the 
oxide bridge of µ-oxo Fe(III)PPIX (i), while π- π interactions are formed between the porphyrin ring system 
and the quinoline ring of CQ (ii). Hydrogen-chlorine contacts are also observed between the methyl hydrogen 
atoms of the porphyrin ring system (yellow) and the 7-chloro substituent of CQ (green) (iii).135 
 
 
Figure 1.19 Model of the (a) docked CQ-Fe(III)PPIX complex simulated in the MD study. (b) Important 
interactions between CQ and the µ-oxo Fe(III)PPIX dimer in the docked model of the CQ-[µ-oxo-Fe(III)PPIX] 
complex. Reproduced with permission from reference 135. 
 
1.5.4.2 Quinoline Interactions with Haemozoin 
An alternative hypothesis regarding the inhibition of β-haematin formation is the direct interaction between 
the antimalarial drug and the fastest growing surface of β-haematin crystals. 37,39,114 In 1996, Sullivan et al. 
detected CQ in close association with haemozoin crystals in a study in which they investigated the distribution 
of [3H]-labelled CQ inside parasitized RBCs, using electron microscope autoradiography (Figure 1.20 (a)).114 
The authors further showed that in vitro, binding of the [3H]-labelled quinoline inhibitor to the haemozoin 
crystal strongly depends on the addition of haem substrate, which they suggested pointed to a haem-quinoline 
complex being incorporated into the growing haemozoin to impede further haemozoin formation (Figure 1.20 











Figure 1.20 (a) An electron microscope autodiograph of [3H] CQ distribution in the digestive vacuole. There 
is direct overlap with the haemozoin crystals. (b) Proposed model for the inhibition of haemozoin formation. 
The incorporation of the haem-quinoline complex into growing haemozoin, thought to be a polymer at the 
time. The capping was thought to prevent further elongation. Reproduced with permission from reference 114. 
 
A few years later, Buller et al. identified the fastest growing β-haematin crystal face (001), and subsequently 
showed theoretically that quinoline antimalarial drugs are able to bind into crevices created at this face and are 
stabilised by exposed functional groups of Fe(III)PPIX (Figure 1.21 (a)).39 These functional groups include 
methyl and vinyl groups, propionic acid and aromatic surfaces (running parallel to the a-axis). When CQ 
(monoprotonated) is bound to the (001) β-haematin crystal face, energetically-favourable hydrogen bonding 
interactions include Cldrug···H3Cporphyrin (3.0 Å), Ndrug···HC=Cporphyrin (2.4 Å), NHdrug···O2Cporphyrin (2.7 Å) and 
NHdrug···C=Cporphyrin (2.7 Å) (Figure 1.21 (b)). Once adsorbed, the authors proposed that CQ is more tightly 
bound within the crevices than QN, owing to the exocyclic amine chain of CQ being longer and more flexible 
than that of QN. The authors were able to compare the antimalarial activity of the various quinolines to their 
theoretical surface binding sites to the (001) face.  
More recently, similar structural aspects were observed when Dodd et al. demonstrated that CQ is able to form 
a complex with the Gallium(III) protoporphyrin IX µ-propionato dimer ([Ga(III)PPIX]2) in both methanol 
solution and solid state.137 The structure of the CQ-Ga(III)PPIX reciprocal dimer complex provides a structural 
model for the haem-drug interaction of CQ and a µ-propionato dimer of Fe(III)PPIX as observed in haemozoin 
(outlined in grey dashed line (b)). The crystal structure of [Ga(III)PPIX]2 (Figure 1.21 (c)), determined by 
crystallography, reveals a six-coordinate metal centre, with CQ forming hydrogen bonds to both  the axial 
methoxide ligand and the propionate side chain through the quinolinyl nitrogen atom and the tertiary amino 
group, respectively. When the Fe(III) centre of Fe(III)PPIX in aqueous solution is in a low spin state with a 
water molecule as the sixth ligand, the authors further proposed a similar complex structure may form between 
CQ and Fe(III)PPIX, as that of [Ga(III)PPIX]2.137 However, the existence of a CQ-(µ-propionato-Fe(III)PPIX) 
complex as the dominant species in specifically an aqueous solution is much less certain.138,139 The structure 
does, however, provide experimental evidence of the interaction that are likely within the binding pocket on 
the crystal surface. There, the unligated face of the Fe(III)PPIX µ-propionato dimer is exposed to the inhibitor, 












Figure 1.21 β-haematin crystal capping. (a) A model of β-haematin viewed along the a-axis, showing exposed 
propionic acid, aromatic surfaces, vinyl and methyl groups at the (001) face. The crevices outlined in green, 
are binding sites proposed for quinoline antimalarial drugs. Quinolines are able to dock into the grooves. (b) 
CQ bound to the (001) β-haematin crystal face along the a-axis. Reproduced from reference 39. (c) The crystal 
structure of [Ga(PPIX)(OMe)(CQ)]2. A propionate bridged dimer is generated by inversion symmetry of the 
two CQ enantiomers which are hydrogen bonded to the propionate carboxylate. Reproduced with permission 
from reference 137. 
 
1.5.4.3 The Inhibition of β-Haematin Formation 
1.5.4.3.1 Pyridine Hemichrome Inhibition of β-Haematin (Phiβ) Assay 
A large amount of literature has shown the ability of quinoline antimalarial drugs and related compounds to 
inhibit β-haematin formation.59,51,115,114 In light of these observations and evidence suggesting that the 
inhibition of haemozoin formation is the most probable target of antimalarial drugs, the discovery of new 
antimalarial compounds has been of great interest. One of the main approaches in discovering such compounds 
is the development of assays to screen compounds for β-haematin inhibitory activity.  
Since the earliest measurement of the inhibition of β-haematin formation in 1992 by Slater and Cerami,115 
numerous approaches to detecting and measuring β-haematin inhibition have been developed,140,141,142,143,144 
most of which had several disadvantages for high-throughput screening. Owing to this, Ncokazi and Egan 
developed a reliable, fast and cheap colorimetric pyridine (ferri)hemichrome inhibition of β-haematin (Phiβ) 
assay, which is based on the solubilisation of free Fe(III)PPIX by 5% (v/v) aqueous pyridine pH 7.5.145 The 
interaction of pyridine with free haem results in the formation of a characteristic orange-pink monomeric low-
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spin bis-pyridyl complex in solution (Figure 1.22 (a)), which can be monitored at an absorbance maximum at 
405 nm, which allows quantitation of the percentage free Fe(III)PPIX in a Fe(III)PPIX-β-haematin mixture. 
With increasing pyridine concentration, the authors showed that the broad and relatively weak Soret band of 
the aqueous Fe(III)PPIX π-π dimer species at 389 nm displays a red shift to a longer wavelength of 404 nm 
(Figure 1.22 (b)). The sharper and more intense peak is an indication of monomerisation of the iron porphyrin, 
which together with the other spectroscopic changes at longer wavelengths, are consistent with the 
coordination of two pyridine ligands to the iron centre of the porphyrin (pyr-Fe-pyr). The pyridine molecules 
displace the axial water molecule of 5-coordinate haematin and form a low-spin complex.119 It was importantly 
noted that conditions under which pyridine only reacts with Fe(III)PPIX, rather than β-haematin, should be 
investigated. The authors found that pure pyridine and strongly basic aqueous pyridine solutions decompose 
β-haematin to form a Fe(III)PPIX-pyridine complex, while neutral or mildly basic aqueous solutions 
containing 5-10% (v/v) pyridine (pH 7.5) do not react with β-haematin. 
 
 
Figure 1.22 Interaction of pyridine with Fe(III)PPIX. (a) A schematic of the low-spin bis-pyridyl complex of 
Fe(III)PPIX in 5% (v/v) aqueous pyridine solution. (b) The effect of increasing pyridine on the spectrum of 
Fe(III)PPIX in aqueous solution indicates a red shift in the Soret band. The arrows indicate the direction of 
change as the pyridine concentration is increased. The spectral changes are consistent with coordination of two 
pyridine ligands to the iron centre of Fe(III)PPIX. Reproduced with permission from reference 145. 
 
The Phiβ assay was subsequently used in the study to quantify the inhibition of β-haematin formation by 
quinoline antimalarials and related compounds. The Phiβ assay is now routinely used to identify β-haematin 
inhibitors (Figure 1.23), where a more intense orange-pink colour is a result of greater quantities of unreacted 
Fe(III)PPIX, indicating greater β-haematin inhibitory activity by test compounds.145 The absorbance data 
obtained from the Phiβ assay can further be manipulated in order to reflect the percentage β-haematin formed 



















Figure 1.23 An example of a 96-well plate in which 47 compounds were screened for their ability to inhibit 
β-haematin formation using the Phiβ assay. 5% (v/v) aqueous pyridine (pH 7.5) was used to quench the reaction 
in order for the β-haematin inhibitors to be identified by direct visual inspection (orange-pink colour). 
Reproduced with permission from reference 145. 
 
1.5.4.3.2 The Effect of Quinoline Antimalarial Drugs on the Kinetics of β-Haematin Formation 
Despite the knowledge that antimalarial drugs are able to inhibit β-haematin formation, little is known about 
the effect of quinoline antimalarial drugs and related compounds on the kinetics of the growth process. 
Previous studies reported only the effects of quinoline antimalarials on Fe(III)PPIX crystal growth at fixed 
time points.141,146,147,148 In an attempt to study the kinetics of Fe(III)PPIX crystal growth, Chong and Sullivan 
developed a spectrophotometric high-throughput β-haematin crystal growth determination assay which is 
based on the differential solubility of free Fe(III)PPIX versus crystalline Fe(III)PPIX.149 They found that the 
inhibition of Fe(III)PPIX crystal growth is reversible in the presence of both CQ and QD, and that the activity 
of the inhibiting compounds decreases at longer time periods, suggesting that the IC50 value of a compound, 
which is the concentration at which β-haematin is inhibited by 50%, is dependent on incubation time. 
In 2005, Egan and Ncokazi150 confirmed the observations made by Chong and Sullivan149 by investigating the 
inhibition of β-haematin formation in the presence of quinoline antimalarial drugs CQ, AQ, QD and QN. β-
Haematin formation was brought about using 4.5 M acetate, pH 4.5 at 60 °C and the unreacted haematin was 
monitored using the Phiβ assay. A decrease in absorbance of the Fe(III)PPIX-pyridine complex at 405 nm was 
observed in the presence of both CQ and QN as a function of time (Figure 1.24 (a)). Infrared spectroscopy and 
XRD were used to confirm that the decrease in absorbance indeed corresponds to β-haematin formation. The 
authors thus found that β-haematin was able to form in the presence of the antimalarial drugs, albeit at longer 
incubation times. This suggests that the compounds act by decreasing the rate of β-haematin formation, rather 
than inhibiting the process overall.150 A sigmoidal dependence of β-haematin formation on drug concentration 
was observed (Figure 1.24 (b)) and is based on β-haematin formation taking place in three stages; namely 
induction/nucleation, growth/propagation and termination. The authors further indicated the importance of 
incubation time on the inhibitory activity of the quinoline antimalarial drugs.  






Figure 1.24 Inhibition of β-haematin formation by CQ and QN. (a) The absorbance values observed at 405 
nm in the presence of CQ (●) and QN (■) at various incubation times. The experimental data predicts first-
order rate constants. The decrease in absorbance is ascribed to β-haematin formation. (b) The dose-response 
curve for the inhibition of β-haematin formation by CQ. Reproduced with permission from reference 150. 
 
In both independent kinetics studies discussed above, β-haematin formation was brought about in the presence 
of acidic acetate buffers, either at high incubation temperatures or long incubation periods. Previous kinetics 
studies performed in model-lipid mixtures, however, have returned biologically relevant half-life values for 
the formation of β-haematin.73,74,151 Recently, Gildenhuys et al. carried out a detailed kinetics investigation on 
the formation of β-haematin in the presence of CQ, and QD40, and subsequently, AQ and QN.152 In contrast to 
previous kinetics studies, they made use of biomimetic lipid emulsion conditions (pH 4.8, 37 °C) to mediate 
β-haematin formation. The experimental procedure was performed in 15 mL Falcon centrifuge tubes, which 
was overall time-consuming. However, in studying the effects of quinoline antimalarial drugs on the kinetics 
of β-haematin formation at a lipid-water interface, the authors found that there is a decrease in the rate at which 
β-haematin is formed at low drug concentrations, while a decrease in the final yield of β-haematin is observed 
at high drug concentrations (Figure 1.25).  
 





















Figure 1.25 The effect of chloroquine on the kinetics of β-haematin formation. Differences in the rate of β-
haematin formation are observed for increasing drug concentrations at low concentrations (black to red) with 
the same yield of β-haematin forming. At high drug concentrations (maroon), a decrease in the final yield of 
β-haematin is observed. Reproduced with permission by reference 40. 
(a) (b)





In order to verify that the observed decrease in absorbance measured as a function of time is indeed caused by 
the formation of β-haematin, and not the formation of an unknown aggregate of Fe(III)PPIX or a Fe(III)PPIX-
drug complex, they used infrared spectroscopy and PXRD to confirm β-haematin formation in the presence of 
CQ and QD.152  
In order to further account for the observed effects of the quinoline antimalarial drugs on the rate and yield of 
β-haematin formation, Gildenhuys et al. derived their own theoretical model to explain these observations 














}  (Eq. 1.2) 
 
In the above equation, the percentage β-haematin formation depends on various parameters. Y represents the 
fractional yield of β-haematin formation expected in the MPG lipid-mediated system at any given 
concentration, since MPG is unable to convert Haq into β-haematin with an 100% yield.74 z is the rate of β-
haematin formation in the absence of an inhibitor, while k2 is the rate of a proposed irreversible precipitation 
of an inhibitor-haematin complex. [I] is the inhibitor concentration used in each individual experiment and Kads 
is the adsorption equilibrium constant that represents the strength of adsorption of each inhibitor to the fastest 
growing face of β-haematin crystals. The theoretical kinetics model is dependent on time and the amount of 
free sites available for continued β-haematin crystal growth. For the full derivation of the kinetics model, the 
reader is kindly referred to reference 40 and 152. 
The authors hypothesized that β-haematin crystal growth is the rate-determining process, and therefore the rate 
of β-haematin formation would be expected to depend on the rates of crystal nucleation and growth, 
respectively. In light of this, they developed this crystal growth kinetic model. Based on the hypothesis that 
antimalarial drugs are able to adsorb onto the fastest growing face of β-haematin crystals in order to impede 
further growth, an idea originally put forward by Leisorowitz and co-workers39,153 as a proposed mechanism 
for the inhibition of β-haematin formation, a mechanistic explanation of the effect of antimalarial drugs on the 
rate of β-haematin formation was considered (Scheme 1). The processes shown in the scheme account for the 
parameters included in the theoretical kinetics model (Equation 1.2). 
In Scheme 1, the growth of β-haematin crystals, βH(s), proceeds as free haematin, H(aq), is incorporated at free 
surface binding sites, S, with z, the rate constant of β-haematin formation (i). In the presence of an inhibitor, 
I(aq), this process is slowed down, since the inhibitor now competes with free haematin for the free sites. This 
is considered to be a reversible adsorption process since the drug adsorbs and desorbs to the crystals with Kads 
as the equilibrium adsorption constant, which indicates the strength of adsorption of each inhibitor (ii). When 
present in high concentration, an inhibitor may show preference to bind to free haematin to form a precipitated 
inhibitor-haematin complex, IH(s), therefore preventing the inclusion of free haematin into β-haematin. This 





latter process results in a decrease in the yield of β-haematin formation, with k2 being the rate constant of the 
precipitation reaction. It is proposed that zobs is expected to dominate k2 at low drug concentrations, however, 
at relatively higher concentrations, k2 is expected to have an influence and cause the observed decrease in the 
overall yield of β-haematin. 
 
 
Scheme 1 The proposed kinetic model to explain the effect of quinoline antimalarial drugs on the rate and 
yield of β-haematin formation. Free Fe(III)PPIX, H(aq), competes for the free surface binding sites, S, in the 
presence of an inhibitor, Iaq. The formation of β-haematin, βH(s), (i) thus slows down by the adsorption of an 
inhibitor onto the β-haematin crystal surface, IS(s), in a reversible adsorption process with an adsorption 
equilibrium constant, Kads (ii). In the presence of high inhibitor concentrations, the inhibitor may show 
preference to bind to free Fe(III)PPIX, forming a precipitated inhibitor-Fe(III)PPIX complex, IH(s) with a rate 
constant k2. Adapted from reference 40 and 152. 
 
Using the Avrami equation (Equation 1.1), which has been used to model crystallisation processes as 
previously described in section 1.4.3.1, the observed exponential kinetics were modelled. In previous studies 
in which β-haematin formation was brought about in an acetate buffer medium, the kinetics of formation 
appeared to exhibit a sigmoidal time dependence, with the Avrami constant (n) equal to 4, indicating sporadic 
nucleation and crystal growth in three dimensions.64 The yield of β-haematin in the lipid-mediated system as 
a function of time, however, was shown to display an exponential dependence. This too can be accounted for 
by the Avrami equation (Equation 1.1), however, with the Avrami constant equal to 1. In this case, the equation 
becomes mathematically indistinguishable from that of first order kinetics. As mentioned before, when the 
Avrami constant is equal to 1, β-haematin formation involves a fixed number of preformed nuclei and crystal 




















with the long needle-like morphology of β-haematin crystals observed in previous studies.155,156 In the crystal 
growth kinetic model, adsorption of an inhibitor onto the growing face of β-haematin crystals is reminiscent 
of adsorption predicted by the Langmuir isotherm, where the extent of monolayer coverage of a solid surface 
by an adsorbent gas molecule is related to the partial pressure of the absorbent. In this case, however, the 
degree of adsorption, θ, is dependent on the concentration of the drug in solution, [I], and Kads is the adsorption 





     (Eq. 1.3) 
 
Using the kinetic model represented by equation 1.2, the kinetics of β-haematin formation in the absence and 
presence of an inhibitor may be predicted, and are found to adhere to exponential behaviour (Figure 1.26). It 
is observed that the final yield of β-haematin remains almost constant at low drug concentration, however, 













Figure 1.26 The kinetics profile of β-haematin formation predicted by the kinetic model (Eq. 1.2) in the 
absence (black line) and the presence of increasing inhibitor concentration (grey lines). The trace obtained in 
the presence of the highest inhibitor concentration is shown in purple. Adapted from reference 40 and 152. 
 
Furthermore, according to the adsorption model, at drug concentrations where Langmuir adsorption is likely 
to dominate (Equation 1.4), it is predicted that a plot of the inverse of zobs, the observed rate constants, as a 
function of increasing drug concentration will be linear at low concentrations (Figure 1.27). Linear regression 
in this region allows the rate constant of β-haematin formation in the absence of an inhibitor, z, as well as Kads, 
to be determined from the y-intercept (y0) and slope values, respectively (Equation 1.5 and 1.6) 
 

























Figure1.27 The plot of the inverse of the observed rate constants, zobs, as a function of increasing inhibitor 
concentration (purple line, fitted to Eq. 1.4), is predicted to be linear at low concentrations (black line). Linear 










     (Eq. 1.6)
 
The kinetic model further proposes that it is possible to predict the dose-response behaviour of a drug from the 
respective kinetics profile by investigating expected yields of β-haematin at individual time points as a function 
of increasing drug concentration (Figure 1.28 (a) and (b)). The model gives rise to sigmoidal dose-response 
curves at longer incubation times, while at shorter incubation times, the dose-response curves adhere to a 
simple hyperbolic function. Finally, the kinetic model is also able to predict that IC50 values, the concentration 
at which β-haematin formation is inhibited by at least 50%, extracted from the generated dose-response curves, 
are dependent on incubation time (Figure 1.28 (c)). The dependence of IC50 on time is most pronounced at 
short incubation times. Overall the data conform to a hyperbolic function; at longer incubation times, the 
individual dose-response curves are predicted to converge with relatively no change expected in the IC50 value. 
At longer incubation times it is observed that a slice through the kinetics profile at any given incubation time 
(dash lines together in Figure 1.28 (a)) will generate similar dose-response curves (grey line in Figure 1.28 
(b)), which will in turn result in similar IC50 values. This observation accounts for the hyperbolic shape in 
Figure 1.28 (c). The hyperbolic increase in IC50 values as a function of time observed here is in agreement to 
what Egan et al. observed in 2005.150 The authors also reported that the IC50 values become larger as the 
incubation time is increased, and that the IC50 increases steeply with shorter incubation times and more 
gradually at longer incubation times. 






Figure 1.28 The kinetics of β-haematin formation predicted by the kinetic model (Eq. 1.2). (a) Taking slices 
through the kinetics profile at several time points (broken lines), the dose-response curve of an inhibitor can 
be predicted. (b) The dose-response curves as the best fits of the numerical output generated at different times 
from (a). At longer incubation time, dose-response curves are sigmoidal (grey line), compared to hyperbolic 
at short incubation times (black line). (c) The dependence of IC50 values on incubation times. Based on the 
theoretical outputs in (a), the corresponding IC50 values from each curve are predicted. The hyperbolic function 
shows that the effect on the IC50 values is more pronounced at shorter incubation times. Reproduced from 
reference 40 and 152. 
 
Following data analysis using the derived kinetics model, a linear correlation was observed between the IC50 
values obtained in the lipid system and the biological activities reported against the chloroquine-sensitive (3D7 
and HB3) and –resistant (K1 and PH3) parasite strains (Figure 1.29 (a)). The observed linear correlation is a 
strong indicator that the lipid emulsions provide a valid system in which to investigate drug activity.40 
The Kads values determined for each antimalarial drug were subsequently compared against the biological 
activity determined against the chloroquine-sensitive 3D7 parasite strain, in order to assess whether the 
hypotheses underpinning the theoretical model (namely adsorption) could be related to the biological 
mechanism of quinoline antimalarials in any way (Figure 1.29 (b)).152 The linear correlation between the 
experimental and biological data further suggest that the strength by which a compound is able to adsorb to 


































Figure 1.29 Inhibition of β-haematin formation in the presence of antimalarial drugs at the lipid-water 
interface. (a) Linear correlations of the IC50 values obtained independently after 30 minute with biological 
activity against CQS strains (3D7 (●) and HB3 (■), solid line, r2 = 0.92) and CQR strains (PH3 (○) and K1 
(□), dashed line, r2 = 0.97). The data points for CQ against the CQR strains have been excluded from the linear 
regression analysis. Reproduced with permission from reference 40. (b) Linear correlation (r2 = 0.69) between 
the observed Kads values and the IC50 for the biological activity against CQS 3D7 strain for AQ, CQ, QD and 
QN. Reproduced with permission from reference 152. 
 
The kinetics data provided by Gildenhuys et al.40 strongly support a mechanism of quinoline antimalarial drug 
action by adsorption to the growing face of haemozoin in the lipid-mediated system. It is, however, essential 
that the theoretical model be tested by further investigating the effects of other β-haematin inhibitory 
compounds, including non-quinolines, on the kinetics of β-haematin formation. The current experimental 
system involving 15 mL Falcon tubes would not, however, be efficient to investigate larger numbers of 
compounds. In addition, a significant shortfall of the model is that independent measurements of drug 
adsorption to β-haematin crystals are also required to further support the kinetics data. To date no such data 









1.6 Aims and Objectives 
 
1.6.1 Aims 
Following a careful literature review of malaria, the Plasmodium falciparum parasite, haemozoin and the 
current understanding on the possible mechanisms of antimalarial drug action on haemozoin formation, the 
aim of the current study is to: 
Investigate the effect of diverse β-haematin inhibitors on the kinetics of β-haematin formation, using 
the lipid-mediated system. 
This aim is underpinned by the hypothesis that the β-haematin inhibitory activity of a compound is 
related to its strength of adsorption to free surface binding sites on the fastest growing face of β-
haematin crystals.  
 
1.6.2 Objectives 
In order to achieve the above-mentioned aim, the specific objectives set out in this research project were to: 
1. Develop a new, improved-throughput lipid-mediated assay in which to investigate the inhibition of β-
haematin formation. 
2. Validate the newly-optimized assay as a means of assaying drug activity by introducing clinically-
relevant antimalarial drugs into the system. 
3. Introduce a larger set of quinoline-based β-haematin inhibitors into the system and investigate their 
effects on the kinetics of β-haematin formation. 
4. Introduce a set of non-quinoline inhibitors into the system and investigate their effects on the kinetics 
of β-haematin formation. 
5. Investigate the strength of direct adsorption of β-haematin inhibitors independently. 
 
1.6.3 Proposed Compounds to be Investigated 
Owing to the increase in resistance to clinically-relevant antimalarial drugs,1,157 there is a crucial need to 
develop novel antimalarial haemozoin inhibitors. Understanding haemozoin formation and the mechanism of 
antimalarial drug action is central to this. In particular, investigating the effect of inhibitors other than quinoline 
antimalarial drugs on the kinetics of β-haematin formation is important. The two groups of compounds 
investigated in this study include short-chain CQ analogues (Figure 1.30 (a)),158 as well as a series of 
benzamide non-quinolines (Figure 1.30 (b)), with all compounds having β-haematin inhibitory activity. 
 






Figure 1.30 (a) A series of N1, N1-diethyl-N2-(4-quinolinyl)-1, 2-ethanediamine compounds with different 
substituents at the 7-position on the quinoline ring includes the 7-chloro (Q-Cl), -iodo (Q-I), -trifluoromethyl 
(Q-CF3), -methoxy (Q-MeO) and –trifluoromethylthio (Q-SCF3) 4-aminoquinolines.158 (b) A series of 
benzamide non-quinoline inhibitors with different substituents on the central aromatic ring, nQ-KW16, -17, -


















All of the materials that were used in this research project were of the highest purity and analytical grade, and 
were purchased from known commercial suppliers. All of the materials were used as obtained, without further 
purification, and are listed in Table 2.1.  
 
Table 2.1 Materials used throughout the study and their suppliers 
MATERIALS SUPPLIERS 
Solids  
Citric acid monohydrate Sigma-Aldrich 
DL-α-Palmitin Sigma-Aldrich 
Haemin (bovine)  Sigma-Aldrich 
Haematin (porcine) Sigma-Aldrich 
N-2-[hydroxyethyl]piperizine-N’-[2-ethanesulfonic acid] (HEPES) Sigma-Aldrich 
Sodium hydroxide pellets Sigma-Aldrich 
Sodium acetate trihydrate Sigma-Aldrich 
Sodium citrate tribasic dihydrate Sigma-Aldrich 
Phosphorus pentoxide Sigma-Aldrich 
Liquids and Solvents  




Methanol AR Kimix Chemicals 
Nitric acid AR Kimix Chemicals 
1-Pentanol Sigma-Aldrich 
Pyridine Sigma-Aldrich 
Antimalarial drugs  
Amodiaquine dihydrochloride dihydrate  Sigma-Aldrich 
Chloroquine diphosphate Sigma-Aldrich 
Mefloquine hydrochloride Sigma-Aldrich 
Atovaquone Sigma-Aldrich 
Quinidine sulphate dihydrate Sigma-Aldrich 
Quinine hemisulphate hydrate Sigma-Aldrich 
Quinoline and non-quinoline inhibitors  
Quinolines: Short-chain CQ analogues158 Re-synthesized by Mr J. B. Hay (US) 
Non-quinolines: Benzamide series Synthesized by Dr K. J. Wicht (UCT) 
 







2.2.1 Analytical Balance 
An A&D Company HR-200 standard balance scale was used to weigh off materials weighing more than 10 
mg and a Sartorius GMBH Göttingen sensitive balance scale was used to weigh off smaller quantities.  
 
2.2.2 Centrifuge 
A Hermle Labortechnik centrifuge (Z 206) with a maximum speed of 6000 rpm was used to centrifuge large-
volume samples in 15 mL Greiner Falcon centrifuge tubes. A Z 233 M-2 Hermle Labortechnik GbmH 
centrifuge, with a maximum speed of 15000 rmp, was used to centrifuge smaller volumes in 2 mL eppendorf 
tubes. 
 
2.2.3 High Vacuum Pump 
An Edwards Max high vacuum pump was used to dry materials overnight. 
 
2.2.4 Infrared Spectroscopy 
A NexusTM FT-IR spectrometer from Thermo Nicolet Instruments fitted with a Golden Gate attenuated total 
reflection (ATR) accessory was used to record ATR-IR spectra. 
 
2.2.5 Magnetic Stirrer Hot Plate 
Heidolph MR-2002 and JKI JK-MSH-PRO standard magnetic stirrer hot plates were used to stir and heat 
solutions. 
 
2.2.6 Micro Glass Syringes 
Microliter glass syringes (10 µL, 25 µL and 50 µL), obtained from Hamilton, were used for the accurate 
delivery of small volumes of solutions. Glass is also preferred when handling solutions of haematin as it has 
been shown to adsorb to plastic.82,87 
 






Kinetics experiments were performed in a fan-assisted oven set at the required temperature (37 ± 1 °C). 
 
2.2.8 pH Meter 
A Mettler Toledo FE20 pH meter was used to perform all of the pH measurements. The electrode was 
calibrated using pH buffer solutions (pH 4 and pH 7) obtained from Crison. 
 
2.2.9 Powder X-Ray Diffraction 
A PANalytical X-ray Powder Diffractometer was used to record PXRD data. 
 
2.2.10 Scanning Electron Microscopy 
A Leo 1430 VP scanning electron microscope was used to obtain structural images of samples. The images 
show the surface morphology of the material.  
 
2.2.11 Single- and Multi-Channel Micro Pipettes  
For volumes greater than 25.0 µL, micro-pipettes were routinely used. Axygen Scientific single-channel (AP-
20, AP-200, AP-1000 and AP-5000) and Gilson multi-channel (P8X20 and P8X200) pipettes were used. 
 
2.2.12 Ultrasonic Water Bath 
An Elma TranssonicDigital ultrasonic water bath was used for direct adsorption studies. An operating 
temperature of 37 ± 1 °C was maintained for the duration of the measurements, for which the ultrasound power 
level 2 was used. 
 
2.2.13 UV-Visible Spectroscopy 
A Thermo Scientific Multisakan GO UV-Visible spectrophotometer was used to record single wavelength 
readings as well as UV-visible spectra. 
 






A VORTEX V1-plus device was used to mix solutions thoroughly. 
 
2.2.15 Water Bath 
In some cases, experiments were performed at the required temperature (37 ± 1 °C) using a MEMMERT water 
bath. 
 
2.3 Computer Software 
 
Different computer software and programmes were used in this study to obtain and analyse data (Table 2.2). 
 
Table 2.2 Computer software and programmes used throughout the study 
PROGRAMME VERSION USE 
Chem Draw Ultra 12.0 Drawing molecular structures of compounds 
GraphPad Prism 6.0 Analysis and graphing of data 
Mendeley 1.14 Referencing and Bibliography 
Microsoft Excel 2010 Handling and analysis of raw data 
OMNIC 7.2 Recording ATR-IR spectra of samples 
PANalytical Data Collector 4.1.0.25 Collect PXRD data 
SkanIt Multiskan GO 3.2 Obtaining UV-vis absorbance readings 
SmartSem 5.05 Scanning electron imaging of samples 
X’Pert HighScore Plus 2.2.5 Processing of PXRD data 
  





2.4 General Precautions in Sample Preparations and Handling Washing of Glassware and 
Plasticware 
 
Glass-distilled water was used to prepare water solvent solutions throughout the experiments. All glass- and 
plasticware was washed with soap-water and rinsed with glass-distilled water and wash-acetone. Fe(III)PPIX-
contaminated glass syringes, cuvettes, glass- and plasticware were allowed to soak in 0.1 M NaOH for at least 
one hour. After rinsing extensively with water, the cuvettes, glass- and plasticware were washed with 1 M 
HNO3, followed by extensive rinsing with water. This procedure is important since Fe(III)PPIX adsorbs to 
glass- and plasticware.82,87 All glassware were either air dried or dried in an oven at 37 °C after washing. All 
pyridine-contaminated 24- and 96-well plates and lids were discarded immediately after use. New sterile plates 
were used for every new experiment. 
 
2.5 General Preparations 
 
This section describes the solutions that were prepared often owing to their frequent use in the different 
experiments carried out. The materials that were used to prepare these solutions have previously been listed in 
Table 2.1. 
 
2.5.1 50.0 mM Stock Solution of Citrate Buffer, pH 4.8 
Citric acid monohydrate (5.255 g, 24.95 mmol) was dissolved in 450.0 mL distilled water. On adding a 
concentrated solution of sodium hydroxide dropwise, the pH was adjusted to 4.8. The solution was then made 
to volume in a 500 mL volumetric flask.  
 
2.5.2 1:9 (v/v) Acetone: Methanol Solution 
A solution was prepared in a 100.0 mL volumetric flask consisting of 10.0 mL of acetone, after which the 
solution was made to volume with methanol. 
 
2.5.3 0.10 M NaOH Solution 
Solid NaOH pellets (1.000 g, 250.0 mmol) were dissolved in distilled water to a volume of 250.0 mL in a 
volumetric flask. 





2.5.4 2.0 M Stock Solution of HEPES Buffer, pH 7.5 
HEPES acid (47.66 g, 200.0 mmol) was dissolved in 80.00 mL distilled water. On adding a concentrated 
solution of sodium hydroxide dropwise, the pH was adjusted to 7.5. The solution was then made to volume 
with distilled water in a 100 mL volumetric flask. 
 
2.5.5 3.03 mM Lipid Solution 
The neutral lipid, 1-monopalmitoyl-rac-glycerol (MPG), (10.0 mg, 30.26 μmol) was dissolved in 10.0 mL of 
the 1:9 acetone: methanol solution. A fresh solution was prepared for each set of experiments. 
 
2.5.6 3.16 mM Haematin Solution 
Haematin (10.0 mg, 15.79 μmol) was dissolved in 2.00 mL of 0.10 M NaOH in a 15 mL Greiner Falcon 
centrifuge tube. 3.00 mL of the 1:9 acetone: methanol solution was added after complete dissolution. A fresh 
solution was prepared for each set of experiments. 
 
2.5.7 30:30:40 (v/v) Pyridine: Aqueous Buffer: Acetone Solution 
10.0 mL of 2.0 M HEPES buffer and 30.0 mL of pyridine were added to 40.0 mL acetone and thoroughly 
mixed together. The solution was made up to 100.0 mL in a volumetric flask by adding distilled water. 
 
2.5.8 0.20 M Stock Solution of HEPES Buffer, pH 7.5 
HEPES acid (4.766 g, 20.0 mmol) was dissolved in 80.00 mL distilled water. On adding a concentrated 
solution of sodium hydroxide dropwise, the pH was adjusted to 7.5. The solution was made up with distilled 
water to 100.0 mL in a volumetric flask. 
 
2.5.9 5: 45: 50 (v/v) Pyridine: Aqueous Buffer: Acetone Solution 
10.0 mL of 0.20 M HEPES buffer and 5.00 mL of pyridine were added to 50.0 mL acetone and thoroughly 
mixed together. The solution was made up to 100.0 mL in a volumetric flask by adding distilled water. 
  





Chapter 3. The Effect of Quinoline Inhibitors on the Formation of β-Haematin 




The inhibition of β-haematin (synthetic haemozoin) formation by clinically-relevant antimalarial drugs has 
been of interest for a long period of time and to date, different systems have been investigated to probe their 
mode of action in this regard.59,149,150 In a recent study conducted in our laboratory, the inhibition of β-haematin 
formation has been investigated in a lipid-water interface system using the modified Phiβ assay,40 in which the 
amount of free Fe(III)PPIX in a Fe(III)PPIX-β-haematin mixture is quantified (see section 1.5.4.3.1 for details 
of the Phiβ assay). The study made use of monopalmitoyl-rac-glycerol (MPG) as a model lipid, and was the 
first to systematically investigate the kinetic effect of four quinoline antimalarial drugs on the formation of β-
haematin under biomimetic conditions. A kinetic model underpinned by the Langmuir adsorption isotherm 
was used to analyse the data, and the authors suggested that the β-haematin inhibitory activity of a compound 
is related to its strength of adsorption to free surface binding sites on the growing β-haematin crystals.40 These 
initial findings warranted further investigation, the most important being to study the effect of additional 
inhibitors, in order to validate the hypothesis. Furthermore, the assay used in the original study was time-
consuming, and by improving the turnaround time per compound, it was proposed that a larger set of 
compounds could be investigated. In the current study, clinically-relevant antimalarial drugs were initially 
used to optimize an improved-throughput assay compared to the previous work. Having successfully 
developed this more efficient assay, it has been possible to extend the data set to include a series of short-chain 
chloroquine analogues,158 all of which contain the quinoline nucleus. Investigating a larger set of compounds 
is of great importance to validate the hypothesis and substantiate the proposed theoretical kinetic model. For 
each compound, activity and kinetics experiments have been carried out.  
This chapter provides a detailed discussion of the experimental methods followed and results found, regarding 
both the activity- and kinetics studies for quinoline-based β-haematin inhibitors.  
 
  





3.2 Optimization of the Phiβ Assay using known Antimalarial Drugs 
 
The antimalarial drugs used in the first part of the study were the clinically-relevant quinoline compounds, 
namely amodiaquine (AQ), chloroquine (CQ), quinidine (QD), quinine (QN) and mefloquine (MQ). Their 
molecular structures have been presented previously in Figure 1.16. 
 
3.2.1 Experimental Methods 
3.2.1.1 Introducing Antimalarial Drugs into the Aqueous Citrate Buffer 
Four quinoline antimalarial drugs, namely AQ, CQ, QD and QN, were all used in their salt forms, enabling 
them to be readily solubilised in the aqueous citrate buffer. A drug-containing stock solution of citric acid 
monohydrate (50.0 mM, pH 4.8) was prepared in a similar manner as described in section 2.5.1, however, the 
appropriate quantity of each antimalarial drug (Table 3.1) was also included. Further optimization was required 
to introduce MQ into the system, as it is monoprotic and not readily soluble in aqueous solution. MQ was 
therefore dissolved in the 1:9 acetone: methanol solution (section 2.5.2), which was used to dissolve and 
introduce the lipid into the system. This will be discussed in further detail in section 3.2.1.3 
 
Table 3.1 Quantities of antimalarial drugs in salt form required to prepare a 100.0 mL† stock solution in 50.0 







AQ 464.80 0.02 0.9 
CQ 515.86 0.10 5.2 
QD 391.45 0.20 7.9 
QN 391.45 0.30 11.4 
MQ‡ 414.08 0.20 8.3 
† The volume can be adjusted according to the amount needed for a specific experiment. ‡ MQ is insoluble in the aqueous citrate buffer. 
The mass represented here is the mass needed to prepare 100.0 mL of a 0.2 mM solution, however, it was dissolved and introduced in 
a 1:9 acetone: methanol solution. This is discussed in section 3.2.1.3. 
 
3.2.1.2 Antimalarial Drug Activity Studies 
Studies were carried out to determine the IC50 value, which is the concentration required to inhibit β-haematin 
formation by 50%, for each antimalarial drug in the lipid-water interface system. In these experiments, the 
incubation time was fixed while the concentrations of all antimalarial drugs were varied. 
All of the experiments were performed in sterile 24-well polystyrene cell culture plates. Each well has an 
internal diameter of 1.6 cm and has a maximum volume capacity of 3.5 mL. The plates were incubated in an 
oven to ensure a consistent temperature of 37 °C throughout the experiment. The concentration range of each 
antimalarial drug was chosen in close proximity to what had previously been determined by Gildenhuys et 





al.40 and the relative β-haematin inhibitory activity of each drug in the Phiβ and NP40 assays was also 
considered. A series of at least ten to twelve different drug concentrations were prepared by diluting the drug-
containing stock solution (section 3.2.1.1.) with drug-free citrate buffer (section 2.5.1) using calibrated micro-
pipettes.  
Two plates were used to accommodate twelve different concentrations simultaneously, each column 
representing a different concentration (columns 0-11, Figure 3.1). Each test well contained 1.0 mL of drug-
containing citrate buffer in total. Moving from left to right over the plate the concentrations increased from 
zero drug to the highest drug stock concentration. Each concentration was measured in triplicate (rows A-C) 
and a single control was also included for each concentration (row D). The plates, which had been loaded with 
the buffer, were pre-incubated in the oven at 37 °C for 45 minutes, during which time the lipid and Fe(III)PPIX 
solutions were freshly prepared.  
 
 
Figure 3.1 Representation of two 24-well plates used during drug activity experiments. Increasing drug 
concentrations are loaded from left to right over the plate and each drug concentration is measure in triplicate. 
A control is also included for each drug concentration. 
 
Solutions containing 200.0 µL of lipid and 5.00 µL of Fe(III)PPIX stock solutions (sections 2.5.5 and 2.5.6) 
were premixed in the wells of a 96-well plate, using multi-channel micro pipettes. Excluding the twelve control 
wells this adds up to 36 pre-mix solutions that needed to be prepared per drug activity study (three triplicate 
of each concentration × twelve different concentrations). The control wells (row D) were used to monitor the 
state of the buffer and the lipid solution only, and thus did not contain the Fe(III)PPIX solution. The aliquots 
of lipid-Fe(III)PPIX solution were added dropwise to the pre-incubated buffer using a syringe with a needle 
diameter of 0.5 mm, yielding an interface between the hydrophobic lipid emulsion droplets and hydrophilic 
buffer regions after solvent mixing. The plates were allowed to incubate in the oven for a further four hours, 
which was chosen arbitrarily in initial experiments.  
Following the incubation period, the reaction was quenched by adding 241.0 µL of the 30:30:40 (v/v) pyridine: 
aqueous buffer: acetone solution (section 2.5.7) into each well to yield an end solution that contained 5% (v/v) 











0 2 3 41 8765 109





pyridine overall. After manually agitating the plate for one minute to ensure that the pyridine had interacted 
fully with any unreacted Fe(III)PPIX, the plate was left to stand for 15 minutes to allow visible lipid precipitate 
to settle. A 200.0 µL aliquot of the supernatant in each well was then transferred to an empty well in a clean 
96-well plate and the absorbance value for each well was measured at 405 nm. This absorbance value was 
compared to that of the zero-drug control, and was used as a measure of the amount of unreacted Fe(III)PPIX 
remaining at each drug concentration, from which the IC50 value could be determined.  
Measurements were conducted in triplicate for each antimalarial drug to improve the reliability of the results. 
The observed absorbance values were plotted as a function of increasing drug concentration and fitted to a 
sigmoidal or hyperbolic function, using nonlinear least squares fitting in GraphPad Prism. The IC50 value for 










Figure 3.2 A schematic indication of how the absorbance values at A405 were used to calculate the IC50 values 
for each drug. Inhibition of β-haematin formation by 50% was determined by subtracting the absorbance of 
Fe(III)PPIX measured in the absence of drug (Ai) from that obtained at high drug concentration (Af) and 
multiplying the product by 0.5. The drug concentration corresponding to this absorbance value (A50) is the 
concentration of drug required to inhibit 50% of β-haematin formation and is termed the IC50 value. 
 
3.2.1.3 Non-Aqueous Soluble Antimalarial Drugs 
As mentioned above, MQ is insoluble in the aqueous citrate buffer solution, and hence has been treated 
differently compared to the other antimalarial drugs. MQ was therefore dissolved in a 1:9 acetone: methanol 
solution and incorporated into the aqueous citrate buffer in each well within a 100.0 µL aliquot before the pre-
incubation period. The quantity of MQ dissolved in the acetone: methanol stock solution was equal to the 
amount that would be expected in an aqueous citrate buffer stock solution if the drug was soluble. The 
concentrations were thus calculated relative to the total volume of the system in each well. The lipid-
Fe(III)PPIX premix solution was prepared in the remaining 100.0 µL of 1:9 acetone: methanol solution, which 
was therefore double the concentration used previously to ensure the same lipid- and Fe(III)PPIX final 





concentrations in each well compared to the aqueous-soluble compounds. The premix solution was added 
dropwise into each well as described above (section 3.2.1.2). 
 
3.2.1.4 The Effect of Incubation Time on Drug IC50 Values 
A study investigating the effect of time on drug activity (IC50) was conducted for CQ and QD. The procedure 
described in section 3.2.1.2 was followed, except that for each experiment, varying time periods ranging 
between one and one hundred hours (1, 2, 4, 5, 8, 16, 24, 32 and 100 hours) were used for incubation. The 
reactions were monitored, and data were analysed, as described previously. 
 
3.2.1.5 Antimalarial Drug Kinetics Studies  
Kinetics studies were carried out in order to determine the equilibrium adsorption constant, Kads, for each 
antimalarial drug in the lipid-water interface system. In these experiments, the incubation time, as well as the 
concentration of each antimalarial drug, were varied in order to obtain a full profile for each β-haematin 
inhibiting compound.  
The same procedure as outlined for the drug activity studies in section 3.2.1.2 was followed to monitor the 
kinetics of β-haematin formation in the presence of different drug concentrations. The solutions were prepared 
and introduced into the 24-well plates in a similar manner as before. The number of concentrations that were 
investigated ranged from six to eight, with six being most common. The range of concentrations investigated 
was different for each drug, depending on the β-haematin inhibitory activity, which was determined in the drug 
activity studies, as mentioned above. Lower concentrations were introduced into the aqueous buffer for more 
active drugs, compared to less active drugs that required higher doses. For convenience, and to prevent 
disturbance of the interface, one plate was prepared per incubation time. Nine different incubation time periods 
were chosen, ranging from 0 up to 32 hours (0, 0.5, 1, 2, 4, 8, 16, 24 and 32 hours).  
The premix solution delivered to each well contained 200.0 µL of lipid- and only 2.00 µL of Fe(III)PPIX 
solution.74 After the incubation period, the reaction was quenched by adding 240.4 µL of the 30:30:40 (v/v) 
pyridine: aqueous buffer: acetone solution into each well. As before, the absorbance of a 200.0 µL sample was 
measured in a dry 96-well plate at 405 nm. 
Kinetics studies were also conducted in triplicate for each antimalarial drug to improve the accuracy of the 
results. All of the data were plotted and analysed by non-linear least squares fitting, using GraphPad Prism.  
The Kads value for each antimalarial drug was then determined from the respective analyses as described in 
section 3.2.1.6, as well as in Chapter 1, and further discussed in the following section. The experimental 
procedures described for drug activity- and kinetics studies in sections 3.2.1.2 and 3.2.1.5 are shown in the 
flow diagram in Figure 3.3. 






Figure 3.3 Flow diagram of the experimental procedures for inhibitor activity- and kinetic studies. (1) 24-well 
plates were prepared with drug-containing buffer and pre-incubated for 45 minutes in a 37 °C oven. (2) Premix 
solutions containing 200 µL lipid- and 5.00 µL (activity studies) or 2.00 µL (kinetic studies) Fe(III)PPIX were 
prepared in 96-well plates and introduced into each well with a 0.5 mm needle syringe. (3) Plates were left to 
incubate in an oven set at 37 °C for four hours (activity studies) and up to 32 hours (kinetic studies). After 
quenching the reaction in each well with the 30:30:40 pyridine: aqueous buffer: acetone solution to ensure 5 
% (v/v) pyridine in the end, a 200 µL aliquot of the supernatant was transferred to a 96-well plate (4) and the 
absorbance at 405 nm was read as a measure of the amount of unreacted Fe(III)PPPIX (5). 
 
3.2.1.6 Analysis of Kinetics Data 
The experimental absorbance data obtained at 405 nm represents the amount of free Fe(III)PPIX that remains 
in the system at the end of a specific incubation period. The data were compared to a zero-drug control value, 
following which they were converted into a percentage value, quantifying the amount of β-haematin formed 
in a given time. By plotting these values as a function of time, and fitting them to a simple exponential kinetic 
equation, the observed rate constant, zobs, for the formation of β-haematin in the presence of a particular drug 
concentration was determined. According to the adsorption model based on the Langmuir isotherm (Equation 
1.4), it is predicted that a plot of the inverse of zobs as a function of increasing drug concentration will generate 
a linear correlation at low drug concentration (Figure 3.4 (a)). Linear regression in this region allows for both 
the slope and y-intercept values to be determined, which in turn assists in calculating the rate constant for β-
haematin formation in the absence of an inhibitor, z, as well as Kads (using the equations inserted in Figure 3.4 
(a)). By fitting the kinetics data to Equation 1.2 (repeated below as Eq. 3.1 for ease of reference), known 
parameters, namely, Kads, z, the inhibitor concentration and the fractional yield of β-haematin formation 
expected in the MPG lipid-mediated system, are used as constraints in the equation. The values of Kads and z 
were determined from the linear regression analysis, while the rate constant for the precipitation of a proposed 
drug-haem complex, k2, was allowed to refine freely in order to generate the best fit of the experimental data 
to the model (Figure3.4 (b)). Since this competing precipitation process is still poorly understood, accurate 
values for k2 were not investigated in the current study and it is found that the k2 value can generally 














}  (Eq. 3.1) 
































Figure 3.4 Predicted kinetics of β-haematin formation in the presence of an inhibitor.40 (a) A plot of the inverse 
of the observed rate constants, zobs, as a function of increasing inhibitor concentration (purple line) yields a 
linear correlation at low concentrations (black line). Linear regression in this region allows the Kads and z values 
to be calculated from the slope and intercept values, respectively. (b) Kinetic traces observed in the absence 
(black line) and presence of increasing inhibitor concentrations (grey lines). The trace obtained in the presence 
of the highest inhibitor concentration is shown in purple. 
 
3.2.2 Results 
The previously-modified Phiβ assay used to investigate the inhibition of β-haematin at a lipid-water interface,40 
has several disadvantages and limitations from the point of view of medium- to high-throughput screening of 
β-haematin inhibitors. The assay is overall time-consuming, used unnecessarily large quantities of materials, 
had multiple centrifugation steps, and used less efficient absorbance measurement reading methods, all of 
which resulted in a slow turnaround time per compound. This prompted the revisions and further optimizations 
carried out in the current study, which has allowed a greater number of compounds to be investigated. The 
results obtained have facilitated a broader understanding of the inhibition phenomenon in a biomimetic system.  
 
3.2.2.1 Optimization of Assay 
The assay was optimized by introducing 24-well plates as the reaction vessel, as opposed to the 15 mL Greiner 
Falcon centrifuge tubes that were used previously. 24-well plates were chosen since the internal diameter of a 
single well is identical to that of a tube (1.6 cm). In keeping the internal diameter constant, the surface area in 
each vessel remains unchanged, which in turn meant that the maximum percentage yield of β-haematin formed 
would also be consistent.74  
Experiments were initially incubated by floating the 24-well plates in a water bath. However, longer incubation 
times were required using this approach since there is considerably less area that is in contact with the water 
in the case of the wells as compared to the fully immersed tubes. Furthermore, non-reproducible and 
inconsistent results were obtained, possibly as a consequence of irregular heat distribution across the well, but 
also as a result of condensation that formed on well lids. In the case of the latter, this produced changes in 
solvent composition within the well, as well as changes to concentrations of the reagents. Exchanging the water 





bath for a fan-assisted oven produced more consistent results as better temperature control was achieved and 
condensation was eliminated. An added benefit of using the oven over a water bath was the greater number of 
plates that could be incubated in the former, facilitating more efficient means with which to conduct the study. 
The oven is advantageous over the water bath in that it provides greater consistency and better results overall. 
An equal volume of the lipid-Fe(III)PPIX premix solutions was introduced into the system as before, while 
the volume of aqueous citrate buffer was decreased due to the smaller well capacity. Since the surface area of 
each well was the same as previous experiments carried out in tubes, as mentioned above, the difference in the 
buffer bulk was not expected to interfere in the formation of β-haematin.  
UV-visible measurements by means of a single cuvette (2.0 mL) were also improved upon by introducing 96-
well plates for simultaneous measurement of multiple samples. 
Under these revised conditions, the yield of β-haematin in the absence of an inhibitor was found to be the same 
as in the original approach. Interestingly, however, a ten-fold decrease in the rate of β-haematin formation was 
observed, with the rate decreasing from 0.171 ± 0.04 min-1 to 0.019 ± 0.002 min-1 (Figure 3.5). 
 






















Figure 3.5 Rate of β-haematin formation in the absence of an inhibitor. The previous rate observed using 15 
mL Greiner Falcon tubes (●) is ten-fold faster compared to the rate determined in 24-well plates (●). A decrease 
in the rate of β-haematin formation is observed (arrow). The observed rate constants determined from these 
curves are 0.171 ± 0.04 min-1 and 0.019 ± 0.002 min-1, respectively. 
 
In an attempt to understand the observed ten-fold decrease in the rate constant of β-haematin formation in the 
absence of an inhibitor, an independent study was performed to investigate the influence of the solvent 
concentrations in the 24-well system. Since all other quantities were the same, the difference in rate was 
presumed to arise from the larger proportion of acetone: methanol used relative to the buffer volume in the 24-
well method as opposed to in the tubes. To probe this, β-haematin formation was performed in 15 mL Falcon 
tubes, as demonstrated in the previous study,40 however, with an increased proportion of the acetone: methanol 





solution relative to the buffer, such that the ration was the same as in the wells. It was first considered to 
decrease the acetone: methanol volume relative to the buffer in the wells in order that it is the same as that 
previously used in the tubes, however, this resulted in very small quantities to work with. Keeping the lipid- 
and Fe(III)PPIX premix solution the same as before, an additional volume of acetone: methanol solution was 
therefore introduced into the aqueous citrate buffer to ensure that the final acetone: methanol concentration in 
each tube was the same compared to the concentration in each well. The experiment was carried out over a 
period of time, ranging from 0 to 32 hours incubation time, followed by quenching with 1.0 mL of pyridine: 
aqueous buffer: acetone and single UV-vis measurement readings, using a cuvette. 
Under these conditions, the yield of β-haematin in the absence of an inhibitor was found to be the same as in 
the original tube approach, as well as in the 24-well plate. Interestingly however, the same ten-fold reduction 
in the rate of β-haematin formation was obtained in this adapted system, thus confirming that the volume of 
acetone: methanol relative to the buffer affects the rate of β-haematin formation. The rate of β-haematin 
formation in the tubes decreased from 0.171 ± 0.04 min-1 to 0.023 ± 0.003 min-1, which is consistent with the 
rate of β-haematin in the 24-well plates (Figure3.6).  
Due to the significant decrease in the rate of β-haematin formation in the new assay (in the 24-well plates), 
overall incubation periods for both activity- and kinetics experiments were increased to 32 hours to ensure 
reaction completion. Even though shorter incubation times are preferable, increased incubation times are 
serendipitous, because previous incubation times were so short that they were difficult to measure. In 
increasing the incubation times, the kinetics can be more easily measured, and with greater accuracy. All of 
the important differences and similarities between the previous method and the new assay are summarized in 
Table 3.2. 
 






















Figure 3.6 Kinetics of β-haematin formation in the absence of an inhibitor. The increased concentration of 
acetone: methanol in the tube method (●) produces a ten-fold reduction in the rate constant of β-haematin 
formation and is in good agreement with that determined using 24-well plates (●).The observed rate constants 
determined from the curves are 0.023 ± 0.003 min-1 and 0.019 ± 0.001 min-1, respectively. 





Table 3.2 A comparison between the previous and new assay to investigate the inhibition of β-haematin 
formation 
Previous Assay New, Optimized Assay 
Equipment  
15 mL Falcon tubes 24-well sterile plates 
Water bath, 37 °C Oven, 37 °C 
Reaction (Quantities)  
5 mL 50 mM Citrate buffer, pH 4.8 1 mL 50 mM Citrate buffer, pH 4.8 
Pre-incubation time, 30 minutes Pre-incubation time, 45 minutes 
200 µL lipid 200 µL lipid 
5 µL (activity), 2 µL (kinetic) Fe(III)PPIX 5 µL (activity), 2 µL (kinetic) Fe(III)PPIX 
Incubation periods, 0-240 minutes Incubation periods, 0-1920 minutes 
Measurement   
1 mL 30: 30: 40 Pyridine: HEPES: Acetone 0.24 mL 30: 30: 40 Pyridine: HEPES: Acetone 
10 minutes centrifuge and leave to settle Manually agitated and leave to settle for 15 minutes 
2.0 mL aliquot reading in cuvette 0.2 mL aliquot reading in 96-well plates 
 
There is overall a vast improvement compared to the previous method used to investigate the inhibition of β-
haematin at the lipid-water interface. The main advantage of the new assay is the faster turnaround time per 
compound to investigate both the drug activity- and kinetic studies, irrespective of the longer incubation 
periods required per compound. In order to validate the newly-optimized assay as a means of assaying drug 
activity against β-haematin formation in the lipid-water system, the observed drug activity- and kinetic 
adsorption results then needed to be compared to previously-determined results. In order to thus fully compare 
the two different protocols with each other, the new assay was first validated by investigating five known 
antimalarial drugs, namely CQ, AQ, QD, QN and MQ. Both drug activity and kinetic studies were carried out 
to investigate the effect these compounds would have on the formation of β-haematin. 
 
3.2.2.2 Antimalarial Drug Activity Studies 
Drug activity studies were performed independently to determine the IC50 value for each antimalarial 
compound (as described in section 3.2.1.2). The IC50 value determined for a specific inhibitor, as defined 
previously, is the drug concentration required to inhibit β-haematin formation by 50%. The dose-response 
curves for the inhibition of lipid-mediated β-haematin formation by AQ, CQ, QD, QN and MQ are shown in 
Figure 3.7. The data were collected after a four-hour incubation period, since longer incubation times are 
required in the 24-well plates in order to account for the ten-fold decrease in the observed rate. This incubation 
period is eight times longer than the 30 minutes incubation period used for the tube method, however, since 
the incubation time was chosen arbitrarily in the previous study, it was presumed to be sufficiently long 
enough. The data show how the proportion of free Fe(III)PPIX, measured spectroscopically as a bis-pyridyl 
Fe(III)PPIX complex at 405 nm,74,145 changes as a function of increasing drug concentration. In all five cases, 
an increase in the absorbance at 405 nm is observed as a function of increasing drug concentration. This is 





expected, since an increase in drug concentration would inhibit the conversion of free Fe(III)PPIX into β-
haematin to a greater extent, and hence an increase in the absorbance of free Fe(III)PPIX will be observed. 
The observed IC50 values for each drug (Table 3.3) were determined by fitting the experimental data to either 
a sigmoidal or a simple hyperbolic function as explained earlier in Figure 3.2. Interestingly, the dose-response 
curves for AQ, CQ and MQ conform to a sigmoidal fit, while those for QD and QN, conform to a hyperbolic 
function. According to the theoretical model, this suggests that an incubation time longer than four hours may 
be required for compounds such as QD and QN in order for the IC50 values to be meaningfully compared to 
the others.  
 































































Figure 3.7 The inhibition of β-haematin formation by antimalarial drugs at the lipid-water interface using the 
newly-developed 24-well plate assay. Dose-response curves determined in drug activity studies after a four-
hour incubation period as a function of increasing drug concentration for (a) AQ, (b) CQ, (c) QD, (d) QN and 
(e) MQ. The IC50 value for each drug is determined by fitting the data either to a sigmoidal (a, b and e) or a 
hyperbolic (c and d) function. The r2 values are 0.94, 0.98, 0.93, 0.77 and 0.95, respectively. 





Table 3.3 IC50 values obtained for the inhibition of β-haematin formation by antimalarial drugs at the lipid-
water interface in 24-well plates compared to previously used tubes.40,152  
Antimalarial Drug 24-Well Plates (µM)† Falcon Tubes (µM) 
AQ 5.9 ± 0.3 9.0 ± 0.4 
CQ 18.8 ± 0.6 16.4 ± 0.5 
QD 20.1 ± 4.1 51.1 ± 5.8 
QN 31.0 ± 8.3 73.9 ± 12.8 
MQ 22.9 ± 0.6 12.2 ± 0.1 
†Error calculated as standard error of the mean (SEM), following three experimental repeats, each including triplicate data points. 
 
While the absolute values do not agree, the IC50 values determined in the current study are in good agreement 
when compared to previously-determined IC50 values.40,152 Both sets of values follow the same trend, with drug 
activity increasing from QN to AQ as follows; QN<QD<CQ<AQ. The linear correlation observed between 
these IC50 values is shown in Figure 3.8 (a), with an r2 value of 0.78. The P value is larger than 0.05, however, 
indicating that the correlation is non-significant. This is most likely due to there being only four points in the 
correlation. MQ is not included in the evaluation between the previous and the new assay, since the drug was 
introduced differently into the lipid-water interface system in both cases. Despite the insignificant correlation, 
the good agreement between the IC50 values obtained via the two protocols did provide sufficient validation to 
progress with the study of additional compounds. 
Different systems in which β-haematin formation is investigated are frequently compared to one another to 
establish or validate if their outcomes regarding the activity of a drug are related. Drug activities obtained in 
the current lipid-water system were thus compared to the drug activities determined in vitro in the Phiβ acetate 
assay145 and the NP40 detergent-mediated assay.159 A non-significant linear correlation, with an r2 value of 
0.68, is observed when comparing the IC50 values of each drug against the respective equivalents determined 
in the Phiβ acetate assay (Figure 3.8 (b)). When comparing the IC50 values to those determined in the NP40 
assay, which is a lipid environment mimic, a significant linear correlation, with an r2 value of 0.93 and P value 
< 0.05, is observed (Figure 3.8 (c)). These two relationships are important when considering the efficacy of 
the optimized 24-well plate method, as a means to determine inhibitory activities biomimetically.  
Having demonstrated that the observed activity in the biomimetic system does correlate with β-haematin 
inhibitory activity determined in related systems, the observed IC50 values were also compared to the biological 
activities previously determined against a CQ-sensitive (CQS) strain of the malaria parasite, 3D7.147 A linear 
correlation is observed (Figure 3.9), which is statistically significant, with an r2 value of 0.91, and a P value < 
0.05. Overall, taking the correlations in Figures 3.8 and 3.9 into account, the data indicate that the newly-
optimized lipid-mediated assay is indeed a valid system in which to investigate drug activity.  






















































































Figure 3.8 The inhibition of β-haematin formation by antimalarial drugs at the lipid-water interface. The 
correlation between the observed IC50 values, obtained after 4 hours in the 24-well plate assay, compared to 
previously determined (a) IC50 values in the Falcon tubes,40 (b) IC50 equivalents in the Phiβ acetate assay145 
and (c) IC50 values in the NP40 detergent-mediated assay.159 The r2 values for the linear correlations are 0.78, 
0.68 and 0.93, respectively, of which only the latter is a significant fit with a P value < 0.05. 
 


























Figure 3.9 The inhibition of β-haematin formation by antimalarial drugs in the lipid-water interface system. 
The linear correlation between the observed IC50 values, obtained after 4 hours in 24-well plate assay, 
compared to previously determined biological activity against a CQ-sensitive strain, 3D7 (r2  value of 0.91, P 
value < 0.05).147 





3.2.2.3 The Effect of Incubation Time on Drug IC50 Values 
An additional independent study investigating the effect of incubation time on drug activity was carried out 
for CQ and QD. An increase in IC50 values is observed as a function of increasing incubation time for both 
drugs (Figure 3.10). In both cases, the data showed a hyperbolic dependence in agreement with that predicted 
by the theoretical kinetic model (see section 1.5.4.3.2) These results are also consistent with what has 
previously been observed from time studies conducted in the tubes.152 Together with the activity study, it is 
clear that the same trend is observed in the 24-well plates compared to the previously-used tubes, suggesting 
that the two systems yield the same information and are comparable. 
 


































Figure 3.10 The influence of incubation time on the observed IC50 values. The IC50 values obtained in the 
lipid-water interface system using the new 24-well plate assay as a function of increasing incubation time for 
(a) CQ and (b) QD. Both datasets conform to a hyperbolic function with r2 values of 0.88 and 0.99, respectively. 
 
3.2.2.4 Antimalarial Drug Kinetics Studies  
Due to the rapid rate at which β-haematin formation occurs in the lipid-water interface system (pH 4.8, 37 °C), 
compared to the acetate system (pH 4.5, 60 °C),64 it has been feasible to investigate the kinetics of this process 
in the presence of various inhibitors. Kinetics studies using CQ were initially conducted to assist in the 
optimization of the modified Phiβ assay in 24-well plates. With the new method optimized, full kinetics 
profiles were collected for the formation of β-haematin in the presence of additional antimalarial drugs, namely 
AQ, QD, QN and MQ. Taking into account the proposed theoretical kinetic model,40 which is based on the 
premise that adsorption of an inhibitor onto the growing crystal face of β-haematin is important, it has been 
possible to draw conclusions regarding the effect of each inhibitor on the formation of β-haematin. 
Furthermore, it has been possible to determine equilibrium adsorption constants, Kads, which is essentially the 
main aim in this section. The model is based mathematically on the Langmuir isotherm, as well as the Avrami 
equation, as discussed previously in section 1.5.4.3.2.40 This section focusses on the effect of each antimalarial 
drug on the formation of β-haematin, compared to what has previously been accounted for in the Falcon tubes. 
The effect of CQ is discussed in detail below, followed by a brief summary of the results obtained for the other 





clinically-relevant quinoline antimalarial drugs. A detailed kinetic investigation of the formation of β-haematin 
in the absence and presence of CQ was carried out by introducing different concentrations of CQ into the 
aqueous phase of the biomimetic system. Given that CQ showed good β-haematin inhibitory activity in the 
lipid-water system (IC50 = 18.8 µM, which is equivalent to 0.0188 mM), a concentration range of 0.01 to 0.10 
mM was considered. The concentration ranges used for the other antimalarial drugs were chosen according to 
their activity relative to that of CQ. The procedure outlined in section 3.2.1.6 was followed for kinetics data 
analysis. Both z and Kads were calculated from the slope and intercept values determined from the linear region 
of the plot in Figure 3.11 (a). By fitting the kinetic data to Equation 3.1 and using these parameters as 
constraints, the best fit of the experimental kinetic data was generated and is found to be in good agreement 
with the proposed theoretical kinetic model (Figure 3.11 (b)). During the fitting process, the values for k2 were 
allowed to refine freely. It is shown that the same percentage β-haematin yield is formed, however, a decrease 
in the rate of β-haematin formation is observed as the CQ concentration is increased. Following the 
incorporation of higher CQ concentrations, a notable decrease in the final yield of β-haematin is observed.  
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Figure 3.11 Kinetics of β-haematin formation in the presence of chloroquine. (a) A plot of the inverse of the 
rate constants, zobs, as a function of increasing CQ concentration yields a linear correlation (black line) with an 
r2 value of 0.99 at low concentrations. Kads (165.9 ± 34.8 mM) and z (0.017 ± 0.003 min-1) values were 
computed from the slope (9844 ± 697 min. mM-1) and intercept values (59.3 ± 11.7 min). The best fit of the 
experimental data to Equation 1.4 is shown in purple and corresponds to an r2 value of 0.84 (b) Kinetic traces 
observed in the absence (●) and presence of increasing concentrations of CQ: 0.01 (●), 0.02 (●), 0.025 (●), 
0.03 (●) 0.05 (●), 0.075 (●) and 0.10 (●) mM. The r2 values are 0.95, 0.93, 0.95, 0.91, 0.94, 0.86, 0.59 and 
0.38, respectively. 
 
A kinetics profile for each of the other antimalarial drugs is presented below, which includes the plot of the 
inverse of zobs as a function of increasing drug concentration, fitted to Equation 1.4 (Figure 3.12, left panel), as 
well as the plot of the percentage β-haematin formed over time, fitted to the theoretical kinetic model (Equation 
3.1) (Figure 3.12, right panel). A table summarizing the calculated Kads and z values for each antimalarial drug 
is also provided (Tables 3.4). The kinetics effects of AQ, QD and QN have been investigated previously, 
however, this study is the first to investigate the effect of MQ on the lipid-mediated formation of β-haematin.  
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Figure 3.12 Kinetics of β-haematin formation in the presence of antimalarial drugs. Left panel (a, c, e, g): a 
plot of the inverse of the rate constant, zobs, as a function of increasing drug concentration, yields a linear 
correlation (black line) at low concentrations from which the Kads and z values were computed from the slope 
and y-intercept values. The best fit of the experimental data to Equation 1.4 is shown in purple. Right panel 





(b, d, f, h): kinetic traces fitted to Equation 3.1 observed in the absence and presence of increasing inhibitor 
concentrations. The antimalarial drugs investigated were amodiaquine, quinidine, quinine and mefloquine. 
The linear correlation (black line) and the best fit of the experimental data to Equation 1.4 (purple curve) shown 
in the left panel of Figure 4.5 (a, c, e and g), correspond to good r2 values (0.99, 0.99, 0.96 and 0.96) and (0.99, 
0.76, 0.97 and 0.86) for AQ, QD, QN and MQ, respectively. The kinetic traces fitted to Equation 3.1 in the 
right panel of Figure 3.12 (b, d, f and h) also correspond to good r2 values for each drug at each respective 
concentration. In the case of CQ, the r2 values for the fit of the data at each concentration range between 0.38 
and 0.95. Fits with lower r2 values are observed at higher concentrations (r2 = 0.38 for 0.1 mM) and may 
possibly be attributed to the formation of the proposed drug-haem complex, for which the solubility in aqueous 
pyridine is still unknown. The r2 values for the kinetics traces are between 0.89-0.93, 0.48-0.96, 0.88-0.95 and 
0.72-0.97 for AQ, QD, QN and MQ, respectively. 
 
Table 3.4 The best fit values to the theoretical kinetic model for β-haematin formation in the presence of AQ, 







z (min-1) k2 Kads (mM-1) 
Log Kads  
(M-1) 
CQ 9844 ± 697 59.3 ± 11.7 0.017 ± 0.003 0.105 165.9 ± 34.8 5.22 ± 0.33 
AQ 23830 ± 3461 62.1 ± 14.4 0.016 ± 0.004 0.155 384 ± 105 5.58 ± 0.44 
QD 3447 ± 211 56.0 ± 12.9 0.018 ± 0.004 0.022 61.6 ± 14.7 4.79 ± 0.38 
QN 4160 ± 591 74.3 ± 27.3 0.013 ± 0.005 0.004 55.9 ± 22.0 4.75 ± 0.63 
MQ 594.7 ± 89.9 52.9 ± 1.7 0.019 ± 0.001 0.003 11.2 ± 0.3 4.05 ± 0.04 
†Error calculated as standard error of the mean (SEM), following three experimental repeats, each including triplicate data points. 
 
It is observed that the rate constant of β-haematin formation in the absence of an inhibitor, z, is statistically the 
same for the various antimalarial drugs. The value of z in all five cases is approximately 0.02 min-1, which is 
ten-fold lower than that determined in the Falcon tubes. It was observed that the value of the rate constant for 
the proposed competing precipitation process, k2, could take on a wide range of values, however, the reported 
values above were chosen in order to generate good fits to the theoretical model for each drug, respectively. 
For the antimalarial drugs, k2 varied between values of 0.003 and 0.155. Interestingly, values of k2 appear to 
decrease with a decrease in Kads values, however, this was not investigated further. Important relationships are 
observed between the Kads values determined for the antimalarial drugs and their respective IC50 values 
determined in the previous section. These relationships are discussed in the following section. 
  





3.2.3 Relationships between Drug Activity and Strength of Adsorption 
After performing both activity- and kinetic studies with the known antimalarial drugs at the lipid-water 
interface, the relationship between the observed IC50 and Kads values was investigated. A linear correlation 
with an r2 value of 0.83 (Figure 3.13 (a)) suggests that the inhibitory activity of a compound may very well be 
related to its strength of adsorption to the growing β-haematin crystal in the lipid-mediated system. This 
observation lends possible insight into understanding the mechanism of the inhibition of β-haematin formation 
in biomimetic systems. Subsequently, the Kads values were compared against the biological activity reported 
against the CQS parasite strains, NF54,160 3D7147 and D10.160 Linear correlations, with r2 values of 0.68, 0.93 
and 0.60, respectively, are observed between these values (Figure 3.13 (b-d)) and indicate a good agreement 
between the biological and experimental data. These correlations are, however, not significant (except in the 
case of the 3D7 parasite strain), indicated by P values > 0.05. This is in part due to an insufficient number of 
data points included in the analysis, since MQ was omitted from these correlations. It was thus recognized that 
in order to draw any meaningful conclusions, it would be important to extend the data set further, by 
introducing other inhibitors into the system. This was achieved by investigating additional quinoline 
derivatives that had previously been shown to be β-haematin inhibitors.158 























































































Figure 3.13 Important correlations observed for antimalarial drugs. The linear correlations between the 
observed Kads values and (a) the IC50 values determined in the lipid-water interface system (24-well plates) and 
the biological IC50 values determined previously against the (b) NF54,160 (c) 3D7147 and (d) D10160 CQ sensitive 
parasite strains. The r2 values are 0.83, 0.68, 0.93 and 0.60, respectively. In all four correlations MQ has been 
omitted as an outlier (indicated by the open circle). 





3.3 Extending the System to Other Quinoline-based β-Haematin Inhibitors 
 
After optimizing and validating the 24-well plate method of the Phiβ assay to investigate the inhibition of β-
haematin at the lipid-water interface, it was considered to extend the study in this system even further to include 
other β-haematin inhibitors. The 4-aminoquinoline inhibitors used in this section are short chain chloroquine 
derivatives with different substituents at the 7-position. These compounds were previously synthesized in a 
study by Kaschula et al.158 to investigate structure-activity relationships and were chosen for use in the current 
study owing to their simple structures and based on their β-haematin inhibitory activities (referred to as BHIA50 
in the original reference). The compounds were kindly resynthesized by Mr J. Hay for the current study, and 
their molecular structures have been presented previously in Figure 1.30 (a). 
 
3.2.1 Experimental Methods 
3.3.1.1 Introducing the Chloroquine Derivatives into the Aqueous Citrate Buffer 
A series of N1, N1-diethyl-N2-(4-quinolinyl)-1, 2-ethanediamines with different substituents at the 7-position 
on the quinoline ring have been investigated previously.158 The 7-chloro (Q-Cl), -iodo (Q-I), -trifluoromethyl 
(Q-CF3), -methoxy (Q-OMe) and -trifluoromethylthio (Q-SCF3) 4-aminoquinolines were, however, 
resynthesized for the purpose of this study, and were made available in their free base forms. As such, they are 
completely insoluble in the aqueous citrate buffer, however, can easily be converted into their salt forms by 
protonation at the terminal amine and quinoline nitrogen atoms (highlighted in blue in Figure 3.14). By 
dissolving each compound in a small amount of ethylacetate and protonating it by the addition of an excess of 
moderately strong acid, HNO3, the salt form of the compound precipitated out of solution. After extensive 
washing with ethylacetate and allowing the product to dry overnight on a high vacuum pump, the desired salt 
could be recovered ([fb+2H]2+(NO3-)2, where fb = free base). Once in their salt form, these compounds were 
readily soluble in the aqueous citrate buffer. Stock solutions of the citric acid monohydrate buffer (50.0 mM, 
pH 4.8), including the appropriate mass of each 4-aminoquinoline inhibitor (Table 3.5), were prepared in a 
similar manner as described for the antimalarial drugs in section 3.2.1.1.  
 
 
Figure 3.14 Structure of the short-chain CQ analogues investigated in this study. The terminal amine and 
quinoline nitrogen atoms, which are protonated to yield the salt form of these compounds, are indicated in 
blue, where X = Cl, I, CF3, OMe or SCF3, respectively.158 
.3.  





Table 3.5 Quantities of short-chain CQ analogue salts required to prepare a 100.0 mL† stock solution in 50.0 








Q-Cl 403.81 0.10 4.0 
Q-I 498.26 0.10 4.9 
Q-CF3 437.37 0.20 8.8 
Q-OMe 399.39 0.40 16.0 
Q-SCF3 469.44 0.20 9.4 
†The volume can be adjusted according to the amount needed for a specific experiment. 
 
3.3.1.2 Short-chain CQ Analogue Activity Studies 
Studies were carried out to determine the IC50 value for the 4-aminoquinoline compounds in the lipid-water 
interface system. In these experiments, the incubation time was fixed, while the concentrations of each 4-
aminoquinoline β-haematin inhibitor were varied. Due to a limited amount of compound provided, a complete 
activity study could unfortunately not be conducted for the 7-methoxy aminoquinoline derivative. 
The procedure described in section 3.2.1.2 was followed to investigate the activity of the remaining four 4-
aminoquinoline compounds, however, due to limited quantities of each compound provided, triplicate studies 
could not be repeated three times for all the compounds as before. 
 
3.3.1.3 Short-chain CQ Analogue Kinetics Studies  
Kinetics studies were carried out in order to determine the Kads value of each 4-aminoquinoline compound in 
the lipid-water interface system. In these experiments, the incubation time, as well as the concentration of each 
β-haematin inhibitor, were varied in order to obtain a full profile for each compound. 
The procedure described in section 3.2.1.5 was followed to investigate the kinetics of β-haematin formation in 
the presence of the 4-aminoquinoline compounds, however, due to limited quantities of each compound 
provided, triplicate studies could not be repeated three times for all of the compounds. 
 
3.2.2 Results 
3.3.2.1 Short-chain CQ Analogue Activity Studies 
Similarly to the antimalarial drugs, inhibitor activity studies were performed independently of the kinetics 
studies to determine the IC50 value for each short-chain CQ analogue (as described in section 3.2.1.2). The 
dose-response curves for the inhibition of β-haematin formation by Q-Cl, -I, -CF3 and –SCF3 are shown in 
Figure 3.15. The observed IC50 values for each inhibitor (Table 3.6) were determined by fitting the data to 
either a sigmoidal or a simple hyperbolic function. Three of the inhibitors, namely Q-Cl, -I and –SCF3, yielded 
3





a good sigmoidal fit with r2 values of 0.94, 0.99 and 0.64, respectively. The data for Q-CF3 conformed to a 
hyperbolic function with an r2 value of 0.90. Again, this may suggest that an incubation period longer than four 
hours is required for complete inhibition by Q-CF3. In all four cases, an increase in the absorbance at 405 nm 
is observed as a function of increasing inhibitor concentration. This is expected, since an increase in inhibitor 
concentration would inhibit the conversion of free Fe(III)PPIX into β-haematin to a greater extent, and hence 
an increase in the absorbance of free Fe(III)PPIX will be observed.  
 


















































Figure 3.15 The inhibition of β-haematin formation by short-chain CQ analogue inhibitors at the lipid-water 
interface. Dose-response curves determined in activity studies after a four-hour incubation period as a function 
of increasing inhibitor concentration for the 4-aminoquinolines with (a) -Cl, (b) -I, (c) –CF3 and (d) –SCF3 
substituents. The IC50 value of each quinoline inhibitor is determined by fitting the data to either a sigmoidal 
(a, b and d) or a hyperbolic (c) function. 
 
Both the BHIA50, as well as the β-haematin inhibition ability determined spectroscopically (βHI) for each 
compound are reported in Table 3.7. The BHIA50 values were previously-determined in an acetate buffer 
system,158 while the βHI is indicated by a + for a β-haematin inhibitor and a – for a non- β-haematin inhibitor. 
According to their BHIA50 values, these compounds appear to be moderately comparable in activity compared 
to CQ,142 except Q-OMe, which is expected to be inactive. Unfortunately, the activity of Q-OMe could not be 
determined in the lipid-water interface system owing to the limited amount of material provided. 





Table 3.6 Comparative IC50 values obtained for the inhibition of β-haematin formation by a series of 
chloroquine derivatives in the lipid-water interface system in 24-well plates and those determined previously 
in an acetate buffer system.142,158 
Aminoquinolines 24-Well Plates (µM)† βHI₸ BHIA50╪ 
Q-Cl 29.8 ± 0.7 + 2.2 ± 0.2 
Q-I 35.7 ± 0.9 + 2.8 ± 0.2 
Q-CF3 55.5 ± 9.9 + 8.0 ± 2.0 
Q-OMe ND‡ - >20 
Q-SCF3 167.3 ± 9.0 + 2.1 ± 0.3 
†Error calculated as standard error of the mean (SEM), following at least two experimental repeats, each including triplicate data points, 
‡Not determined due to limited amount available, ₸Infrared determination of inhibition of β-haematin formation, ╪BHIA50 in 
equivalents of aminoquinoline relative to haematin to inhibit 50% conversion, iii  
 
Interestingly, when plotting the observed IC50 values obtained in the lipid-water interface system for the 
combined set of quinoline inhibitors (antimalarials and aminoquinolines) against their BHIA50 
counterparts,142,158 no obvious correlation is observed (Figure 3.16). The Q-SCF3 analogue (circled in purple), 
which was found to be a relatively active β-haematin inhibitor in the acetate system, is readily identified as 
inactive when comparing its activity in the lipid-water system. Since the two different in vitro systems mediate 
β-haematin formation in different manners, it is likely that compounds may display different activity results. 
The observation does, however, suggest that the lipid-mediated system may be a better model for activity 
determination than the acetate model, since it is biologically more relevant than that of the acetate model. As 
mentioned before in section 1.4.3.1, the acetate method also displays a completely different crystallization 
behaviour compared to the lipid system, suggesting that the lack of correlation is perhaps somewhat 
unsurprising. Owing to the limited amount of activity data available for the 4-aminoquinoline compounds, no 
additional correlations could be further investigated between the β-haematin inhibitory activity values, 
determined in the current lipid-mediated system and other in-vitro assay systems (the NP40-detergent mediated 
system for example). 
 




















Figure 3.16 The correlation between the observed IC50 values, obtained after 4 hours in the 24-well plate assay, 
compared to previously determined BHIA50 values in an acetate medium assay. 142,158 





3.3.2.2 Short-chain CQ Analogue Kinetics Studies  
The kinetics studies were also extended from the known antimalarial drugs to investigate the effect of other 
quinoline-based β-haematin inhibitors. This study is the first to investigate the effect of other quinoline-based 
inhibitors on the lipid-mediated formation of β-haematin. Full kinetics profiles were collected for the formation 
of β-haematin in the presence of Q-Cl, Q-I, Q-CF3, Q-OMe and Q-SCF3. Taking into account the proposed 
theoretical kinetic model, which is based on the premise that adsorption of an inhibitor onto the growing crystal 
face of β-haematin is important, it is possible to explain the effect of each inhibitor on the formation of β-
haematin, and to determine their equilibrium adsorption constants, Kads, which is essentially the main aim in 
this section. The procedure outlined in section 3.2.1.6 was followed for kinetics data analysis. 
A comprehensive kinetics profile for each short-chain CQ analogue inhibitor is presented below, which 
includes the plot of the inverse of zobs as a function of increasing drug concentration, fitted to Equation 1.4 
(Figure 3.17, left panel), as well as the plot of the percentage β-haematin formed over time, fitted to the 
theoretical kinetic model (Equation 3.1), (Figure 3.17, right panel). A table summarizing the calculated values 
for each antimalarial drug is also provided (Table 3.7). 
Given that Q-Cl showed the greatest β-haematin inhibitory activity of the short-chain CQ analogues in the 
lipid-water system (IC50 = 29.8 µM, which is equivalent to 0.0298 mM), a concentration range of 0.01 to 0.10 
mM was considered. The same or higher concentration ranges were thus considered for the other quinoline 
inhibitors which are less active than Q-Cl. 
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Figure 3.17 Kinetics of β-haematin formation in the presence of short-chain CQ analogues. Left panel (a, c, 
e, g, i): a plot of the inverse of the rate constant, zobs, as a function of increasing inhibitor concentration, yields 
a linear correlation (black line) at low concentrations from which the Kads and z values were computed from 
the slope and y-intercept values. The best fit of the experimental data to Equation 1.4 is shown in purple. Right 
panel (b, d, f, h, j): kinetic traces fitted to Equation 3.1 observed in the absence and presence of increasing 
inhibitor concentrations. 





The linear correlation (black line) and the best fit of the experimental data to Equation 1.4 (purple curve) shown 
in the left panel of Figure 4.17 (a, c, e, g and i), correspond to good r2 values (0.94, 0.93, 0.99, 0.99 and 0.90) 
and (0.78, 0.91, 083, 0.79 and 0.77), respectively, for each of the short-chain CQ analogue inhibitor. The 
kinetic traces fitted to Equation 3.1 in the right panel of Figure 3.17 (b, d, f, h and j) also correspond to good 
r2 values for each inhibitor at each respective concentration. The r2 values for these traces are between 0.61-
0.93, 0.89-0.95, 0.65-0.96, 0.84-0.93 and 0.88-0.93 for Q-Cl, -I, -CF3, -OMe and –SCF3, respectively. 
 
Table 3.7 The best fit values to the theoretical kinetic model for β-haematin formation in the presence of 4-







z (min-1) k2  Kads (mM-1) 
Log Kads  
(K-1) 
Q-Cl 2510 ± 455 67.1 ± 8.52 0.015 ± 0.002 0.090 37.4 ± 8.29 4.57 ± 0.35 
Q-I 4192 ± 572 46.8 ± 17.3 0.021 ± 0.008 0.045 89.6 ± 35.4 4.95 ± 0.63 
Q-CF3 1724 ± 43.6 45.6 ± 2.65 0.022 ± 0.001 0.027 37.8 ± 2.39 4.58 ± 0.10 
Q-OMe 712.5 ± 11.8 69.4 ± 0.76 0.014 ± 0.001 0.010 10.3 ± 0.20 4.01 ± 0.03 
Q-SCF3 1695 ± 277 73.0 ± 15.4 0.014 ± 0.003 0.035 23.2 ± 6.20 4.37 ± 0.43 
†Error calculated as standard error of the mean (SEM), following at least two experimental repeats, each including triplicate data points. 
 
As per antimalarial drugs, it is observed that the rate of β-haematin formation in the absence of an inhibitor, z, 
is the same for all short-chain chloroquine analogues. The value of z in all five cases is approximately 0.02 
min-1, which corresponds to the quinoline antimalarial drugs. The value of the rate constant of the proposed 
competing precipitation process, k2, as mentioned previously, could take on a wide range of values, however, 
the reported values above were chosen in order to generate good fits to the theoretical model for each inhibitor, 
respectively. For the short-chain chloroquine analogues, k2 varied between values of 0.01 and 0.09 for each 
compound, which falls into the broad range of k2 values of 0.004 and 0.450 determined for the antimalarial 
drugs. There is, however, no specific relationship observed between the k2 and respective Kads values. Important 
relationships are observed between the Kads values of these quinoline compounds and the antimalarial drugs 









3.4 Combining Quinoline-based β-Haematin Inhibitors 
 
After investigating the inhibition of β-haematin formation in the lipid-water interface system, it was important 
to consider all the quinoline-based β-haematin inhibitors, including both the antimalarial- and 4-
aminoquinoline compounds, together. To establish whether the behaviour of these compounds conform to the 
hypothesis that the β-haematin inhibitory activity of a compound is related to its strength of adsorption to the 
growing β-haematin crystal, their respective IC50  and Kads values were correlated to each other.  
The observed Kads values were compared to the IC50 values determined for each compound in the current study 
and this yielded a significant linear correlation, with an r2 value of 0.78 (Figure 3.18 (a)). The data points for 
MQ (indicated by an open circle) and Q-OMe have not been included the correlation; MQ is the only compound 
which was introduced differently into the system and owing to limited material, no IC50 value could be 
determined for the latter. There is indeed a direct relationship between the respective Kads and IC50 values 
determined in the biomimetic lipid-mediated system, suggesting that the proposed adsorption of an inhibitor 
to growing β-haematin crystals might possibly be related to the mechanism of inhibition of β-haematin 
formation. 
Subsequently, the Kads values were compared to the biological activity reported against the D10 CQS parasite 
strain for each compound,158 which also yielded a linear correlation (r2 value of 0.67) (Figure 3.18 (b)). There 
is a significant agreement between the biological- and experimental data, further suggesting that adsorption 
might indeed play a critical role in the biological mechanism of action by quinoline inhibitors. 
 






























Figure 3.18 Important correlations observed for quinoline-based β-haematin inhibitors. The linear correlations 
between the observed Kads values and (a) the IC50 values determined in the lipid-water system (24-well plates) 
and (b) previously determined biological activities against the CQS D10 parasite strain for both sets of 
quinoline inhibitors (antimalarials and 4-aminoquinolines).158,160 The r2 values are 0.78 and 0.67, respectively. 
In both cases the data point for MQ (open circle) has been omitted from the linear correlation. 
  







The main focus of this part of the study was to investigate the interaction between quinoline-based β-haematin 
inhibitors, and Fe(III)PPIX, resulting in the inhibition of β-haematin formation. The first important objective 
was to optimize the previously-used modified Phiβ assay. This work built on from preliminary studies reported 
in our laboratory,40 which created a fundamental basis in understanding the behaviour of antimalarial drugs on 
the formation of β-haematin. In order to develop a higher-throughput assay, the same known antimalarial drugs 
were systematically incorporated into the lipid-mediated system, adjusting different variables in the process. 
The main advantage of the optimized assay is the faster turnaround time per individual compound investigated 
in the lipid-mediated system. Previously, it took weeks or months to conduct a detailed kinetics study for a 
single β-haematin inhibitor, hence the effect of only four compounds on the formation of β-haematin had been 
investigated prior to the current study in this system.40 
It has previously been shown by Hoang et al.74 that an increase in the surface area of a vessel in which β-
haematin formation is performed results in a decrease in the overall percentage yield of β-haematin with little 
to no change in the rate of formation. This study evidently suggested that the surface area of a vessel plays a 
major role in the percentage yield of β-haematin formation. Interestingly, in the current study, the same amount 
of β-haematin is formed, but over a longer period of time, when changing the experimental vessel from 15 mL 
Greiner Falcon centrifuge tubes to 24-well plates. The diameter of the two vessels is, however, the same, 
accounting for the same amount of β-haematin formed. The observed ten-fold decrease in the rate of β-
haematin formation in the absence of an inhibitor could be accounted for following an investigation of the 
effect of different solvent concentrations in the system. A higher lipid-Fe(III)PPIX to buffer ratio is present in 
the end volume of each well in a 24-well plate compared to the ratio in each Falcon tube, resulting in higher 
organic solvent (acetone: methanol) concentrations. Based on the proposed evolution of a lipid emulsion during 
solvent mixing rather than the formation of a distinct lipid-water interface,74 it is plausible that the rate of 
diffusion of acetone and methanol, the solvents in which the lipid and Fe(III)PPIX are introduced into the 
system, is slower in each well compared to a faster rate of diffusion in each tube. This in return will have an 
effect on the rate at which the lipid-water interface forms in the system, and hence will influence the rate of β-
haematin formation. By increasing the incubation period, the maximum yield of β-haematin could still be 
attained. 
In order to probe the relative β-haematin inhibitory activity of each antimalarial drug, independent drug activity 
studies were carried out with AQ, CQ, MQ, QD and QN in the newly-optimized lipid-mediated system. When 
comparing the data obtained from the optimized assay to the previously-used lipid-mediated assay, the IC50 
values are in good agreement with one another (Figure 3.8 (a)).40 The observed trend in drug activity is the 
same, with AQ being the most active β-haematin inhibitor, followed by CQ, QD and QN, respectively. The 4-
aminoquinoline antimalarial drugs are more active β-haematin inhibitors in the lipid-water interface system 
than the quinoline methanol antimalarial drugs. Subsequently, the β-haematin inhibitory activity of each drug 





was also compared against previously-determined drug activities obtained from two different in vitro assays. 
The Phiβ acetate assay was one of the first higher-throughput assays developed to investigate the formation of 
β-haematin and the inhibition thereof.145 There is no correlation between the IC50 values determined in the 
current lipid-mediated system and the IC50 values, determined as drug equivalents, in the acetate medium 
(Figure 3.8 (b)). A significant correlation is, however, observed when comparing the relative IC50 values to the 
drug activities determined in the NP40-detergent mediated assay, which is a lipid environment mimic assay 
(Figure 3.8 (c)). These observations suggest that a lipid-mediated environment is more relevant for 
investigating the inhibition of β-haematin formation than previously-used acetate medium assays. 
Furthermore, a good correlation is also observed between the IC50 values obtained from the current system and 
previously-determined activities against the 3D7 CQS parasite strain.147 Overall, taking the correlations in 
Figures 3.8 and 3.9 into account, the data are indicative that the newly-optimized assay, incorporating in the 
lipid-water interface in 24-well plates, is indeed a valid system in which to investigate drug activity  
As the theoretical model predicts, the dose-response behaviour from the respective kinetics profiles generates 
hyperbolic dose-response curves at shorter incubation times, and sigmoidal dose-response curves at longer 
incubation times (Figure 1.28). In the current study, however, both dose-response curves are observed for the 
experimental inhibition data for IC50 determination at a four-hour incubation period for the quinoline β-
haematin inhibitors (antimalarial drugs and short-chain chloroquine analogues). AQ, CQ, MQ, Q-Cl, Q-I and 
Q-SCF3 produce sigmoidal dose-response curves, while QD, QN and Q-CF3 gives rise to a hyperbolic function. 
According to the theoretical model, a hyperbolic dose-response curve is indicative of a measurement having 
been made while the formation of β-haematin is still underway. On the other hand, the model predicts a 
sigmoidal dose-response curve when the incubation time is sufficiently long such that the formation of β-
haematin has reached its maximum. Given the decreased rate of β-haematin formation in the 24-well plates, a 
longer incubation time (four hours) was chosen compared to the earlier studies (30 minutes). In both cases, the 
choice of incubation time was not informed by any particular experiment, and alternative incubation times 
could have been chosen. What is important, however, is that incubation time was fixed for the activity studies, 
allowing comparisons to be made and conclusions drawn based on the variable in the system, namely the 
different inhibitors. 
An independent time study shows that there is a non-linear relationship between the IC50 values and increasing 
incubation time for CQ and QD (Figure 3.10). It is apparent that shorter incubation times have a more 
prominent effect on the IC50 value of a specific drug, while little further change is observed at longer incubation 
times. This is an important observation which was made in the previous study as well, suggesting the 
importance of taking incubation times into consideration when investigating β-haematin inhibitors.40 The 
incubation time at which activity studies were investigated in the current study was chosen arbitrarily as four 
hours, compared to 30 minutes, which was also chosen arbitrarily in the previous study. The fact that the 
absolute magnitude of the IC50 value for a particular drug is marginally different in the two studies may be due 
in part to the fact that measurements were not made at the same incubation time. The increase in incubation 
time in the current study was, however, decided upon owing to the ten-fold decrease observed in the rate of β-





haematin formation. It is important to note that since the IC50 value of a compound is related to incubation 
time, a different IC50 would be expected when a different incubation time is chosen. This would have an impact 
on the overall correlations which are made with the calculated IC50 values in the lipid-mediated system and 
may improve the r2 values of these correlations overall. However, with the current incubation time of four 
hours, the observed correlations still suggest that the lipid-mediated system is a suitable mimic of the in vivo 
environment. 
No significant relationship is observed for the quinoline β-haematin inhibitors (antimalarial drugs and short-
chain chloroquine analogues) when correlating their respective IC50 values obtained in the current lipid-
mediated system to the β-haematin inhibitory activity in an acetate medium system (determined as inhibitor 
equivalents).158 The inhibitory activity for Q-SCF3 was determined to be better than Q-Cl in the acetate 
system,158 however, it appears to be five time less active than the 7-chloro substituted short-chain 4-
aminoquinoline in the lipid-mediated system. The other three inhibitors were found to have similar activities 
relative to each other when comparing the two systems; Q-Cl being more active than Q-I and Q-CF3, 
respectively. This observation further supports the suggestion that the acetate medium, or any other non-
biological medium, as a system of β-haematin formation and inhibition thereof is unfavourable and 
investigating β-haematin inhibitory activities in more biologically-relevant systems, such as the lipid-mediated 
systems, is more effective and sensible. Biologically-relevant systems are in closer comparison to the 
environment in the neutral lipid bodies within the digestive vacuole, in which haemozoin formation occurs in 
vivo. The fact that false positives may occur in the acetate system and not in the lipid system, indicates that the 
latter produces more reliable results. 
In this part of the current study, the effect of quinoline-based β-haematin inhibitors on the formation of β-
haematin was investigated at the lipid-water interface. Compared to the previous kinetics studies,40 similar 
observations were recorded with regards to overall β-haematin inhibition. A decrease in the rate of β-haematin 
formation is observed as the inhibitor concentration is systematically increased, while a decrease in the 
percentage yield of the β-haematin formed is evident when introducing very high concentrations of inhibitor. 
This observation is made throughout the study for the antimalarial drugs and the 4-aminoquinoline analogues, 
suggesting that both sets of quinoline-based inhibitors behave similarly in the inhibition of β-haematin 
formation, even though the decrease in the yield of β-haematin formation is not noticeable for all the inhibitors. 
It is considered that the quinoline-based inhibitors act by decreasing the rate of β-haematin formation at low 
concentrations which are biologically relevant, rather than inhibiting the β-haematin formation completely. It 
has been proposed that the decrease in the rate of β-haematin formation may be accounted for by the 
noncovalent adsorption of the inhibitors to the growing crystal surface of β-haematin,39 while the decrease in 
β-haematin yield at high inhibitor concentration, may be accounted for by the irreversible precipitation of 
Fe(III)PPIX as an inhibitor complex.40 It is known that β-haematin inhibitory compounds are able to associate 
with free Fe(III)PPIX in solution by means of coordination or π-stacking. Such complexation would prevent 
its incorporation into β-haematin,117,118 which would therefore result in a decrease in the final yield of β-
haematin formed. 





The observed rate constant of β-haematin formation in the absence of an inhibitor (z), was determined from 
the plots of the inverse of zobs as a function of increasing inhibitor concentration, in each case. The value in all 
cases for the quinoline-based inhibitors was found to be approximately 0.02 min-1. This observation is 
consistent with what is expected, since z is independent of an inhibitor under similar system conditions. The 
Kads values were also successfully extracted from these plots for each quinoline-based inhibitor, while the 
experimental kinetics data recorded for each inhibitor conform to the proposed theoretical kinetic model used 
to probe the behaviour of each inhibitor in the lipid-mediated system. For the best fit to the model, the Kads and 
z values were constrained to the values attained from the linear regression analysis. Accurate values for k2, the 
rate constant for the proposed competing process that results in the precipitation of haematin, were not 
investigated in the current study, since this process is still poorly understood. The k2 values were thus allowed 
to refine freely in order to generate the best fit of the experimental data to the model. The k2 value can generally 
accommodate a range of values and is the only parameter that was adjusted to generate good r2 fits. In the 
current study, k2 was varied in a broad range between 0.003 and 0.155 for the antimalarial drugs, while a range 
of values between 0.01 and 0.09 was considered for the 4-aminoquinoline inhibitors. It is, however, important 
to be able to determine the k2 values independently for each individual group of inhibitors, and this is 
recommended for future studies to improve our understanding of the system and the interplay between different 
processes involving Fe(III)PPIX. 
Good linear correlations are observed between the observed Kads values and the β-haematin inhibitory activity 
values for the antimalarial drugs determined in the current lipid-mediated system, as well as against different 
biological CQS NF54, 3D7 and D10 parasite strains (Figure 3.13). These correlations suggest that the β-
haematin inhibitory activity of each compound is related to its strength of adsorption, which corresponds to 
the main hypothesis of β-haematin inhibition. However, having only four data points in hand, the correlations 
are not significant. In order to draw a meaningful conclusion about a possible activity-adsorption relationship, 
these drugs were viewed together with a set of short-chain CQ analogues. 
A significant linear correlation with an r2 value of 0.78 (P value < 0.01) is observed between the adsorption 
constants (Kads) and the β-haematin inhibitory activities (IC50) obtained for the quinoline-based β-haematin 
inhibitors (Figure 3.18 (a)). For AQ, the most active compound tested in the lipid-mediated system, the large 
adsorption constant of Kads = 384 ± 105 mM-1 is inversely related to its low IC50 value, 5.9 ± 0.3 µM. Similarly, 
but on the other end of the scale, the least active inhibitor, Q-SCF3 (IC50 value of 167 ± 9.0 µM) adsorbs sixteen 
times weaker, Kads = 23.2 ± 6.20 mM-1. According to the significant relationship observed, it is proposed that 
the strength at which the quinoline-based inhibitors might adsorb to the surface of β-haematin crystals, 
inhibiting further growth, is associated with its β-haematin inhibitory activity, at least in the lipid-water 
interface system.  
Notably, a significant linear correlation with an r2 value of 0.67 is also observed between the Kads values and 
previously-determined biological activity against the CQS D10 parasite strain (Figure 3.18 (b)). It is important 
to notice that the data points are well spread out along the linear line, suggesting that the correlation is not in 
any way a result of points assembling together or the weighting of one particular data point on either side of 





the line. The adsorption-activity correlation is evident and correlating this to the observations made in the lipid-
mediated system, it further suggests that the biological mechanism of haemozoin inhibition by quinoline-based 
inhibitors, might also be via adsorption. The somewhat less-impressive value of r2 may be a consequence of 
several other factors that contribute in the biological system, for example a compounds rate of metabolism and 
rate of accumulation in the digestive vacuole. 
The kinetics β-haematin formation in the presence of the 4-aminoquinoline- and quinoline methanol 
antimalarial drugs, as well as the short-chain CQ analogue inhibitors, all conform to the proposed theoretical 
kinetic model, which was developed in an attempt to explain the effect of each inhibitor on the formation of 
β-haematin in the lipid-mediated system. The results reported in this chapter strongly support the hypothesis 
of inhibitor adsorption to the β-haematin crystal surface, as the mode of action, at least in the case of quinoline-
containing inhibitors. 
  







The previously modified Phiβ assay, used to investigate the inhibition of β-haematin formation in the lipid-
water interface system, was successfully optimized in this study. The assay was developed by primarily 
introducing 24- and 96-well plates, as well recording multiple UV-visible measurements simultaneously. The 
assay was validated as biologically-relevant by investigating the β-haematin inhibitory activity of clinically-
relevant antimalarial drugs. The newly-optimized assay reproduced results similar to what has previously been 
recorded, however, in a faster turnaround time per compound, which led to kinetics studies investigating β-
haematin formation in the presence of these antimalarial drugs. The set of quinoline-based inhibitors was 
increased by introducing a series of short-chain CQ analogues into the system, which had not been investigated 
in this manner to date. Based on the results reported in this chapter, an increase in a quinoline-based inhibitor 
concentration results in a decrease in the rate of β-haematin formation. This was observed at low 
concentrations, while a decrease in the yield of β-haematin formation was observed when introducing higher 
doses of each inhibitor. The kinetics data observed for the non-clinically relevant quinoline-based inhibitors, 
provide great insight into understanding β-haematin inhibition, in adding to what has been reported to date in 
this regard. Overall, the results reported in this chapter suggest that there might be a direct relationship between 
the β-haematin inhibitory activity of a compound and its strength of adsorption to the growing face of β-
haematin crystals.  
  





Chapter 4. The Effect of Non-Quinoline Inhibitors on the Formation of              




Owing to the increase in parasite resistance to previously successful quinoline-based antimalarial drugs, such 
as CQ, the development of novel chemotherapeutic agents is of high imporatnce.161 This is well known to date 
and has been a great motivation behind understanding the mechanism of antimalarial drug action to improve 
rational drug design to overcome quinoline resistance. The kinetics results obtained for the inhibition of β-
haematin formation by quinoline-based β-haematin inhibitors, reported in the previous chapter and based on 
previous studies,40 has provided significant insight regarding the possible mechanism of action of an inhibitor 
on the formation of β-haematin crystals. Based on these results, a complimentary study has been carried out in 
order to investigate the effect of non-quinoline-based β-haematin inhibitors on the formation of β-haematin. 
This is the first study carried out in order to investigate the effect of benzamide non-quinoline β-haematin 
inhibitors in the biologically-relevant lipid-water interface system, using monopalmitoyl-rac-glycerol (MPG) 
to mediate the formation of β-haematin. Introducing these compounds into the system and comparing their 
effect on the kinetics of β-haematin formation relative to the quinoline-based β-haematin inhibitors extends 
the set of compounds for which the theoretical kinetic model developed previously, may be applied. For each 
compound, activity and kinetics experiments have been carried out.  
This chapter provides a detailed discussion of the experimental methods followed and results found, regarding 
both the activity- and kinetics studies for a series of benzamide β-haematin inhibitors.  
  





4.2 Extending the System to Non-quinoline β-Haematin Inhibitors 
 
Having extended the inhibition studies by introducing other quinoline-based inhibitors into the lipid-water 
interface system, it was then considered important to investigate additional β-haematin inhibitors, particularly 
those containing non-quinoline scaffolds. The non-quinoline inhibitors investigated in this section were a series 
benzamide scaffolds varying in substituents on the main aromatic ring, and have been chosen since they were 
readily available from our collaborators and appeared to be active β-haematin inhibitors. Their molecular 
structures have been presented previously in Figure 1.30 (b). 
 
4.2.1 Experimental Methods 
4.2.1.1 Introducing Non-quinoline β-haematin Inhibitors into the Aqueous Citrate Buffer 
The non-quinoline β-haematin inhibitors are completely different in their molecular structure and properties 
compared to the quinoline-based inhibitors, which greatly affects their solubility in the aqueous system. 
Alternative mixed aqueous-organic solvent systems were initially considered promising, however, these 
systems complicated the rates and yields of β-haematin formed. Previous investigations have shown that while 
pH does have a significant effect on the yield of β-haematin, lowering the pH of the aqueous buffer such that 
3.0 < pH < 4.8 would incur only marginal decreases in yield.74 The benzamide compounds were completely 
dissolved in the aqueous citrate buffer by moderately heating the solution and lowering the pH to 3.0. The 
more acidic environment ensured complete protonation and hence solubilisation of each compound. 
Stock solutions of citric acid monohydrate buffer (50.0 mM, pH 3.0), including the appropriate mass of the 
non-quinoline (Table 4.1), were prepared similarly as described in section 3.2.1.1 
 
Table 4.1 Quantities of benzamide non-quinoline compounds required to prepare a 100.0 mL† stock in 50.0 




Concentration (mM) Mass (mg) 
nQ-KW16 316.35 0.15 4.8 
nQ-KW17 374.17 0.05 1.9 
nQ-KW23 361.35 0.10 3.6 
nQ-KW31 319.32 0.50 16.0 
nQ-KW32 374.44 0.10 3.7 
nQ-KW33 348.36 0.10 3.5 
† The volume can be adjusted according to the amount needed for a specific experiment and according to the actual amount available 
of each compound. 
 
 





4.2.1.2 Non-Quinoline Activity Studies 
Studies were carried out to determine the IC50 value for each non-quinoline compound in the lipid-water 
interface system. In these experiments, the incubation time was fixed, while the concentration of the β-
haematin inhibitor was varied.  
The procedure described in section 3.2.1.2 was followed to investigate the activity of the non-quinoline 
compounds, however, due to limited quantities of each compound provided, triplicate studies could not be 
repeated three times for all of the compounds as before. 
 
4.2.1.3 Non-Quinoline Kinetics Studies  
Kinetics studies were carried out in order to determine the Kads value for each non-quinoline compound in the 
lipid water interface system. In these experiments, the incubation time, as well as the concentration of each β-
haematin inhibitor, were varied in order to obtain a full profile for each compound. 
The procedure described in section 3.2.1.5 was followed to investigate the kinetics of β-haematin formation in 
the presence of the non-quinoline compounds, however, due to limited quantities of each product provided, 
triplicate studies could not be repeated three times for all of the compounds. 
 
4.2.2 Results 
4.2.2.1 Solubilising Non-Quinoline β-Haematin Inhibitors 
Owing to the poor solubility of the non-quinoline compounds in the aqueous buffer system (pH 4.8), it was 
necessary to optimize the solvent environment of the assay further to accommodate these compounds in the 
system. Two benzamide compounds, nQ-KW23 and nQ-KW32, were used in solubility tests to investigate 
their behaviour in different solvent systems.  
Initially, attempts were made to dissolve the compounds in the 1:9 acetone: methanol solution and introduce 
them into the system in a similar manner as MQ. However, after a short incubation period, the compounds 
precipitated out of the buffer solution. Owing to the greater hydrophobicity of non-quinoline compounds, an 
alternative option was to dissolve the compounds in organic solvents. Compounds were dissolved in either 
DMSO or acetonitrile (ACN) and added to the aqueous citrate buffer in varying ratios (20:80, 30:70, 40:60, 
50:50, 60:40). Multiple solubility tests, which included and excluded the inhibitor, were investigated at room 
temperature after an hour, and at 37 °C after 15 hours, respectively, to investigate the solubility of the buffer 
and the compounds in these solutions. Interestingly, the two compounds behaved similarly (Table 4.2). The 
only solutions in which the compounds did not precipitate out after 15 hours, was the 40:60, 50:50 and 60:40 
ACN: buffer solutions. To investigate the effects of the change in solvent compositions on β-haematin 
inhibition, free base CQ (CQfb) was employed as a standard. CQfb was dissolved in the solvent containing the 





lowest quantity of organic solvent (40:60) and its ability to inhibit β-haematin was evaluated. The results were, 
however, irreproducible and were inconsistent with the findings obtained in the absence of ACN. Alternatively, 
a different approach was required. 
 
Table 4.2 Solubility tests using nQ-KW23 and nQ-KQ32. Investigating different organic solvent: buffer 
ratios as possible solvent systems for non-quinoline compounds. 
 DMSO: Buffer ACN: Buffer 














20:80  x  x  x  x 
30:70  x  x  x  x 
40:60  x  x     
50:50    x     
60:40   x x     
Control samples without (W/o) an inhibitor (inhib) were also included to monitor the effect of possible buffer precipitation out of 
solution. W: with. : Soluble. x: Insoluble  
 
Subsequently, it was considered that a change in the pH of the aqueous citrate buffer may improve the solubility 
of the benzamide compounds. This hypothesis was made on the basis of the computed pKa values which 
indicated that the compounds would be cationic at pH values lower than 3.162 Upon heating and decreasing the 
pH to 3.0, acidifying the aqueous environment, the benzamide compounds were able to solubilise more readily 
in the aqueous system. Owing to previous pH-dependence studies of β-haematin formation at the lipid-water 
interface,74 kinetics studies in the absence of an inhibitor were carried out in order to investigate the effect of 
the lowering in the pH on the formation of β-haematin. Under these conditions, the yield of β-haematin in the 
absence of an inhibitor was found to be the same as in the original approach (pH 4.8). Interestingly, however, 
a further decrease in the rate of β-haematin formation was observed, with the rate decreasing from 0.02 ± 0.001 
min-1 to 0.01 ± 0.001 min-1 (Figure 4.1) 
 























Figure 4.2 The effect of pH on the kinetics of β-haematin formation (in the absence of an inhibitor) in the 
lipid-water interface system. Curves for pH 4.8 (●) and pH 3.0 (●) were obtained. The observed rate constants 
are 0.02 ± 0.001 min-1 and 0.01 ± 0.001 min-1, respectively. 





4.2.2.2 Non-Quinoline Activity Studies 
Similarly to the quinoline-based inhibitors, inhibitor activity studies were performed independently of the 
kinetics studies to determine the IC50 value for each non-quinoline compound (section 3.2.1.2). The dose-
response curves for the inhibition of β-haematin formation by the benzamide β-haematin inhibitors are shown 
in Figure 4.2.  
 








































































Figure 4.2 The inhibition of β-haematin formation by non-quinoline inhibitors at the lipid-water interface. 
Dose-response curves were determined in activity studies after a four-hour incubation period as a function of 
increasing inhibitor concentration for the benzamides (a) nQ-KW16, (b) nQ-KW17, (c) nQ-KW23, (d) nQ-
KW31, (e) nQ-KW32 and (f) nQ-KW33. The IC50 value of each non-quinoline inhibitor is determined by 
fitting the data either to a sigmoidal (a, b, d, e and f) or a hyperbolic (c) function. 





The observed IC50 values for each inhibitor (Table 4.3) were determined by fitting the data either to a sigmoidal 
or a hyperbolic function. Five of the benzamide compounds, namely nQ-KW16, -KW17, -KW31, -KW32 and 
–KW33, yielded a good sigmoidal fit with r2 values of 0.65, 0.69, 0.71, 0.66 and 0.76, respectively, while the 
data obtained for nQ-KW23 fit to a hyperbolic function with an r2 value of 0.64. In all six cases, an increase in 
the absorbance at 405 nm is observed as a function of increasing inhibitor concentration. As before, an increase 
in the concentration of an inhibitor is expected to inhibit the conversion of free Fe(III)PPIX into β-haematin, 
and hence an increase in the concentration of free Fe(III)PPIX, measured as the bis-pyridyl complex, is 
observed. 
 
Table 4.3 IC50 values obtained for the inhibition of β-haematin formation by non-quinoline compounds in 
the lipid-water interface system and those determined previously in NP40 and against the NF54 strain.163 
Non-Quinolines 24-Well Plates (µM) 
NP40-detergent 
(µM) 
Bio. Activity NF54 
(µM) 
nQ-KW16 43.8 ± 4.9 506.9 ± 32.6 9.09 ± 3.94 
nQ-KW17 6.2 ± 1.4 9.05 ± 0.69 0.57 ± 0.14 
nQ-KW23 7.0 ± 2.7 6.99 ± 0.23 1.35 ± 0.15 
nQ-KW31 221 ± 16 260.3 ± 7.2 313 ± ND 
nQ-KW32 7.7 ± 0.9 13.25 ± 0.70 1.61 ± 0.16 
nQ-KW33 9.8 ± 0.6 22.18 ± 1.44 3.04 ± 0.46 
Error calculated as standard error of the mean (SEM), following at least two experimental repeats, each including triplicate data points. 
 
The IC50 values were compared to the activities previously-determined in vitro in the NP40 detergent-mediated 
assay,163 in order to further validate the newly-optimized lipid assay. A linear correlation with an r2 value of 
0.96 was obtained (Figure 4.3), however, the correlation excludes the IC50 data for nQ-KW16 (circled in 
purple). This compound appeared to be extremely inactive in the NP40 system, however, owing to its moderate 
biological activity, it was selected for testing in the lipid-water interface system where it was also observed to 
be moderately active. 
 






















Figure 4.3 Investigating the inhibition of β-haematin formation by non-quinoline inhibitors in the lipid-
mediated system. The correlation between the observed IC50 values compared to previously determined IC50 
values in the NP40 detergent-mediated assay163 (the trend excludes the IC50 data for nQ-KW16). r2 = 0.96. 





The biological activity of each compound against the NF54 parasite strain was determined by our collaborators 
who provided the benzamide compounds for this study.163 When comparing the observed IC50 values obtained 
in the lipid-water interface system to these biological values, a significant linear correlation is evident with an 
r2 value of 0.95 (Figure 4.4). There is a good agreement between the experimental and biological activity of 
these compounds, validating the lipid-water interface system, using 24-well plates, even further for 
investigating inhibitors other than quinoline-based compounds.  
 



















Figure 4.4 Investigating the inhibition of β-haematin formation by non-quinoline inhibitors in the lipid-
mediated system. A linear correlation is observed between the observed IC50 values and the biological activity 
against a CQS parasite strain, NF54163 with an r2 value of 0.95.  
 
4.2.2.3 Non-quinoline Kinetics Studies  
This study is the first to investigate the effect of non-quinoline inhibitors on the lipid-mediated formation of 
β-haematin. Full kinetics profiles were collected for the formation of β-haematin in the presence of nQ-KW16, 
nQ-KW17, nQ-KW23, nQ-KW31, nQ-KW32 and nQ-KW33. Taking into account the proposed theoretical 
kinetic model, which is based on the premise that adsorption of an inhibitor onto the growing crystal face of 
β-haematin is important, it was possible to determine the equilibrium adsorption constants, Kads, as well as the 
rate of β-haematin formation in the absence of an inhibitor, z, for each benzamide compound. The procedure 
outlined in section 3.2.1.6 was followed for the analysis of all kinetics data of each compound.  
A comprehensive kinetics profile for each non-quinoline inhibitor is presented below, which includes the plot 
of the inverse of zobs as a function of increasing drug concentration, fitted to Equation 1.4 (Figure 4.5, left 
panel), as well as the plot of the percentage β-haematin formed over time, fitted to Equation 3.1 (Figures 4.5, 
right panel). A table summarizing the calculated values for each compound is also provided (Tables 4.4).  
Compound nQ-KW16 was shown to be the least active of the benzamides in the lipid-water system (IC50 = 
43.8 µM, which is equivalent to 0.0438 mM), and a concentration range of 0.01 to 0.15 mM was considered. 
Lower concentration ranges were considered for the remaining non-quinoline inhibitors, which are more active 
than nQ-KW16. 
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Figure 4.5 Kinetics of β-haematin formation in the presence of non-quinoline inhibitors. Left panel (a, c, e, g, 
i): a plot of the inverse of the rate constant, zobs, as a function of increasing inhibitor concentration, yields a 
linear correlation (black line) at low concentrations from which the Kads and z values were computed from the 
slope and y-intercept values. The best fit of the experimental data to Equation 1.4 is shown in purple. Right 
panel (b, d, f, h, j): kinetic traces fitted to Equation 3.1 observed in the absence and presence of increasing 
inhibitor concentrations. 





The linear correlation (black line) and the best fit of the experimental data to Equation 1.4 (purple curve) shown 
in the left panel of Figure 4.5 (a, c, e, g and i), correspond to good r2 values (0.99, 0.90, 0.90, 0.88 and 0.93) 
and (ND, 0.84, 0.80, 0.79 and 0.74), respectively, for each of the non-quinoline inhibitors. The experimental 
data for nQ-KW16 (in a) was not fit to Equation 1.4 owing to insufficient amount of data points. The kinetic 
traces fitted to Equation 3.1 in the right panel of Figure 4.5 (b, d, f, h and j) also correspond to good r2 values 
for each inhibitor at each respective concentration. The r2 values for these traces are between 0.87-0.97, 0.60-
0.95, 0.42-0.95, 0.89-0.94 and 0.78-0.95 for nQ-KW16, -17, -23, 32 and -33, respectively. 
 
Table 4.4 The best fit values to the theoretical kinetic model for β-haematin formation in the presence of 








z (min-1) k2 Kads (mM-1) 
Log Kads  
(M-1) 
nQ-KW16 195.2 ± 12.0 98.5 ± 0.7 0.010 ± 0.001 0.0015 1.98 ± 0.12 3.30 ± 0.10 
nQ-KW17 5507 ± 1294 100.9 ± 8.7 0.010 ± 0.001 0.2000 54.6 ± 13.7 4.74 ± 0.40 
nQ-KW23 6179 ± 1488 89.7± 8.5 0.011 ± 0.001 0.1000 68.9 ± 17.8 4.84 ± 0.41 
nQ-KW32 6275 ± 1649 152.0 ± 19.6 0.010 ± 0.001 0.0055 41.3 ± 12.1 4.62 ± 0.47 
nQ-KW33 1782 ± 275 80.8 ± 6.8 0.012 ± 0.001 0.0300 22.1 ± 3.9 4.34 ± 0.28 
†Error calculated as standard error of the mean (SEM), following at least two experimental repeats, each including triplicate data points. 
 
As was the case for the quinoline-based β-haematin inhibitors, it was observed that the rate of β-haematin 
formation in the absence of an inhibitor, z, was the same for all non-quinoline compounds. The value of z in 
all five cases is approximately 0.01 min-1, which interestingly is lower than that of the quinoline-based 
compounds, however, this observation is due to the lower pH (3.0) of the aqueous buffer used in this section 
of the studies, compared to the quinoline inhibitors. The value of the rate constant for the proposed competing 
precipitation process, k2, as mentioned previously, could take on a wide range of values, however, the reported 
values above were chosen in order to generate good fits to the theoretical model for each inhibitor, respectively. 
For the non-quinoline compounds, k2 varied between values of 0.0015 and 0.20. There is no significant 
relationship observed between the k2 and Kads values of the non-quinoline compounds. Important relationships 
are observed between the Kads values of the non-quinoline compounds and their respective IC50 values 
determined in the previous section, as well as interesting relationships with the quinoline inhibitors. These 
relationships are discussed in the following two sections. 
 
  





4.2.3 Relationships between Drug Activity and Strength of Adsorption 
After performing both activity- and kinetic studies with the benzamide non-quinoline inhibitors at the lipid-
water interface, the relationship between the observed IC50 and Kads values was investigated. A linear 
correlation, with an r2 value of 0.98 was obtained (Figure 4.6 (a)), which strongly suggests that the strength of 
inhibitor adsorption to the growing β-haematin crystal is directly related to its inhibition activity in this 
biomimetic system. This relationship supports the proposed hypothesis that the more active a compound, the 
stronger it will adsorb to the β-haematin crystal face. 
The Kads values were also correlated with the biological activity data reported against the NF54 parasite 
strain,163 which yielded a linear regression, with an r2 value of 0.82 (Figure 4.6 (b)). This correlation indicates 
a good agreement between the biological and experimental data. Both of these correlations are significant with 
a P value smaller than 0.05. These correlations are in agreement with those observed for the quinoline-based 
inhibitors, suggesting that all three groups of inhibitors investigated in this project might conform to the same 
mechanism of action when inhibiting the formation of β-haematin in vitro. This in turn might be related to the 
biological mechanism for haemozoin inhibition. In the following section the correlations between all three sets 
of compounds are discussed. 
 






























Figure 4.6 Important correlations observed for non-quinoline β-haematin inhibitors. The linear correlations 
between the observed Kads values and (a) the IC50 values determined in the lipid-water system and (b) the 
biological IC50 values previously-determined against the NF54 parasite strain.163 The r2 values are 0.98 and 
0.82, respectively, with P < 0.05 in both cases. 
  





4.3 Combining Quinoline- and Non-quinoline-based β-Haematin Inhibitors 
 
In an attempt to address the question whether a single mechanism of action exists for β-haematin inhibitors, 
the data for non-quinoline inhibitors were combined with the results obtained for the quinoline inhibitors in 
the previous chapter. A direct relationship between the respective Kads and IC50 values determined in the lipid-
mediated system for each individual set of inhibitors (Figure 4.7 (a)) was obtained. Significant linear 
correlations, with r2 values of 0.78 and 0.98, are observed between the Kads values and the IC50 values obtained 
in the lipid-water interface system for the quinoline and non-quinoline inhibitors, respectively. Interestingly, 
however, it is observed that the data for the two families fall on separate lines. Furthermore, some of the 
quinoline and non-quinoline inhibitors are observed to have nearly identical IC50 values, yet distinctly different 
Kads values. This suggests that certain non-quinoline compounds may be equally active with regards to their β-
haematin inhibitor activity, yet adsorb to a lesser extent to the crystal surfaces than some quinoline compounds. 
This observation suggest that these two classes of compounds may behave differently after all. 
Subsequently, the Kads value for each compound was compared with the corresponding biological activities 
reported against the NF54 parasite strain.160,163 Considering the quinoline antimalarial and non-quinoline 
inhibitors separately, two linear correlations were obtained with r2 values of 0.68 and 0.82, respectively (Figure 
4.7 (b)). A significant linear correlation is also obtained, however, when considering both classes of 
compounds as a single group (r2 = 0.68, P < 0.05) (Figure 4.7 (b)). The short-chain chloroquine analogues 
could not be included in the correlation as they were not tested against the NF54 strain. 
 
































Figure 4.7 Important correlations observed between quinoline and non-quinoline inhibitors. (a) The linear 
correlations between the Kads and the IC50 values obtained in the lipid-water system for the quinoline- (●) and 
non-quinoline inhibitors (●), with r2 values of 0.79 and 0.98, respectively. (b) The linear correlations between 
the obtained Kads values and the biological activity previously-determined against the NF54 parasite strain160,163 
for the antimalarial (●) and non-quinoline inhibitors (●), with r2 values of 0.61 and 0.81, respectively. 
 





When the antimalarial drugs and the non-quinoline inhibitors are considered as one group, no significant 
correlation is observed between the β-haematin inhibitory activities and the NF54 biological activities for these 
compounds (Figure 4.8). A relationship can, however, be observed when the two groups of compounds are 
investigated separately.  
 




















Figure 4.8 No correlation is observed between the IC50 values obtained in the lipid-water interface system and 
the NF54 biological activities160,163 for the antimalarial drugs (●) and the non-quinoline inhibitors (●), when 
they are considered as a group of compounds. 
  







The aim of the work presented in this chapter is directly related to that of the work reported in the previous 
chapter, namely to investigate the inhibition of β-haematin formation, however, by introducing non-quinoline 
inhibitors into the lipid-water interface system. The introduction of other β-haematin inhibitors, which are 
structurally different to those possessing a quinoline moiety, into the system was considered, since parasite 
resistance to known quinoline-based antimalarial drugs has increased in recent years.161 Chemically-distinct 
compounds possessing the same mode of action are attractive as new antimalarial drug candidates and are thus 
investigated in this study. This is the first study carried out in order to investigate the effects of benzamide 
inhibitors on the kinetics of β-haematin formation in the lipid-mediated system. 
Owing to their poor solubility in aqueous medium, the newly-optimized assay was further modified to facilitate 
the incorporation of the benzamide non-quinoline compounds into the aqueous citrate buffer system. To readily 
solubilise the compounds in the aqueous solvent, the pH was lowered to 3. Hoang et al.74 has previously 
determined the pH dependence of β-haematin formation in the lipid-water interface system and recorded a 
bell-shaped curve, indicating maximum β-haematin production between pH 3 and 4. This aided the decision 
to lower the pH, since optimal β-haematin formation was still expected, and subsequently confirmed, in the 
biomimetic system. 
In order to probe their relative β-haematin inhibitory activities, independent activity studies were carried out 
with a series of benzamide β-haematin inhibitors in the newly-optimized system. Again, as previously noted 
for the quinoline inhibitors, some of the inhibitors conform to a sigmoidal dose-response curve, while others 
conform to a hyperbolic dose-response curve. In this case, only one benzamide compound, nQ-KW23, fits to 
a hyperbolic function, suggesting that a four-hour incubation time may simply be too short of a time for nQ-
KW23 to inhibit β-haematin formation, compared to the other compounds for which a four-hour incubation 
time may be enough or too long. 
A significant relationship is observed between the IC50 values obtained in the current lipid-water interface 
system and the NP40 detergent-mediated system (Figure 4.3), justifying the relevance of lipid-mediated 
systems, which are biologically more relevant in which to investigate β-haematin inhibition. The obtained IC50 
values show a good correlation to what has previously been reported against the CQS NF54 parasite strain 
(Figure 4.4). This indicates that the lipid-mediated assay is an efficient system in which inhibitor activity can 
be determined. The relative β-haematin inhibitory activity of each compound is similar in the three systems 
(lipid-water, NP40 and biological); it was found that nQ-KW17 is the most active inhibitor, while nQ-KW31 
is the least active inhibitor in the series. An IC50 value of 221 ± 16 µM was obtained for nQ-KW31 within the 
lipid-water interface system, indicating the inactive nature of this compound as a β-haematin inhibitor. This is 
in agreement to what has been reported for nQ-KW31 against the CQS NF54 parasite strain and in the NP40 
detergent-mediated system. Interestingly, the IC50 value obtained for nQ-KW16 is not in agreement with what 
was previously obtained in the NP40 detergent-mediated system. It was found that the inhibitor is moderately 





active in the lipid-mediated system, however, it was reported to be completely inactive in the NP-40 detergent-
mediated system. This suggests that the lipid-mediated system is ultimately a better biomimetic system, when 
comparing the activity to what has been obtained against the NF54 parasite strain. 
Furthermore, kinetics studies were carried out in the lipid-mediated system in order to investigate the effect of 
each non-quinoline compound on the formation of β-haematin. A decrease in the rate of β-haematin formation 
is observed as the inhibitor concentration was systematically increased. This observation may be accounted 
for by the reversible adsorption process of the inhibitor to the surface of β-haematin crystals, decreasing the 
rate of formation, rather than inhibiting it completely. A noticeable decrease in the yield of β-haematin 
formation is observed at high inhibitor concentrations for nQ-KW16, nQ-KW23 and nQ-KW32. The 
noticeable decrease in the yield of β-haematin is not observed for the other inhibitors, suggesting that a higher 
inhibitor concentration might be required in order for the proposed precipitation of the inhibitor-haematin 
complex to become evident. The observed decrease in the percentage yield of β-haematin formation may be 
accounted for by a Fe(III)PPIX-inhibitor complex forming in solution.117,118 This may suggest that the 
inhibitors which show this noticeable decrease in the yield may form precipitation complexes with the free 
haematin more rapidly than other inhibitors. Upon fitting the inverse of the observed rate constants as a 
function of increasing inhibitor concentration, the respective Kads and z values are determined for each 
inhibitor. The rate constant in the absence of an inhibitor is identical for all the non-quinoline inhibitors, with 
z values equal to ≈ 0.01 min-1, which is feasible, since z is independent of the inhibitor under similar system 
conditions. The rate constant is, however, lower in the pH 3 aqueous citrate buffer compared to the pH 4.8 
buffer system, in which the quinoline-based inhibitors were investigated  
The experimental kinetics data recorded in this study conform to the proposed theoretical kinetic model, 
suggesting that the model is valid for inhibitors other than only quinoline-based inhibitors. Similar to the 
quinoline inhibitors, the Kads and z values were determined from the linear regression analysis, and used for 
the best fit to the model. Accurate values for k2, the rate constant for the competing process that results in the 
precipitation of haematin, were not investigated in the current study, since this process is still poorly 
understood. The k2 values were thus allowed to refine freely to generate the best fit of the experimental data to 
the model. The k2 value can generally accommodate a range of values and is the only parameter that was 
allowed to vary in order to generate good r2 fits. In the current study, k2 was varied in a broad range between 
0.0015 and 0.20 for the benzamide non-quinoline inhibitors. 
A significant linear correlation, with an r2 value of 0.98 (P value < 0.01) is observed between the adsorption 
constants (Kads) and the β-haematin inhibitory activities (IC50) obtained for the non-quinoline β-haematin 
inhibitors (Figure 4.6 (a)). It was found that nQ-KW23 has the largest Kads value of the all the non-quinoline 
inhibitors, however, it was expected that nQ-KW17, the most active inhibitor, to have the largest adsorption 
constant. These respective Kads values are close to each other in magnitude (68.9 ± 17.8 compared to 54.6 ± 
13.7 mM-1), however, the log Kads values only deviate by 0.1 log units from each other, resulting in the good 
linear correlation. nQ-KW16, which was found to be the least active benzamide inhibitor in the lipid-mediated 
system, obtaining an IC50 value seven times larger than that of nQ-KW17, was found to have the weakest 





adsorption constant, Kads = 1.98 ± 0.12 mM-1. Similar to the quinoline inhibitors, this significant correlation 
suggests that the strength at which this group of non-quinoline inhibitors may adsorb to the surface of β-
haematin crystals, inhibiting further growth, is associated with its β-haematin inhibitory activity, in the lipid-
water interface system. 
Another significant linear correlation, with an r2 value of 0.82 (P value < 0.04) is observed when considering 
the relationship between the Kads values obtained from the lipid-mediated system and previously-determined 
biological β-haematin inhibitory activities reported against the CQS NF54 parasite strain. Subsequently, the 
adsorption-activity correlation for this group of non-quinoline compounds is evident and correlating this to the 
observations made in the lipid-mediated system, it further suggests that the biological mechanism of 
haemozoin inhibition by non-quinoline-based inhibitors, might also be via adsorption. 
Irrespective of the individual correlation observed between the Kads and the IC50 values of each set of quinoline- 
and non-quinoline-based β-haematin inhibitors, it is important to consider the two groups of β-haematin 
inhibitors together. Figure 4.7 shows two plots in which the following correlations were investigated: the Kads 
and IC50 values obtained in the lipid-mediated system for both sets of quinoline-and non-quinoline-based 
inhibitors (a) and the Kads values obtained in the lipid-mediated system against the biological CQS NF54 
parasite strain for the antimalarial drugs and non-quinoline-based inhibitors (b). The IC50 values obtained in 
the lipid-mediated system against the biological CQS NF54 parasite strain for the antimalarial drugs and non-
quinoline-based inhibitors Figure 4.8.  
Even though the linear trends for each individual set of inhibitors are good, an important observation is made 
regarding the β-haematin inhibition mechanism of action by these compounds. Three fundamentally important 
observations are; firstly, there is indeed a significant correlation between the obtained Kads values and the 
biological activities determined against the CQS NF54 parasite strain, when considering the antimalarial drugs 
and non-quinoline-based inhibitors together (Figure 4.7 (b), r2 value of 0.68). This suggests that the inhibitor 
concentration required to inhibit haemozoin formation by 50%, is dependent on the specific strength of 
adsorption of a specific inhibitor to a haemozoin crystal surface. Secondly, when considering the plot of the 
observed IC50 values against the biological activities determined against the CQS NF54 parasite strain for the 
same group of inhibitors, the antimalarial drugs and non-quinoline-based inhibitors, no correlation is observed 
(Figure 4.8) There is, however, separate correlations for the two individual inhibitor families, however, the 
data points are completely random when they are considered together. These observations are contradictory 
towards each other, since both the β-haematin inhibitory activity and the Kads values were determined in the 
same biologically relevant, lipid-mediated system. Thirdly, it is interesting to notice that there are compounds 
which have virtually the same β-haematin inhibitory activity, however, their respective Kads values differ 
greatly from each other (Figure 4.7 (a)). As an example, AQ and nQ-KW17 both possess similar log IC50 
values; -5.23 and -5.21, respectively, however, their Kads values differ more than seven-fold; 384 ± 105 mM-1 
and 54.6 ± 13.7 mM-1, respectively. Similarly, the Kads value for Q-I is nearly forty-five-fold larger than that 
of nQ-KW16, however, they were found to have similar β-haematin inhibitory activity. There are consequently 
inhibitors that adsorb stronger than others, however, their relative β-haematin inhibitory activity is the same. 





These observations raise further questions in understanding β-haematin inhibiting compounds and their mode 
of action by which they inhibit β-haematin formation, since these compounds appear to behave differently 
when they are compared together as a group of β-haematin inhibitors. 
When considering the main kinetic model, Equation 1.2, which explains the effect of an inhibitor on the 
formation of β-haematin,40 it is evident that there are two factors, namely Kads and k2, that may contribute to 
individual inhibitors possessing the same IC50 value. In an attempt to rationalize the interplay between these 
two factors, arbitrary values were chosen initially for z, Kads and k2 in the kinetic model. A series of curves are 
obtained for the percentage β-haematin formation as a function of time (Figure 4.9 (a)). The decrease in the 
rate and overall yield of β-haematin formation are observed as previously described; the decrease in rate being 
accounted for by the adsorption of an inhibitor to the β-haematin crystal surface and the decrease in the yield 
being attributed to the proposed irreversible precipitation of a Fe(III)PPIX-inhibitor complex. When the IC50 
value for β-haematin inhibition is measured, essentially the expected percentage inhibition of β-haematin at a 
specific time point as a function of drug concentration is investigated. It is possible therefore to predict a dose-
response curve from the kinetics profile by examining expected yields at a particular time point, as a function 
of drug concentration. The dose-response curve obtained from the original set of kinetics traces at a specific 
time point yields a specific IC50 value (Figure 4.9 (b)). 
However, by increasing the arbitrary value for Kads ten-fold, and keeping z and k2 constant, another series of 
curves are obtained (Figure 4.9 (c)). It is evident that the rate of β-haematin formation slows down more 
dramatically with increasing inhibitor concentration. Likewise, a dose-response curve obtained from the set of 
curves, at a specific time point, as a result of increasing Kads, thus also yields a specific IC50 value (Figure 4.9 
(d)). If Kads is increased ten-fold, however, less of the inhibitor is needed to inhibit β-haematin formation by 
50% and the IC50 value is expected to be lower. Indeed this is the case if the two theoretical data sets are 
compared with one another. 
By increasing the original arbitrary value of k2 five thousand-fold, hence rapid precipitation of the Fe(III)PPIX-
inhibitor complex, and keeping the original values for z and Kads constant, another series of curves, different 
from the original, are obtained (Figure 4.9 (e)). A more distinct decrease in the overall yield of β-haematin 
formation is observed after each addition of inhibitor concentration. Measuring the IC50 value at the same time 
point, a predicted dose-response curve is obtained (Figure 4.9 (f)). In both cases (Figure 4.9 (d) and Figure 4.9 
(f)), β-haematin formation is inhibited by at least 50% after the fourth addition of the inhibitor.  
Another interesting observation is made when the dose-response curves obtained after increasing Kads and k2, 
respectively, are compared to the original. The slight sigmoidal-shaped dose-response curve changes in shape 
to a less sigmoidal function, and rather fits a hyperbolic function. This suggests that the incubation time may 
not be exclusively responsible for the shape of the respective dose-response curves, however, this, along with 
the rate of precipitation, k2, should be investigated further. 











































































































Figure 4.9The kinetic behaviour of β-haematin formation explained by the theoretical model (Equation 1.2). 
Left panel: percentage β-haematin formed over time. Arbitrary values for z, Kads and k2 yields a series of curves 
(a). By increasing Kads ten-fold, a rapid decrease in the rate of formation can be observed (c) and by increasing 
k2 five thousand fold, compared to the original arbitrary value, a significant decrease in the β-haematin 
formation is observed in the series of curves (e). Right panel: dose-response curves. The IC50 values in all three 
cases are obtained from the predicted dose-response curves (b, d and f), by slicing through the curves in (a), 
(c) and (e) at a specific time point (broken lines).  
 
An extremely important realisation is evident when plotting the percentage β-haematin inhibition against the 
log of the inhibitor concentration in each of the above cases and overlaying the resultant dose-response curves. 
In the one case the value of Kads was increased (black curve), while in the other, the value of k2 was increased 
(purple curve), however, the same IC50 value is obtained in both cases (Figure 4.10). The broken line indicates 
the actual IC50 value at β-haematin inhibition by 50%, and it is evident from the two points overlaying each 
other, that these IC50 values are in close proximity to each other.  























Figure 4.10 Overlapping the dose-response curves obtained in both cases with increasing Kads () and 
increasing k2 (), respectively, yields virtually the same IC50 values. 
 
There are thus two reasons that account for individual inhibitors possessing the same IC50 values; either via 
strong inhibitor adsorption (Kads) or rapid precipitation of the Fe(III)PPIX-inhibitor complex (k2). This is 
possibly the rationale behind the observations which were made in the study regarding certain inhibitors that 
adsorb stronger than others with the same β-haematin inhibitory activity in the lipid-mediated system. The 
individual two factors, Kads and k2, are in turn determined by sub-factors, which are dependent on individual 
inhibitor families. Kads is dependent on the extent of adsorption of an inhibitor onto the fastest growing face of 
the β-haematin crystal, which is currently being investigated computationally in order to better understand 
structure-activity relationships of β-haematin inhibitors. As mentioned previously in this study, the process of 
precipitation of a haematin-inhibitor complex is still poorly understood and requires further investigation. 
Based on our knowledge from this aqueous system and method of β-haematin inhibition, it is considered that 
the extent of the solubility of an inhibitor may greatly contribute to the rate of the precipitation complex 
forming between Fe(III)PPIX and the respective inhibitor. It is thus crucial to investigate this further and will 
be discussed in more detail in Chapter 6. 
  







The current, newly-optimized assay was further developed in order to investigate a wider set of β-haematin 
inhibiting compounds. Non-quinoline compounds of the benzamide series were introduced into the lipid-water 
interface system, by decreasing the pH of the aqueous buffer to 3. The inhibitory activity, as well as the effects 
on the kinetics of β-haematin formation, of these compounds was successfully investigated in the lipid-
mediated system. A decrease in the rate of β-haematin formation in the absence of an inhibitor, compared to 
the rate in the pH 4.8 aqueous buffer system, was observed. Based on the results reported in this chapter, a 
similar observation to that of the quinoline-based inhibitors was made; an increase in the benzamide inhibitor 
concentration resulted in a decrease in the rate of β-haematin formation at low concentrations, while a decrease 
in the yield of β-haematin formation was observed when introducing higher doses of each inhibitor. The 
kinetics results are in agreement to what is predicted by the theoretical kinetic model and also suggest that β-
haematin inhibitory activity may be related to the strength of adsorption of an inhibitor to the growing face of 
a β-haematin crystal. By introducing the non-quinoline compounds into the lipid-mediated system, and fitting 
the experimental kinetic data to the proposed kinetic model, provides further insight into understanding the β-
haematin inhibition process. The validity of the model has been extended, since a set of both non-clinically 
related quinoline- and non-quinoline-based inhibitors has been introduced into the system. The results reported 
in this chapter further introduced thought-provoking information, which concerns quinoline and non-quinoline 
β-haematin inhibitors possessing virtually the same β-haematin inhibitory activity, however, appearing to 
adsorb stronger than one another. According to the theoretical kinetic model, it is evident that the IC50 values 
are dependent on both Kads and k2. A further understanding in the competing precipitation process of the 
inhibitor-Fe(III)PPIX complex is required to account for the behaviour of different β-haematin inhibitors. 
Additional kinetics studies, including different series of non-quinoline β-haematin inhibitors are also required 
to further extend the biological-relevant system of β-haematin inhibition. It is also important to investigate the 
adsorption of inhibitors to β-haematin independently, since kinetics alone cannot account for the proposed 
mechanism of action in β-haematin inhibition. 
 









The results reported in the previous two chapters have provided considerable insight into understanding the 
possible mechanism of action of the inhibition of β-haematin formation, however, kinetics alone cannot 
account for this proposed chemical inhibition process occurring. These findings warranted further 
investigation, in which evidence for adsorption of inhibitors to β-haematin was independently confirmed. 
Direct adsorption studies have previously been investigated in our laboratory using two known antimalarial 
drugs, CQ and QD.152 These studies were, however, time-consuming and were carried out as preliminary 
studies with little optimization. This motivated a more detailed investigation into the direct adsorption to the 
surface of pre-formed β-haematin crystals by known antimalarial drugs, AQ, CQ, QD and QN, and a short-
chain CQ analogue, Q-CF3. The method in which the direct adsorption studies are performed was optimized 
in order to investigate a greater number of inhibitors in a shorter period of time. By calculating the proposed 
amount of inhibitor adsorbed to the β-haematin crystals using Beer’s Law, and considering the Langmuir 
Isotherm, which explains monolayer coverage of an adsorbent to a solid surface, the relative strength of 
adsorption of an inhibitor to β-haematin crystals, K, was determined for each compound respectively. This is 
the first detailed study to investigate the direct adsorption of four antimalarial drugs and a short-chain CQ 
analogue to the surface of β-haematin crystals, enabling one to obtain an actual adsorption value. 
 
  





5.2 Experimental Methods 
 
The methods in this section describe how the aqueous citrate buffer solution was prepared in order to 
investigate the adsorption of 4-aminoquinoline and quinoline methanol antimalarial drugs, as well as a short-
chain CQ analogue, directly to pre-formed β-haematin crystals. The direct adsorption of CQ, AQ, QD, QN and 
Q-CF3 was investigated, respectively. 
 
5.2.1 β-Haematin Synthesis 
5.2.1.1 Preparation of β-Haematin at the Lipid-Water Interface 
Four Scott Duran crystallising dishes (internal diameter of 9 cm), containing 50.0 mL of the 50.0 mM sodium 
citrate buffer (section 2.5.1), and covered with tin foil, were pre-incubated in a water bath set at 37 °C for 30 
minutes, during which time the lipid and Fe(III)PPIX solutions were freshly prepared. Solutions containing 
1.0 mL of the lipid and 0.50 mL of the Fe(III)PPIX stock solutions (section 2.5.4 and 2.5.5) were premixed in 
a 2.0 mL Eppendorf tube, using micro pipettes. The 1.5 mL aliquots of lipid-Fe(III)PPIX solution were added 
dropwise to the pre-incubated buffer using a syringe with a needle diameter of 0.5 mm, yielding an interface 
between hydrophobic and hydrophilic regions after solvent mixing. Following an incubation period of 30 
minutes, the contents of all four glass vessels were agitated to release the product into the bulk aqueous 
medium. The total volume (~206.0 mL) was distributed equally into 15 mL Falcon Greiner centrifuge tubes 
which were then centrifuged at 4000 rpm for 10 minutes. The supernatant was removed from the pellet, and 
discarded. The pellet was subsequently washed with 1.0 mL of the 5:45:50 (v/v) pyridine: aqueous buffer: 
acetone solution (section 2.5.9) to remove unreacted Fe(III)PPIX. The product was dried in a desiccator over 
phosphorus pentoxide for up to 52 hours before further analysis and use.73 
 
5.2.1.2 Preparation of β-Haematin at the Pentanol-Water Interface 
The same procedure as outlined in section 5.2.1.1 was followed to prepare β-haematin at the pentanol-water 
interface, however, as a lipid alternative, 10.0 mL of 1-pentanol were layered on top of the 50.0 mL aqueous 
buffer. Since the pentanol is not miscible with water, two layers form, to create the pentanol-water interface. 
The pentanol-water interface system is a model for the lipid system.73 1.0 mL of the Fe(III)PPIX solution was 
added dropwise to the pre-incubated pentanol-water interface system. Following the incubation period of 45 
minutes, the solid material was collected by centrifugation and unreacted haematin was removed by washing 
the pellet with 1.0 mL of the 5:45:50 (v/v) pyridine: aqueous buffer: acetone solution. The remaining product 
was dried in a desiccator over phosphorus pentoxide for up to 52 hours before further analysis and use.73 
 





5.2.2 Direct Adsorption Studies 
Direct adsorption studies were carried out independently to the kinetics studies, to determine the extent to 
which a specific β-haematin inhibitor adsorbs to β-haematin. In contrast to the kinetics studies, these studies 
investigated the adsorption of inhibitors to pre-formed β-haematin crystals, rather than investigating the effect 
of the inhibitor on the real-time formation of β-haematin. In these experiments, the incubation time was fixed 
while the concentrations of all inhibitors were varied. A series of at least ten different inhibitor concentrations 
was prepared by diluting the inhibitor-containing stock solution with zero-drug citrate buffer (section 2.5.1) 
using calibrated micro-pipettes. These studies were conducted for four antimalarial drugs, AQ, CQ, QD and 
QN, as well as a short-chain CQ analogue, Q-CF3. 
All of the experiments were performed in 2.0 mL Eppendorf tubes, containing 1.0 mg of preformed β-haematin 
crystals (prepared from the pentanol-water interface, section 5.2.1.2). The β-haematin crystals were initially 
ground together to yield a homogenous sample of small crystallites and to increase the concentration of 
individual crystals over large clumps. Following the addition of 1.5 mL of inhibitor-containing citrate buffer 
(50 mM, pH 4.8) to each Eppendorf tube, the tubes were placed in a floating tray and allowed to incubate in 
an ultrasonic water bath at 37 °C, set on power level 2, for sixteen hours. Each concentration was measured in 
triplicate and a single control which excluded β-haematin was also included for each concentration. One 
experiment thus included 40 individual Eppendorf tubes (4 × 10) per compound. 
Following the incubation period, a 200.0 mL aliquot of the supernatant was transferred to a clean 96-well plate 
and the UV-visible absorbance spectrum of each experiment was measured and compared to the initial 
spectrum before the incubation period. The proposed amount of inhibitor adsorbed to the β-haematin crystals 
was calculated from Beer’s Law plots as described in section 5.3.2.2. By fitting the experimental data to the 
Langmuir Isotherm, using GraphPad, the adsorption constant, K, which is the relative strength of adsorption 
to the β-haematin crystals, could be determined for each inhibitor. The experimental procedure for direct 
adsorption studies is shown in Figure 5.1. 
 
 
Figure 5.1 Flow diagram of the experimental procedure followed for performing direct adsorption studies. (1) 
Finely, ground β-haematin crystals were (2) weighed off as 1.0 mg samples in 2.0 mL Eppendorf tubes. (3) 
On adding different concentration inhibitor-containing citrate buffer solutions, the tubes were placed in 
floating trays and incubated in an ultrasonic water bath at 37 °C for sixteen hours. (4) Single wavelength 












5.3.1 Characterisation of β-Haematin Crystals 
The formation of good quality β-haematin crystals is required in order to investigate the adsorption of quinoline 
inhibitors onto the crystal surface of β-haematin directly. β-haematin crystals can generally be recovered from 
the lipid-water and pentanol-water interface system, as well as from an acetate medium solution.64 The direct 
adsorption studies were carried out using β-haematin crystals recovered from the pentanol-water interface 
system first, since crystals grown from this environment are of a better quality compared to the crystals grown 
in the lipid-water interface system. The formation of β-haematin was confirmed after the samples had been 
carefully characterised using attenuated total reflection infrared spectroscopy (ATR-IR), powder X-ray 
diffraction (PXRD) and scanning electron microscopy (SEM). 
β-Haematin is comprised of cyclic dimers formed following the reciprocal coordination of the propionate 
group of each Fe(III)PPIX molecule coordinating to the metal centre of the neighbouring Fe(III)PPIX 
molecule.37 The ATR-IR spectra for the β-haematin crystals recovered from the lipid-water interface system 
(Figure 5.2 (a)) and the pentanol-water interface system (Figure 5.2 (b)) are in good agreement with the 
literature.35 The characteristic absorbance bands present at 1662 and 1205 cm-3 are assigned to the propionate 










































Figure 5.2 β-Haematin formation and characterization. ATR-IR spectra of β-haematin crystals recovered from 
the lipid-water (a) and pentanol-water (b) interface system. The peaks indicated with the dotted line at 1662 
and 1205 cm-1 are characteristic of β-haematin, confirming the formation of the crystalline material. 
 
The PXRD patterns of β-haematin crystals recovered from the lipid-water interface system (Figure 5.3 (a)) and 
the pentanol-water interface system (Figure 5.3 (b)) correspond to what has previously been observed in the 
literature,73,150 again confirming the formation of β-haematin. Both the reflection peaks denoted as (100) and 
(131) are characteristic of β-haematin crystals. The sharpness of the peaks indicate a greater degree of 
crystallinity in the pentanol system. 



































Figure 5.3 β-Haematin formation and characterization. Powder X-ray diffraction patterns of β-haematin 
recovered from the lipid-water (a) and pentanol-water (b) interface system. The two reflections at (100) and 
(131) are characteristic of the crystal planes in β-haematin. 
 
The SEM micrographs are also characteristic of β-haematin formation.58 The images represent the β-haematin 
crystals recovered from the lipid-water interface system (Figure 5.4 (a)) and the pentanol-water interface 
system (Figure 5.4 (b)). Multiple samples of β-haematin were recovered and collected for characterization. 
Good quality β-haematin crystals were further used in the direct adsorption studies. 
 
 
Figure 5.4 β-Haematin formation and characterization. Scanning electron micrographs of β-haematin 
recovered from the lipid-water (a) and pentanol-water (b) interface system. 
 
5.3.2 Direct Adsorption Studies 
The direct adsorption of CQ and QD to preformed β-haematin crystals has previously been investigated in our 
laboratory by monitoring the extent of depletion of the inhibitor from solution when in the presence of β-
haematin crystals.152 However, the experimental method was time-consuming, used less efficient absorbance 
measurement reading methods, and had a slow turnaround time per compound. This prompted the revisions 
and further optimizations carried out in the current study, which has allowed a greater number of compounds 
to be investigated. 
(a) (b)





5.3.2.1 Method of Optimization 
When considering an experimental method for direct adsorption studies, the primary objective was to maintain 
conditions in line with those used in the activity and kinetics studies as far as possible. The temperature at 
which the direct adsorption studies were carried out was thus increased from room temperature (~25 °C) to   
37 °C. To ensure homogeneity of the β-haematin weighed off into Eppendorf tubes, samples were ground 
together. The studies were also carried out in a heated ultrasonic water bath; in this way, it was assumed that 
crystallites would not clump together, thus ensuring maximal contact between the inhibitor in solution and the 
β-haematin crystal surfaces. The efficiency of measurement of each inhibitor concentration was improved by 
transferring a 200.0 µL aliquot of the supernatant from each tube to a 96-well plate and performing multiple 
absorbance readings simultaneously. 
The optimization steps outlined above have resulted in considerable improvement compared to the previous 
method used to investigate the direct adsorption of inhibitors to preformed β-haematin crystals. All of the 
important differences and similarities between the previous and the new method are summarized in Table 5.1.  
 
Table 5.1 A comparison between the previous and new experimental direct adsorption method. 
Previous Method Optimized Method 
2.0 mL Eppendorf tubes 2.0 mL Eppendorf tubes 
1.0 mg preformed β-haematin crystals 1.0 mg preformed β-haematin crystals 
2.0 mL inhibitor-containing buffer solutions 1.5 mL inhibitor-containing buffer solutions 
Room temperature 37 °C 
Incubation period, 72 hours Incubation period, 16 hours 
Unshaken Shaken continually in ultrasonic water bath 
2.0 mL aliquot measurements in cuvette 0.2 mL aliquot measurements in 96-well plates 
 
5.3.2.2 Recording Initial UV-visible Spectra 
A full UV-visible spectrum was recorded from 200-600 nm for different concentrations of AQ, CQ, QD, QN 
and Q-CF3 respectively, in order to determine the maximum absorbance wavelength of each inhibitor (Figure 
5.5). The wavelengths selected for monitoring throughout the direct adsorption studies were 342, 344, 332, 
344 and 341 nm, for AQ, CQ, QD, QN and Q-CF3, respectively. After placing the preformed β-haematin 
crystals in a solution containing a particular concentration of an inhibitor, the absorbance reading of the 
supernatant at the relevant reference wavelength was measured after 16 hours (At) and compared to the initial 
absorbance (Ai) reading.  
 

































































Figure 5.5. UV-visible spectra of antimalarial inhibitors dissolved in aqueous citrate buffer, pH 4.8. Maximum 
absorbance peaks are indicated for (a) AQ, (b) CQ, (c) QD, (d) QN and (e) Q-CF3 in the absorbance range of 
200-600 nm from initial low (●) to high (●) inhibitor concentrations. 
 
5.3.2.3 Beer’s Law Plots 
The amount of each respective inhibitor, which remains in solution after a fraction of molecules have adsorbed 
onto the β-haematin crystals over a period of time, can be calculated by implementing Beer’s Law equation. 
By definition, it is evident from the Beer’s Law equation (Eq. 5.1) that the transmission of light through a 
solution is related to its concentration. In the relationship, A is the absorbance being measured of the material 
in solution, ԑ is the molar absorptivity, c is the concentration of the material in solution and l is the path length 
of light through the sample.164 
 
𝐴 =  𝜀𝑐𝑙     (Eq. 5.1) 
 
By plotting the initial measured absorbance, Ai, of each inhibitor as a function of increasing concentration, c, 
a linear correlation is observed (Figure 5.6, black lines), from which each specific inhibitor molar absorptivity, 





ԑ, can be extracted from the slope value. The path length of the sample, 𝑙, which in this case is the depth of the 
well in a 96-well plate, was determined for each compound from a Beer’s Law plot conducted in a 96-well 
plate (it is thus important to ensure exactly 200.0 µL aliquots are in each well). A decrease in absorbance of 
each inhibitor is observed when plotting the measured absorbance after 16 hours incubation time (At) as a 
function of increasing inhibitor concentration (Figure 5.6, purple lines). A more distinct decrease in absorbance 
is observed for AQ, CQ and Q-CF3, compared to the small decrease in absorbance observed for QD and QN. 
An inhibitor control sample, excluding the β-haematin crystals, which was investigated under consistent 
experimental conditions, was also included and measured after 16 hours for each inhibitor concentration 
(Figure 5.6, grey lines). The absorbance values obtained for the control samples (Ac) were similar to the initial 
absorbance measurements, indicating no decrease in all cases, which strongly suggests that the observed 
decrease in absorbance observed after 16 hours (purple lines), can most likely be accounted for by inhibitor 
adsorption to the β-haematin crystals present in the solution. 
 

























































Figure 5.6 Direct adsorption studies in 50.0 mM citrate buffer, pH 4.8. Beer’s Law plots of the maximum 
absorbance peak of (a) AQ, (b) CQ, (c) QD, (d) QN and (e) Q-CF3, measured at 342, 344, 332, 344 and 341 
nm, respectively, show a decrease in At after 16h (●), compared to Ai (●). An inhibitor control, excluding β-
haematin, indicated no decrease in absorbance (●), which supports the hypothesis of inhibitor- β-haematin 
adsorption.  





5.3.2.4 Explaining the Observed Direct Adsorption Behaviour using the Langmuir Isotherm 
It is apparent from the Beer’s Law plots in section 5.3.2.3 that a decrease in the inhibitor concentration in 
solution does indeed occur over a period of time for all compounds, when present together with β-haematin 
crystals in an aqueous citrate buffer solution. To further extract valuable information from the experimental 
data, the Langmuir Isotherm was again considered. In order to calculate the amount of inhibitor adsorbed to 
the β-haematin sample, the experimental data were fitted to equation 5.2, which is a mass-balance form of the 





1 +𝐾 ∙ 𝐶𝑒
     (Eq. 5.2) 
 
The Langmuir Isotherm is based on monolayer coverage and constant binding energy between a solid surface 
and adsorbent,165 which is in this case β-haematin and the inhibiting inhibitor, respectively. In the above 
equation, qe represents the mass of the adsorbed inhibitor per mass of β-haematin crystals at equilibrium, while 
Ce is the inhibitor concentration in solution when the amount of inhibitor adsorbed equals qe, i.e. the inhibitor 
concentration after adsorption. Qa0 represents the maximum adsorption capacity (the amount of adsorption 
corresponding to monolayer coverage) and K is the adsorption constant, or the Langmuir constant, quantifying 
the relative strength of inhibitor adsorption onto the β-haematin crystals. 
Ce values for each inhibitor concentration are calculated by substituting the absorbance values, measured after 
16 hours, as well as the extracted ԑ values (determined from the slope as mentioned above), into Equation 5.1. 
(with 𝑙 = 1). Values of qe are calculated by subtracting Ce from the initial concentration, and converting it into 
the actual mass of inhibitor adsorbed per milligram of β-haematin.  
The experimental data of qe as a function of increasing Ce for each inhibitor are plotted in Figure 5.7. Ce is 
increasing owing to the initial increase in inhibitor concentrations. The experimental data conform to a non-
linear fit of Equation 5.2 with r2 values of 0.94, 0.91, 0.89, 0.91 and 0.93 for AQ, CQ, QD, QN and Q-CF3 
respectively. Default constraints were set for the K and Qa0 values to be greater than 0. 
Subsequently, fitting the experimental data to Equation 5.2, yields K and Qa0 values for each inhibitor. These 
values are given in Table 5.2. The values of K are of most interest, since these values represent the proposed 
relative strength at which the inhibitor adsorbs to the β-haematin crystals. 
 



































































































Figure 5.7 Direct adsorption studies in 50.0 mM citrate buffer, pH 4.8. The best fits of the mass of the inhibitor 
adsorbed per mg β-haematin crystals (m(inh)A/mg BH), against the inhibitor concentration remaining in 
solution after adsorption ([inh]S) to the Langmuir Isotherm for (a) AQ, (b) CQ, (c) QD, (d) QN and (e) Q-CF3 
yields the adsorption constant K. The r2 values are 0.94, 0.91, 0.89, 0.91 and 0.93, respectively. 
 
Table 5.2 Direct adsorption studies in 50.0 mM citrate buffer, pH 4.8. The K and Qa0 values were obtained 
from the best fits to the form of the Langmuir Isotherm Equation given by equation 5.1. 
Antimalarial Inhibitor K (mM-1) Log K Qa
0 
AQ 32294 ± 15756 4.51 ± 0.78 0.025 ± 0.005 
CQ 17959 ± 6342 4.25 ± 0.56 0.034 ± 0.005 
QD 12564 ± 4666 4.09 ± 0.59 0.020 ± 0.003 
QN 5961 ± 2572 3.78 ± 0.69 0.024 ± 0.005 











5.3.2.5 Introducing Atovaquone as a Negative Control in Direct Adsorption Studies  
The above reported results for the direct adsorption studies lend great insight into understanding the observed 
inhibitor depletion in solution in the presence of preformed β-haematin crystals. The assumption that an 
inhibitor adsorbs to the β-haematin crystal surface may, however, only be validated with additional 
experiments supporting these observations.  
It was consequently considered to investigate the effect of a non-β-haematin inhibitor, namely atovaquone 
(AtQ, Figure 5.8), on the direct adsorption to β-haematin crystals. Since AtQ exhibits very weak or no β-
haematin inhibitory activity,140,149 no significant adsorption between AtQ and the β-haematin crystals, and 
hence no decrease in AtQ concentration over a period of time, was expected. 
 
 
Figure 5.8 Structure of Atovaquone. 
 
Owing to the insoluble nature of AtQ in the aqueous citrate buffer, the compound was alternatively dissolved 
in acetonitrile. The same procedure was then carried out in order to investigate the direct adsorption of AtQ. 
The Beer’s Law plot (Figure 5.9 (a)) shows no decrease in the AtQ absorbance after 16 hours (purple curve), 
compared to the initial absorbance measurement (black curve) at 330 nm. A control sample, excluding the β-
haematin crystals, which was investigated under similar experimental conditions, was included and measured 
after 16 hours (grey curve), and indicated no decrease in the absorbance values. These results are, however, 
not conclusive on their own, since the experimental environment in which the adsorption studies were carried 
out is somewhat different, owing to the inclusion of acetonitrile, from the biologically-relevant citrate buffer 
system.  
Subsequently, the direct adsorption study of free base chloroquine (CQfb) was carried out in order to investigate 
the effect of the solvent and to validate the observations which were made for AtQ. The Beer’s Law plot 
(Figure 5.9 (b)) shows a decrease in CQfb absorbance after 16 hours (purple curve), compared to the initial 
absorbance measurement (black curve) at 330 nm. A control, excluding the β-haematin crystals was included 
and measured after 16 hours (grey curve), and indicated no decrease in the absorbance values. 
These observations are similar to that observed for the antimalarial inhibitors, suggesting that the extent of 
CQfb depletion can be accounted for the possible adsorption to the β-haematin crystal surfaces in acetonitrile, 
which in turn strongly supports the conclusion reached above that AtQ did not adsorb to the β-haematin 





crystals. Subsequently, fitting the experimental data to Equation 5.2, yields the adsorption constant for CQfb 
from the best fir curve, with an r2 value of 0.92 (Figure 5.9 (c)). A log K value of 4.43 ± 0.54 was obtained for 
CQfb, which is in good agreement to the adsorption value obtained for CQ in the citrate buffer system (4.25 ± 
0.56). 
 











































Figure 5.9 Direct adsorption studies in acetonitrile. Beer’s Law plots of the maximum absorbance peak of (a) 
AtQ measured at 330 nm, shows no decrease in absorbance after 16h (●), compared to the initial absorbance 
(●), and (b) CQfb measured at 330 nm, shows a decrease in absorbance after 16h (●), compared to the initial 
absorbance (●). An inhibitor control, excluding β-haematin, indicated no decrease in absorbance for both AtQ 
and CQfb (●). (c) The best fits of the mass of the inhibitor adsorbed per mg β-haematin crystals, against the 
inhibitor concentration remaining in solution after adsorption, to the Langmuir Isotherm for CQfb, yields the 
adsorption constant K (r2 = 0.92). 
  





5.4 Combining the Kinetics Adsorption Studies to the Direct Adsorption Studies 
 
The results obtained in the two different studies are compared below in order to evaluate if there is any 
significant correlation between the two independent methods of investigating the proposed adsorption of an 
inhibitor to β-haematin. 
A correlation between the β-haematin inhibitory activity (IC50) and relative strength of adsorption to preformed 
β-haematin crystals (K), yields a good linear relationship, with an r2 value of 0.91 (Figure 5.10 (a)). Statistically 
this trend is significant, indicated by a P value smaller than 0.05.  
Subsequently, a linear correlation between the relative strengths of adsorption, Kads and K, determined in the 
kinetics and the direct adsorption studies, respectively, is observed, with an r2 value of 0.84 (Figure 5.10 (b)). 
The good fit is significant, indicated by a P value smaller than 0.05, and suggests that the quinoline-based 
inhibitors do adsorb to the β-haematin crystal surface. In both cases AQ adsorbs the strongest to the β-haematin 
crystals, while Q-CF3 adsorbs the weakest, which is in agreement with their respective β-haematin inhibitory 
activity. The difference in the absolute values of K determined in the two methods is approximately one log 
unit. This may be due to the fact that in kinetics, the adsorption is expected at the fastest growing face to bring 
about real-time inhibition of β-haematin formation. In the case of the direct adsorption experiments, the β-
haematin is preformed and thus adsorption does not result in inhibition; in this case, it is also possible that the 
inhibitors may have adsorbed to other crystal faces, thus accounting for the overall weaker interaction on the 
primary face (indicated by smaller values of K). 
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Figure 5.10 Direct adsorption studies compared to inhibitor activity and kinetics studies carried out in 50.0 
mM citrate buffer, pH 4.8. Linear correlations between (a) the observed K values, determined in the current 
study, against the IC50 values, determined in the previous inhibitor activity studies and (b) the observed Kads 
values, determined in the kinetic studies, against the K value, determined in the direct adsorption studies, are 
observed for the quinoline-based inhibitors. The r2 values are 0.91 and 0.84, respectively. 
 
 







The focus of this chapter has been to independently investigate the proposed adsorption by quinoline-based 
inhibitors to preformed β-haematin crystals. β-Haematin crystals were successfully synthesized in a pentanol-
water interface system, since this method of preparation yields larger amounts of good quality crystals, 
compared to the lipid-mediated system, and is frequently used as a lipid alternative system for β-haematin 
formation.73 The β-haematin crystals were successfully characterized using infrared spectroscopy, powder X-
ray diffraction and scanning electron microscopy. Only good quality, homogenous β-haematin samples were 
used in the direct adsorption studies. 
Direct adsorption studies have previously been carried out in order to establish whether there is any interaction 
between an inhibitor and the surface of preformed β-haematin crystals. The method of investigation has, 
however, been optimized in the current study, which now has a faster turnaround time per compound, is 
biologically more relevant and measures multiple absorbance readings simultaneously.  
The direct adsorption of four clinically known antimalarial drugs, AQ, CQ, QD and QN, as well as a short-
chain CQ analogue, Q-CF3, was investigated in an aqueous citrate buffer, over 16 hours at 37 °C. A decrease 
in absorbance is observed for all the quinoline inhibitors at their respective maximum absorbance wavelengths 
(Figure 5.6). Interestingly, a greater decrease in absorbance is observed for the two 4-aminoquinoline 
antimalarials, AQ and CQ, compared to the decrease in absorbance observed for the two quinoline methanol 
antimalarials, QD and QN. These observations suggest that more AQ and CQ have interacted with the β-
haematin crystals than the quinoline methanol antimalarial drugs, resulting in a greater decrease in absorbance, 
which is in agreement with the activity results reported in Chapter 3, since it has been observed that AQ and 
CQ are more active β-haematin inhibitors than QD and QN. Higher doses of QD and QN are most likely 
required to induce a larger decrease in absorbance. 
The extent of depletion of each inhibitor in solution may be accounted for by a β-haematin-inhibitor interaction 
occurring. Since no free Fe(III)PPIX is present in the solution, the interaction is not expected to be the 
irreversible precipitation reaction of a Fe(III)PPIX-inhibitor complex. Rather therefore, the only possible 
interaction that may be occurring is direct adsorption of the inhibitor to the β-haematin crystal surface. A 
control sample, which included only the inhibitor-containing buffer, did not indicate a decrease in absorbance, 
which in return supports the above statement. 
Subsequently, the mass of the inhibitor adsorbed per mg β-haematin crystals as a function of the inhibitor 
concentration remaining in solution after adsorption, was fit to the Langmuir Isotherm. Non-linear curves 
(Figure 5.7) were obtained, from which the adsorption constant, K, was determined for each quinoline 
inhibitor. A decrease in the strength of direct adsorption is observed, K decreasing from AQ to Q-CF3; 
AQ>CQ>QD>QN> Q-CF3. AQ may possibly adsorb the strongest to the preformed β-haematin crystals, and 
Q-CF3 the weakest.  





Direct adsorption studies for AtQ indicated no decrease in absorbance, suggesting that no interaction to the β-
haematin crystals occurred, which was expected since AtQ is not a β-haematin inhibitor.140,149 Direct adsorption 
studies for CQfb were, however, carried out in order to validate the observations that were made in the 
acetonitrile environment. A decrease in the concentration of CQfb, similar to the quinoline inhibitors, is 
observed, suggesting that the extent of CQfb depletion in acetonitrile may also be accounted for by the direct 
adsorption to the surface of the preformed β-haematin crystals. This in turn provides support for the case that 
AtQ did not adsorb to the β-haematin crystals. A log K value of 4.43 ± 0.54 for CQfb corresponds well to the 
log K value obtained in the buffer system (4.25 ± 0.56). Regardless of the two different environments in which 
the direct adsorption studies were carried out, the observations that AtQ does not show a decrease in 
absorbance, while CQfb does, suggest that a decrease in inhibitor concentration (as evidence by a decrease in 
absorbance) in the presence of performed β-haematin crystals, is most likely owing to a inhibitor- β-haematin 
adsorption interaction. 
Furthermore, the adsorption constants, K, determined in the independent investigation compared to the β-
haematin inhibitory activity obtained in Chapter 3, show a linear correlation between the quinoline inhibitors 
(Figure 5.10 (a)). The correlation suggests that more active inhibitors, like AQ, adsorb more strongly to the β-
haematin crystals than less active inhibitors, such as Q-CF3. This is in agreement to the overall hypothesis that 
the strength of adsorption of an inhibitor to β-haematin may be related to its relative β-haematin inhibition 
activity. 
Subsequently, a direct correlation is observed between the adsorption constants, Kads, which were determined 
in the kinetics studies, and the adsorption constants, K, which were determined in the direct adsorption studies 
(Figure 5.10 (b)). The linear correlation suggests that the strength of adsorption determined theoretically in the 
kinetics studies are related to their relative strength of adsorption independently. The absolute values differ in 
orders of magnitudes, however, the same trend in adsorption strength is observed for the quinoline-based 
inhibitors. Using preformed β-haematin crystals in the direct adsorption studies is not the same as inhibiting 
β-haematin crystal growth as a dynamic process. The direct adsorption of an inhibitor to the β-haematin 
crystals is furthermore also not face-specific in this case, since inhibitors can adsorb to multiple faces of the 
preformed β-haematin crystal. Unpublished computational data by one of our co-workers suggests that 
interactions at the second fastest growing face may also take place, while the kinetics model is based on the 
fastest growing face only. The absence of the lipid solution in the citrate buffer system, compared to the kinetics 
lipid-water interface system, may possibly have an effect on the extent at which the quinoline inhibitors interact 
with the β-haematin crystals.  
Overall, the most probable inhibitor-β-haematin interaction is considered to be adsorption; however, this still 
cannot be completely confirmed based on the current results alone. Additional studies, investigating the face 
or faces to which adsorption may be occurring, are required to explain the observations reported in this chapter. 
This is currently being investigated computationally, however, independent experimental results would also 
be required to completely understand the mode of inhibitor-β-haematin interaction. 







The previous method in which the direct adsorption of an inhibitor to the surface of β-haematin crystals was 
investigated, has been optimized in the current study. The direct adsorption studies were expanded by 
investigating four clinically known antimalarial drugs, as well as a short-chain CQ analogue. The decrease in 
absorbance for a range of concentrations over a period of time may be accounted for by the possible absorption 
of the inhibitor to the surface of the preformed β-haematin crystals present in the aqueous system. This 
assumption is valid since a control sample, excluding β-haematin crystals, indicated no decrease in absorbance 
when investigated under the similar experimental conditions. By fitting the mass of the inhibitor adsorbed per 
mg β-haematin, against the inhibitor concentration which remains in solution after adsorption to the Langmuir 
Isotherm, the relative strength of inhibitor adsorption to β-haematin crystals, K, was obtained. The K values 
determined in the current study are in agreement to the β-haematin inhibitory activity, as well as the Kads values 
obtained for each inhibitor from the kinetics studies carried out in the lipid system (Chapter 3). The direct 
adsorption studies are, however, not sufficient enough to draw a definite conclusion on the exact inhibition 
mechanism of action, since this experimental method does not provide adequate information on the site of 
inhibitor adsorption. Even though the β-haematin crystal face to which adsorption occurs can be predicted and 
investigated computationally, this should ideally be probed experimentally. 
  





Chapter 6. Overall Conclusion and Future Work 
 
6.1 Overall Conclusion 
 
The main aim of this research project, underpinned by the hypothesis that the β-haematin inhibitory activity 
of a compound is related to its strength of adsorption to free surface binding sites on the fastest growing face 
of the crystalline material, was to investigate the effect of diverse β-haematin inhibitors on the kinetics of β-
haematin formation using a lipid-mediated system.  
This aim was achieved by firstly developing a new, improved-throughput lipid-mediated assay in which to 
investigate the inhibition of β-haematin formation. A previously-used Phiβ assay40 was optimized by 
introducing 24-well plates and was successfully validated as a means of assaying drug activity by introducing 
clinically-relevant antimalarial drugs, namely chloroquine, amodiaquine, quinidine, quinine and mefloquine 
into the system. Having developed this more efficient lipophilic assay, it has been possible throughout this 
project to extend the data set to include short-chain chloroquine analogues, as well as a series of benzamide 
non-quinoline β-haematin inhibitors.  
β-Haematin inhibitory activity was investigated for the first time in this way under biologically-relevant 
conditions (pH4.8, 37 °C). The experimentally-determined IC50 values for all of the compounds show good 
correlation with biological activity determined against various chloroquine-sensitive parasite strains, namely 
3D7, D10 and NF54. Furthermore, the investigation of the kinetics on β-haematin formation at the lipid-water 
interface in the presence of antimalarial drugs, short-chain CQ analogues, as well as the benzamide non-
quinolines, shows that an increase in inhibitor concentration results in a decrease in the rate of β-haematin 
formation. This was observed at low concentrations, while a decrease in the yield of β-haematin formation was 
observed when introducing higher doses of each inhibitor. The exponential kinetics results are similar to what 
has previously been recorded,40 and can be explained by a theoretical kinetic model, previously developed in 
our group.40 Importantly, consistent β-haematin formation rate constants in the absence of an inhibitor were 
observed in the biologically-relevant environment, however, the rate was slightly faster in the pH 4.8 buffer 
solution, compared to pH 3.0. 
The experimental data strongly support a mechanism of inhibitor action via adsorption to the surface of β-
haematin crystals by both sets of quinoline- and non-quinoline inhibitors, and it is proposed that the equilibrium 
between adsorbed and desorbed inhibitor is responsible for the decrease in the rate of β-haematin formation. 
The decrease in the yield of β-haematin at high concentrations may be accounted for by the proposed 
irreversible precipitation of an inhibitor-Fe(III)PPIX complex. The interaction between each individual 
inhibitor and the crystal surface was measured (Kads) and found to correlate well with its β-haematin inhibitory 





activity determined in the lipid-mediated system, as well as the biological activity determined against D10 and 
NF54 chloroquine-sensitive parasite strains, for quinoline- and non-quinoline-based inhibitors, respectively. 
An important observation made during this study is that various quinoline- and non-quinoline β-haematin 
inhibitors can have the same β-haematin IC50 value, yet quite different Kads values. Using the theoretical kinetic 
model it has become evident that both Kads and k2 have a direct effect on the IC50 value of a respective inhibitor. 
It would seem that the interplay between the two parameters determines the overall activity of a family of 
compounds. The formation of inhibitor-haem complexes did not, however, form part of this project, so that 
independent studies regarding k2 are required urgently to improve our understanding of the different processes 
involving Fe(III)PPIX. 
Since kinetics alone cannot account for the proposed mechanism of β-haematin inhibition, independent studies 
were carried out to investigate the relative strength by which an inhibitor is able to adsorb to the surface of 
preformed β-haematin crystals. The interaction between the inhibitor and the preformed β-haematin was 
measured (K) and was found correlate well with the inhibitory activity and Kads values determined in the 
kinetics experiments. 
Overall, this research project provides important insight into the possible mode of β-haematin inhibition by 
quinoline- and importantly, non-quinoline-based inhibitors. Indeed, adsorption (Kads) is an important process 
and was observed to correlate to both β-haematin and biological activities of the compounds investigated. If 
the interactions that aid the adsorption of compounds to surface binding sites are identified, the insight will be 
invaluable in the rational design of novel haemozoin inhibitors. 
 
6.2 Future Work 
 
The results of the work presented in Chapter 3 and 4 regarding the investigation of the kinetics of β-haematin 
formation in the presence of a variety of inhibitors at the lipid-water interface provide a great deal of insight 
into the possible mode of action of these inhibitors, however, the following future studies are proposed to 
further our understanding: 
1. To investigate a wider range of non-quinoline β-haematin inhibitors and determine their effects on the 
kinetics of β-haematin formation in order to demonstrate the validity of the theoretical kinetic model 
further. 
2. To use fluorescence microscopy in conjunction with the β-haematin inhibition studies; by tagging an 
inhibitor with a fluorescent marker, it may be possible to visualise the adsorbed inhibitor on the surface 
of β-haematin crystals. This may contribute definitive insight into the mechanism of action of the 
inhibitors. 





Subsequent to the kinetics of β-haematin formation, which mainly focus on the equilibrium adsorption constant 
of an inhibitor, Kads, in this study, it is evident from the results presented in Chapter 4 that a better understanding 
of the proposed competing precipitation of an inhibitor-Fe(III)PPIX complex is required, and future studies in 
this regard are suggested as follows: 
3. To investigate k2 independently, in order to truly understand how the rate of precipitation of an 
inhibitor and free Fe(III)PPIX in solution plays a role in the formation of an inhibitor-haem complex, 
which in turn may have an effect on β-haematin formation. The solubility of inhibitor-Fe(III)PPIX 
complexes in aqueous pyridine is of high importance and differential solubility of β-haematin 
inhibitors may provide significant insight in this regard. This data will improve the overall 
understanding of the system and of the relationship between different processes involving Fe(III)PPIX. 
The results presented in Chapter 5 further support the hypothesis that β-haematin inhibition is brought about 
by direct adsorption of an inhibitor to preformed β-haematin crystal surfaces, however, subsequent 
experimental proof is still required to further support this phenomenon independently. Future studies in this 
regard include: 
4. Infrared and/or solid-state UV-vis spectroscopic analyses and characterization of β-haematin crystals 
after leaving samples exposed to an aqueous inhibitor solution, in order to probe the presence of an 
inhibitor adsorbed to the preformed β-haematin crystal surface. 
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